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Summary of the thesis 
Studies on pharmacokinetic profiles on some first-line drugs for koalas argue that traditional 
ad-hoc extrapolations of dosages from carnivorous species such as dogs and cats to the koala, 
a folivore, are inappropriate. This research describes changes in plasma concentrations of 
amoxicillin and cefovecin, currently administered by some veterinarians to koalas. A third 
drug, posaconazole, was also investigated as its broad-spectrum antifungal activity might be 
efficacious against cryptococcal infections in koalas. HPLC methods to determine plasma 
concentrations of these antimicrobials were developed and validated. Posaconazole was 
administered at 3 mg/kg to two koalas intravenously and 6 mg/kg to another six koalas orally. 
Based on plasma concentrations, posaconazole is predicted to be efficacious for the treatment 
of cryptococcosis in koalas. An in-vitro study to determine cefovecin binding to plasma 
proteins of koalas and other selected Australian marsupials demonstrated the proportion of 
binding between 12 to 40 %, suggesting that the elimination half-life of cefovecin in these 
species is likely to be shorter than those in the dog and cat. Cefovecin was administered as a 
single bolus (8 mg/kg) to six koalas subcutaneously. Cefovecin plasma concentrations at all 
time points (0 to 96 h) in all animals were below 1 µg/mL, indicating cefovecin has a short 
duration of action in koalas. Amoxicillin was administered to another six koalas at 10 mg/kg 
subcutaneously. Low concentrations of amoxicillin were detected; however, drug instability 
might have contributed towards these findings. Bioassays (agar disc diffusion and broth 
microdilution inhibition assays) were undertaken to confirm amoxicillin and cefovecin HPLC 
results. The bioassay demonstrated variable plasma antibacterial activities at t = 0 h (before 
koalas were medicated). Consequently, the endogenous antibacterial activity of koala blood 
matrices (plasma, serum, etc.) to inhibit E. coli and S. aureus were evaluated. Koala blood 
matrices demonstrated significant variations in inhibiting both pathogens’ growth compared to 
other species studied. Reasons for such variations were unclear but opened a new area for 
x 
 
investigation into koalas’ endogenous antimicrobial activity and how it might be utilised to 
assist this ‘vulnerable’ species control infectious diseases.  
xi 
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1.1 General introduction  
The first pharmacokinetic (PK) study of any therapeutic drug administered to the koala was 
that of enrofloxacin (and marbofloxacin) published by Griffith et al. (2010). Since then, results 
of this and other studies have revealed some significant differences in the PK profiles of first-
line drugs used to treat diseased and injured koalas. Such studies have raised doubts about the 
appropriateness of extrapolating drug dosages from other species such as dogs and cats to 
koalas. For instance, the clearance and half-life of the antifungal drug fluconazole, which is 
reported to scale allometrically with the body weight of most species (Jezequel, 1994), does 
not scale to body weight in koalas (Black et al., 2014). Furthermore, the non-steroidal anti-
inflammatory drug (NSAID) meloxicam has a half-life of 24 h in dogs (Busch et al., 1998), 
approximately 13 h in humans (Turck et al., 1996) and 1.19 h in koalas (Kimble et al., 2013a). 
This research project continues the investigation of the PK profile of some antimicrobial drugs 
administered to koalas. Although not a first-line drug as yet for koalas, the opportunity arose 
to investigate the PK profile of the antifungal posaconazole for this species. Therefore, the first 
research chapter of this thesis investigated the in-vivo PK of posaconazole in clinically normal 
koalas to predict its efficacy for the treatment of cryptococcosis. The next three chapters arose 
in response to requests from wildlife veterinarians for information on the PK profiles of the 
first-line veterinary-registered, antibacterial drugs cefovecin and amoxicillin. Hence, the in-
vitro plasma protein binding (PPB) of cefovecin in koalas and some other Australian 
marsupials was investigated. Subsequently, the in-vivo administration of cefovecin and 
amoxicillin in clinically normal koalas was performed to document changes in plasma 
concentration over time. For the determination of plasma concentrations of posaconazole, 
cefovecin and amoxicillin, individual assays, using high-performance liquid chromatography 
(HPLC) were substantially modified from published methods and validated with koala plasma. 
However, modification and validation of both the cefovecin and amoxicillin assays were 
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challenging. Consequently, in order to confirm the HPLC results, bioassays (agar disc diffusion 
and broth microdilution inhibition assays) were also undertaken. However, the broth 
microdilution assay, which had a greater sensitivity than the agar disc diffusion assay, revealed 
substantial variation in plasma antibacterial activity over time in each individual koala and 
between koalas. Therefore, the last research chapter describes a study comparing antibacterial 
activity of different blood matrices (plasma, serum, etc.) collected from unmedicated koalas 
and other species, resulting in expanding directions for future research into controlling 
infectious disease in koalas and other species. 
The literature review, Chapter 1, commences by providing an overview of the fundamentals 
of antimicrobial drug PKs, followed by a brief description of drug assay development and 
validation, and sample preparation for the HPLC. Then, a summary of relevant koala anatomy 
and physiology is provided for readers unfamiliar with this species along with a discussion of 
issues facing the existence of wild koalas in northern New South Wales (NSW) and south-
eastern Queensland (QLD) (two states on the eastern coast of Australia). Then, information is 
provided on the constituents of the koala’s almost exclusive Eucalyptus spp. foliage diet and 
the known biological activities of some of these constituents. A summary of the relevance of 
PK studies undertaken in this species to date, is also provided. A literature review on 
posaconazole, cefovecin and amoxicillin with an emphasis on their use in veterinary practice 
follows. This chapter concludes with the specific aims of this research. 
Chapter 2 describes the development and validation of an HPLC method for determining 
posaconazole concentrations, followed by a description of the PK profile of posaconazole when 
administered at either 3 mg/kg intravenously (i.v.) or 6 mg/kg orally (p.o.) to clinically normal 
koalas. 
Chapter 3 describes the development and validation of an HPLC method for quantitating 
cefovecin concentrations. This chapter also describes an in-vitro study to determine the 
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proportion of cefovecin that binds to the plasma proteins of selected Australian marsupials as 
well as to those of the horse (used as a comparative species). 
Chapter 4 describes the development and validation of an HPLC method for determining 
cefovecin concentrations in vivo and reports on the plasma cefovecin concentrations when 
administered as a single subcutaneous (s.c.) bolus at 8 mg/kg to clinically normal koalas.  
Chapter 5 describes the development and validation of an HPLC method for determination of 
amoxicillin concentrations and then reports on the plasma concentrations of amoxicillin when 
administered as a single s.c. bolus at 10 mg/kg to clinically normal koalas.  
As Chapters 3 and 4 demonstrate that the HPLC analyses of both cefovecin and amoxicillin 
concentrations in koala plasma were problematic, Chapter 6 describes attempts to utilise 
microbiological assays to confirm the concentration of cefovecin and amoxicillin (as 
determined by HPLC) in koala plasma.  
Chapter 7 investigates the endogenous antibacterial activity of plasma, serum, delayed-
coagulation serum and heated serum of koalas compared to other species (cows, horses and 
sheep).  
Finally, Chapter 8 reviews the major findings and limitations of this research, and then, future 
directions are proposed. 
1.2 Literature review 
1.2.1 Pharmacokinetics and pharmacodynamics of antimicrobial drugs 
Four key physiological processes, absorption, distribution, metabolism and excretion (ADME), 
govern the time course of therapeutic drugs in the body. Pharmacokinetics describes 
concentration changes of a drug and its metabolites in the body over time (Riviere, 2009a). The 
area under the drug concentration vs. time curve (AUC) as an important PK construct 
represents the body’s exposure to the drug and the change in drug concentration in the sampling 
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compartment over time (Baggot, 1978). The AUC can be estimated by the trapezoidal rule, 
whereby the area of trapezoids between time points from the first sampling time point after 
drug administration to infinity are totalled to approximate the total AUC (Gabrielsson and 
Weiner, 2012). Although samples can be collected from any biological fluid or tissue after drug 
administration, blood, usually serum or plasma, is more commonly used to measure drug 
concentration changes over time (Tozer, 1981). The AUC is frequently used as the PK 
component for the pharmacokinetic/pharmacodynamic (PK/PD) relationship which predicts 
antimicrobial efficacy, particularly that of concentration-dependant antimicrobial drugs (as 
described below).  
Pharmacodynamics (PD) describes the drug’s response (the effect of the drug) and correlates 
the dose of the drug with its clinical or pharmacological effects (Quintiliani, 2012, Martinez et 
al., 2013). For antimicrobials the ‘response’ is typically either the bacteriostatic (growth 
inhibition) or bactericidal (killing) ability of the drug (Quintiliani, 2012).  
Pharmacokinetic/pharmacodynamic integration, especially well-defined for antimicrobial 
drugs, describes the dose-concentration-response correlation of a drug and its corresponding 
clinical effects. This PK/PD relationship is used to predict the efficacy of the administered drug 
dosage required to achieve the desired clinical outcome (Toutain, 2002). The target plasma 
concentration used to calculate drug dosage for an antimicrobial agent is usually based on its 
minimum inhibitory concentration (MIC) which is defined as the lowest concentration of a 
specified antimicrobial that inhibits growth of a specific pathogen (Baggot and Giguère, 2013).  
Antimicrobials can be described as having either time-dependent or concentration-dependent 
activity (Craig, 1995, Jacobs, 2001). Beta-lactam antibacterials that include penicillins such as 
amoxicillin, and cephalosporins such as cefovecin have a time-dependent bactericidal pattern, 
i.e. the duration of the exposure is the major determinant of the extent of killing, so the goal of 
dosing for these drugs is to optimise the duration of exposure of the pathogen to the 
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antimicrobial (Craig, 1995, Jacobs, 2001). The duration of the time that unbound plasma 
concentrations of the drug exceed the MIC (T % > MIC) is important for determining the 
therapeutic efficacy of beta-lactam antibacterials (this relationship is illustrated in Figure 1-1). 
Successful therapy for amoxicillin is predicted if the effective concentration during the dosage 
interval is maintained above 40 to 50 % MIC for both susceptible gram-positive and gram-
negative pathogens (Jacobs, 2001, MacVane et al., 2014).  
 
  
Figure 1-1 Time-dependent killing of antibacterials such as beta-lactams (amoxicillin and cefovecin), the 
curve shows the association between serum PK with MIC of a pathogen. Drug A presents a concentration 
of 2 mg/L (2 µg/mL) for 50 % of the dosing interval. Drug B presents a concentration of 2 mg/L (2 µg/mL) 
for 30 % of the dosing interval. The Figure is adapted from ‘Optimisation of antimicrobial therapy using 
pharmacokinetic and pharmacodynamic parameters’ by Jacobs (2001) in Clinical Microbiology and 
Infection, 7, 11, p: 590. 
Some antimicrobials, like aminoglycosides and fluoroquinolones, have a concentration-
dependent bactericidal effect and the goal is to achieve a high concentration of the 
Chapter 1- General introduction, literature review and aims of this research 
 
7 
 
antimicrobial at the site of infection to eradicate the pathogen(s) (Jacobs, 2001). The main 
PK/PD parameters used to predict clinical efficacy of concentration-dependent antimicrobials 
are the ratio of AUC24 (the AUC from 0 to 24 h) to MIC; and / or the Cmax (the maximal or peak 
concentration) to MIC, based on the free plasma concentration of the drug (illustrated in Figure 
1-2) (Jacobs, 2001). 
  
Figure 1-2 Concentration-dependent killing (AUC/MIC and Cmax/MIC ratios), the curve shows the 
association between serum PK with MIC of a pathogen. The Figure is adapted from ‘Optimisation of 
antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters’ by Jacobs (2001) in 
Clinical Microbiology and Infection, 7, 11, p: 592.  
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1.2.2 Pharmacokinetic parameters and indices 
1.2.2.1 Absorption and bioavailability 
Absorption is the transfer of drug molecules from the administration site to the bloodstream 
(Urso et al., 2002). The extent and rate of drug absorption depends upon the route of 
administration, the chemical properties of the drug molecules, the drug formulation and the 
physiological factors such as presence of metabolic enzymes around the site of administration 
(Sakai, 2009). The extent and rate of the drug’s absorption are referred to as the drug 
bioavailability (F) (Riviere, 2009a). For intravenous administration, as the drug is transferred 
directly into the bloodstream, absorption is not required, and Fi.v. equals 1.00. Drug 
administration by extravascular routes (p.o., i.m. and s.c.) may result in lower F due to 
incomplete absorption (Sakai, 2009). The bioavailability of extravascular routes is expressed 
as a proportion of the absolute bioavailability of the i.v. route and is expressed in the following 
equation: 
𝐹 =  
 𝑑𝑜𝑠𝑒𝑖.𝑣. ×  𝐴𝑈𝐶𝑒𝑥𝑡𝑟𝑎𝑣𝑎𝑠𝑢𝑙𝑎𝑟 𝑟𝑜𝑢𝑡𝑒
𝑑𝑜𝑠𝑒𝑒𝑥𝑡𝑟𝑎𝑣𝑎𝑠𝑢𝑙𝑎𝑟 𝑟𝑜𝑢𝑡𝑒 × 𝐴𝑈𝐶𝑖.𝑣.
 
1.2.2.2 Drug distribution, volume of distribution and plasma protein binding 
Once a drug enters the bloodstream, it is distributed throughout the body. The delivery of a 
drug from the bloodstream to the site of action is governed by blood flow, capillary 
permeability, drug ability to penetrate the cellular barriers, the physicochemical properties of 
the drug molecule (lipophilic drugs vs polar and ionised drugs) and the degree of binding of 
the drug to blood and tissue proteins, and blood brain barriers transporters.  
The volume of distribution (Vd) is an important indicator of the apparent dilution of the drug 
in body compartments after dosing (DiPiro et al., 2010). Most polar drugs or drugs that are 
ionised in the plasma, such as amoxicillin and cefovecin, have a limited Vd (150 – 300 mL/kg) 
while lipophilic molecules are distributed extensively throughout body compartments, fluids 
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and tissues (Vd: 1 – 3 L/kg) (Baggot and Giguère, 2013). The Vd is a measure of the proportion 
of the total amount of the drug (A) in the body at time t compared to the concentration of the 
drug in the plasma at time t (Cp) (Kwon, 2001, Toutain and Bousquet-Mélou, 2004b): 
𝑉𝑑𝑡 =
𝐴𝑡
𝐶𝑝(𝑡)
 
The Vd is an important parameter required for calculating the dose to provide a therapeutic 
plasma concentration of the drug (Baggot and Giguère, 2013). As the Vd can change with the 
state of drug disposition, there are several volumes of distribution in the scientific literature. 
Using a non-compartmental model, the Vdarea is that obtained during pseudoequilibrium when 
the net drug distribution between the plasma and tissues reaches equilibrium:  
𝑉𝑑𝑎𝑟𝑒𝑎 =
𝑑𝑜𝑠𝑒
𝐾𝑒𝑙 × 𝐴𝑈𝐶
 
where Kel is the elimination rate constant of the drug that is determined by least squares 
regression analysis of the terminal four to six concentration vs time data points (Baggot and 
Giguère, 2013). In other words, the Kel is the slope of the elimination phase. 
The Vdss occurs when the drug is at steady state and is the most robust Vd as it is independent 
of any elimination process but can only be calculated when the drug is administered as an i.v. 
bolus dose or i.v. infusion (Toutain and Bousquet-Mélou, 2004b; Riviere, 2009b; Baggot and 
Giguère, 2013): 
𝑉𝑑𝑠𝑠 =
𝑑𝑜𝑠𝑒𝑖.𝑣. × 𝐴𝑈𝑀𝐶
(𝐴𝑈𝐶)2
 
where the AUMC is the area under the first moment of the plasma concentration vs time curve 
or the area under the curve of the product of plasma concentration and time [(Cp (t) × t] vs time 
on a linear scale (Baggot and Giguère, 2013). 
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Once distributed into the bloodstream, most drugs bind to plasma proteins in different 
proportions, generally reversibly. The bound fraction acts as a reservoir from which the drug 
dissociates to maintain an unbound to bound equilibrium (Lindup and Orme, 1981). The free 
drug fraction crosses membrane barriers to be distributed to tissues, undergo metabolism, be 
excreted and exhibit pharmacological effects (Vuignier et al., 2010). Therefore, the percentage 
of drug bound to plasma proteins (PPB) can significantly affect the drug PK (Vuignier et al., 
2010). Drugs highly bound to plasma proteins (≥ 80 %) are often confined to intravascular 
spaces and cannot undergo immediate distribution to extravascular spaces (Sakai, 2009, Baggot 
and Giguère, 2013). Furthermore, the protein-bound fraction of the drug is not filtered by the 
glomerulus nor readily undergoes renal tubular secretion; therefore, filtration and / or secretion 
by the kidneys is limited to the free drug fraction in plasma (Taft, 2009). 
Both the PPB and dissociation rate of the drug from proteins can be of great importance in the 
PK profile of the drug. Drugs with high PPB and a slow dissociation rate can result in the drug 
circulating only in the plasma and a reduced Vd. Furthermore, the rate of any metabolism might 
be reduced, and clearance can be prolonged (Li et al., 2015); however, if the drug’s affinity for 
the metabolising enzymes is greater than plasma proteins (such as buprenorphine and fentanyl), 
metabolism might not be affected. 
Many methods are available for measuring PPB including equilibrium dialysis (ED) and 
ultrafiltration (UF) (Trainor, 2007a, Trainor, 2007b). Equilibrium dialysis is the most widely 
used method to quantify drug-protein interactions and is usually regarded as the reference 
method; however, a standardised method for PPB measurement has not been prescribed (Beer 
et al., 2009). Both methods are based on separation of the unbound drug from the bound based 
on differences in the molecular size and / or weight. With ED, the free drug diffuses through a 
semipermeable membrane from the plasma chamber into the protein-free buffer chamber (Beer 
et al., 2009, Vuignier et al., 2010). After incubation at body temperature for a specified time, 
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equilibrium is assumed, so the drug concentration is measured in both compartments and the 
CB (bound drug concentration) can be determined (Beer et al., 2009, Vuignier et al., 2010): 
𝐶𝐵 = 𝐶𝑇 − 𝐶𝑈 
where the CT is total plasma concentration of the drug and CU is the free drug concentration of 
the buffer chamber (Beer et al., 2009).  
Using the drug concentration in both chambers after equilibrium (the instruction of Rapid ED, 
Thermo Fisher Scientific, Scoresby, NSW), the percentage of PPB can be determined via: 
PPB (%)  = 100 % − ([
𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑏𝑢𝑓𝑓𝑒𝑟 𝑐ℎ𝑎𝑚𝑏𝑒𝑟
𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑝𝑙𝑎𝑠𝑚𝑎 𝑐ℎ𝑎𝑚𝑏𝑒𝑟
] × 100 %) 
Equilibrium dialysis has the advantages of being simple, reliable and cost-effective (Beer et 
al., 2009). The major drawback of the ED method is its long duration of equilibrium (generally 
12 – 48 h) (Vuignier et al., 2010). However, smaller commercial ‘Rapid ED’ devices such as 
those from Thermo Fisher Scientific (Scoresby, NSW) are now available that require 
approximately 4 h to reach equilibrium. Subtle shifts in oncotic pressure during dialysis can 
cause water flux from the buffer chamber to the plasma chamber (Huang, 1983, Vuignier et 
al., 2010), thereby, diluting the drug-protein complex compartment and an overestimation of 
the unbound drug concentration (Huang, 1983). Nonspecific membrane adsorption of the drug 
can also occur depending on the membrane material, the drug concentration and the degree of 
drug ionisation (Beer et al., 2009) which can lead to further error. 
The UF method uses a device consisting of two reservoirs separated by a semipermeable filter 
which is available in various molecular cut-offs (Vuignier et al., 2010). After a short 
centrifugation time (average 10 – 15 min), centrifugal force pushes molecules through the pores 
of the semipermeable filter into the ultrafiltrate while proteins and drug-protein complexes are 
retained behind the membrane (Beer et al., 2009, Vuignier et al., 2010). The UF method can 
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be affected by temperature, plasma pH, nonspecific binding of the drug to the membrane and 
protein leakage (Vuignier et al., 2010). The ultrafiltrate volumes should not exceed 40 % of the 
initial plasma volume due to alteration of the protein concentration (Beer et al., 2009). 
Advantages of the UF method are its simplicity and rapidity of the procedure (Beer et al., 2009), 
resulting in this method being used in drug discovery, drug monitoring and PK/PD studies 
(Vuignier et al., 2010). 
1.2.2.3 Elimination, metabolism and excretion, clearance and elimination half-life 
Elimination is the removal of the drug from the body and incorporates the processes of 
metabolism and / or excretion. Metabolism is defined as the drug molecule and / or its 
metabolites undergoing a chemical change. Excretion is the elimination of the unchanged 
parent drug and / or its water-soluble metabolites into the urine (i.e. renal excretion being the 
most important pathway for most drugs) and the biliary-intestinal circulation to be either 
recirculated and / or eliminated into the faeces (Sakai, 2009, Riviere, 2009a, Baggot and 
Giguère, 2013). Lipophilic drugs are mainly eliminated by hepatic metabolism that converts 
them into more hydrophilic metabolites to facilitate their excretion (Riviere, 2009a, Baggot 
and Giguère, 2013). Hepatic metabolism is comprised of two phases: Phase I and Phase II. In 
Phase I, a functional group is added to the parent drug via oxidation, reduction, hydrolysis, 
hydration, dechioacetylation and isomerisation (Riviere, 2009a). In Phase II, the products of 
Phase I metabolism are conjugated to make the metabolites more water soluble (Riviere, 
2009a). During metabolism the parent drug can bypass either phase. 
The PK parameters that describe drug disposition (distribution and elimination together) are 
obtained by monitoring the changes in the drug concentration over time, after administration 
of an i.v. bolus. Therefore, these parameters are independent from the drug dosage 
characteristics that will influence the Cmax, Tmax and AUC. The exception, however, is zero 
order elimination and distribution that is dose dependent and saturable. Primary PK parameters 
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include systemic body clearance (Cl), Vd and half-life (t1/2) which is a hybrid parameter that 
reflects changes in Cl and Vd (Benet, 1983, Van De Waterbeemd et al., 2001). Systemic 
clearance is probably the most important PK parameter to consider in defining a dosage 
regimen for maintaining the required therapeutic plasma concentration of the drug (Toutain 
and Bousquet-Mélou, 2004a). Total body clearance (Clt) describes the ability of the body to 
eliminate a drug and represents the overall rate of the drug elimination from the body 
(Hollinger, 2007). As the overall elimination of most drugs obeys a time-dependent manner 
(i.e. first order kinetics whereby a constant proportion of the drug concentration is eliminated 
from the body per unit time), the systemic clearance of most drugs is constant over the 
therapeutic plasma concentration range. That is why clearance is extremely important in 
clinical PK and in defining the drug dosage (Baggot and Giguère, 2013). The Cl is calculated 
by: 
𝐶𝑙𝑡 =  
𝑟𝑎𝑡𝑒 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 (
𝑚𝑔
𝑚𝑖𝑛)
𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 (
𝑚𝑔
𝑚𝑙 )
 
As the total amount of the drug administered i.v. is assumed to be finally eliminated, the total 
amount of the drug administered and eliminated is equal (Jang et al., 2001). Thus, 
𝐶𝑙 =
𝑑𝑜𝑠𝑒𝑖.𝑣.
𝐴𝑈𝐶𝑖.𝑣.
 
The half-life of a drug defines the time that is required for the drug plasma concentration to fall 
by one half through the elimination process (Baggot and Giguère, 2013). The plasma 
elimination half-life is governed by Cl and Vd (Van De Waterbeemd et al., 2001) and can be 
determined via: 
𝑡1
2
=
0.693 × 𝑉𝑑
𝐶𝑙
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where 0.693 is the natural log of 2 (ln 2). As can be seen in the equation, the half-life can be 
prolonged by increasing the Vd and decreasing the Cl (Van De Waterbeemd et al., 2001). 
As it is assumed that the overall elimination of antimicrobials obeys first order kinetics, their 
half-lives are independent of the administered dose (Baggot and Giguère, 2013). The half-life 
is also calculated by: 
𝑡1
2
=
0.693
𝐾𝑒𝑙
 
where Kel is the elimination rate constant of the drug (Baggot and Giguère, 2013). 
1.2.2.4 Mean residence time 
The mean residence time (MRT) expresses the average total time that molecules of a single 
dose of a drug spend in the body (Baggot and Giguère, 2013). It is the statistical moment 
analogy to t1/2 and can vary with the route of administration. The MRT is calculated by the 
derived AUMC (defined in Section 1.2.2.2) divided by the AUC (Baggot and Giguère, 2013). 
1.2.2.5 The peak concentration and the peak time 
The peak concentration (Cmax) is related to rate of absorption, rate of elimination, dose and 
fraction of the dose absorbed. The time to reach Cmax (Tmax) occurs when rate of absorption 
equals rate of elimination. The Cmax and Tmax are determined either visually or mathematically 
from the change in drug concentration over time (Urso et al., 2002). 
1.2.2.6 Pharmacokinetic analysis 
To transform the plasma drug concentration vs time profile into primary PK parameters (e.g. 
Cl, Vd and t1/2) and other secondary PK parameters (or indices) (e.g. Cmax, Tmax, MRT and 
AUC), one of two common mathematical approaches can be applied: a compartmental or a 
non-compartmental approach (Bonate, 2011). The compartmental approach assumes that the 
body consists of multiple compartments and proposes a hypothetical model to estimate PK 
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parameters and indices (Bonate, 2011). The non-compartmental analysis approach uses a 
numeric method and does not rely on compartmental segmentation of the body (Yamaoka et 
al., 1978); it can be applied to any route of administration to calculate primary PK parameters 
such as Cl, Vd and t1/2, and secondary parameters (or indices) such as F, Cmax, Tmax, AUC and 
MRT. The only assumption in the non-compartmental model is that absorption and disposition 
of the drug obey first-order kinetics (Baggot and Giguère, 2013).  
In order to perform the PK analyses required for this research, commercial assays for 
posaconazole, cefovecin and amoxicillin were not available. Thus, assays for all three drugs 
were developed by the author. The next section of the literature review addresses HPLC for 
the quantification of drug concentrations in plasma, including a description of sample 
preparation and assay validation. 
1.2.3 Determination of drug concentrations in biological matrices 
There are many bioanalytical procedures to quantify drug concentrations in biological matrices 
for a variety of purposes including PK studies. The aim is to develop reliable, accurate, fast 
and efficient procedures for qualitative and quantitative analyses (Nováková and Vlčková, 
2009). Bioanalytical methods can be categorised into three groups: microbiological assays 
(bioassays) (Bennett et al., 1966, Simon and Yin, 1970), physicochemical assays such as HPLC 
(Nováková and Vlčková, 2009) and immunological assays such as enzyme-linked 
immunosorbent assay (ELISA) (Findlay et al., 2000).  
1.2.3.1 High-performance liquid chromatography 
Any analytical technique that requires separation of different molecules from the sample 
mixture is termed chromatography (Meyer, 2004). For separation, the sample mixture is 
introduced into the mobile phase (either gas or liquid) which carries the sample through a 
stationary phase (e.g. column or plane) (Meyer, 2004, Moldoveanu and David, 2017d). While 
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passing through the stationary phase, the different molecules are retained from the flowing 
mobile phase and are later released back into the mobile phase as an aggregation which 
undergoes detection and is displayed in the output (Moldoveanu and David, 2017d). If liquid 
or gas is used as the mobile phase, the process is known as liquid chromatography (LC) or gas 
chromatography (GC), respectively. The stationary phase can be either a solid, surface-active, 
porous material in small-particle form or a thin film of liquid coated on a solid support or 
column wall (Meyer, 2004).  
Liquid chromatographic separation modes include adsorption chromatography, reversed-phase 
chromatography, chemically-bonded-phase chromatography, ion-exchange, ion-pair and ion 
chromatography, size-exclusion chromatography, and affinity chromatography (Meyer, 2004). 
One of the most important mechanisms of chromatographic separation is based on the polarity 
of the whole molecule, or that associated with specific regions of the molecule (Moldoveanu 
and David, 2017c). With adsorption chromatography, a relatively polar material with a high 
specific surface area (e.g. silica being the most popular, or alumina and magnesium oxide) is 
used as the stationary phase and the mobile phase is relatively non-polar incorporating an 
organic solvent ranging from heptane to tetrahydrofuran. The separation effect is provided by 
different attractions of various molecules in the mixture to the stationary phase. Generally, 
polar (a.k.a. water-soluble, hydrophilic or lipophobic) compounds are eluted later than non-
polar (a.k.a. fat-soluble, hydrophobic or lipophilic) compounds (Meyer, 2004). In reversed-
phase chromatography, the rules of the adsorption chromatography are reversed, and the 
stationary phase is non-polar while the mobile phase is relatively polar, and generally, non-
polar compounds are eluted later than polar compounds (Meyer, 2004). 
High-performance liquid chromatography can be a very efficient system to separate 
complicated mixtures of different compounds by molecular weight, polarities and acid–base 
properties in various biological matrices (Nováková and Vlčková, 2009). As the stationary 
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phase contains very small particles, high pressure is required to force the mobile phase through 
the column and this gives rise to the term ‘high-pressure liquid chromatography’ (Meyer, 
2004). The detection output is represented as a chromatogram, with the x-axis as the assay run 
time and the y-axis as the signal intensity (Meyer, 2004). The chromatogram can provide 
directly both qualitative and quantitative information because, for a standardised set of 
conditions, each compound in the mixture has its own elution or retention time (the point at 
which the signal appears on the recorder or screen) which is displayed as a peak of which both 
the area and height are proportional to the amount of the corresponding substance (Meyer, 
2004, Moldoveanu and David, 2017c). 
The HPLC system comprises of a solvent supply system (solvent reservoir and degasser), a 
high-pressure pump, a sample injection device that delivers the samples into the mobile phase, 
a column or stationary phase (usually preceded by a smaller, more readily disposable pre-
column that protects the column from blockages, although separation occurs within the main 
column) and detector(s) for the eluates (i.e. the components leaving the column) (Meyer, 2004, 
Moldoveanu and David, 2017c). The whole system is connected to a computer for controlling 
all components (mobile phase composition and / or pressure, sample injection volume, column 
temperature, etc.) and data recording and processing (see Figure 1-3). The mobile phase 
composition can be changed (i.e. the percentage of each solvent during the analysis run time 
for each sample can be increased or decreased) known as a ‘gradient’ elution or can be kept 
unchanged which is referred to an ‘isocratic’ elution (Moldoveanu and David, 2017c). 
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Figure 1-3 Schematic diagram of an HPLC unit, 1: solvent reservoir; 2: transfer line with frit; 3: pump 
(with manometer); 4: sample injection; 5: column (with oven); 6: detector; 7: waste; 8: data acquisition. 
The Figure is adapted from ‘Practical High-Performance Liquid Chromatography’ Meyer V. R. 4th 
edition, Chapter 1: Introduction, p: 9 (Meyer, 2004).  
The detection and measurement in the HPLC system is generally based on the physicochemical 
properties of the separated analytes which are different from that of the mobile phase 
(Moldoveanu and David, 2017d). Accordingly, the HPLC system can incorporate various 
detector types including ultraviolet visible (UV-Vis), photo diode array (PDA), electrical 
conductivity, fluorescence, mass spectrometer (MS) and refractive detector (Choi, 2011). The 
UV-Vis is only adjustable to a single wavelength of interest while the PDA detector, which is 
the advanced form of UV-Vis detector, can register multiple wavelengths simultaneously 
(Poole, 2003). Therefore, the PDA is suitable to monitor the spectrum for identifying the 
optimal wavelength to detect the target molecule(s). 
Different detectors have different sensitivity ranges such as 0.1 – 1 ng for a UV-Vis detector; 
1 – 10 pg for a fluorescence detector and 1 pg – 1 ng for a mass spectrometer (Moldoveanu and 
David, 2017b, Moldoveanu and David, 2017c).  
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As many compounds absorb UV in the range of 190 – 800 nm, and light absorption is 
proportional to the concentration of the analyte of interest (Moldoveanu and David, 2017b), 
the UV-Vis is the most frequently used detector worldwide for HPLC (Poole, 2003, 
Moldoveanu and David, 2017b). However, due to the lack of specificity, the UV-Vis detector 
is not routinely used for characterisation of unknown compounds (Moldoveanu and David, 
2017b, Moldoveanu and David, 2017c). 
Florescence detection is intrinsically more sensitive than absorption detection, but its 
application is restricted because only a small proportion of organic compounds and drugs that 
absorb light are naturally florescent (Poole, 2003, Moldoveanu and David, 2017c).  
In mass spectrometry molecules are ionised and separated based on their mass-to-charge ratio 
(m/z). A mass spectrum is a fingerprint of the molecule and therefore, MS detection typically 
is capable of identifying unknown compounds (Poole, 2003, Moldoveanu and David, 2017a). 
Liquid chromatography / mass spectrometry (LC/MS) has considerably higher sensitivity (can 
detect concentrations as low as pg/mL) and selectivity, and is a powerful instrument for 
identification and determination of the compounds (Moldoveanu and David, 2017a). 
The refractive detector has the lowest sensitivity compared to other detectors but is the best 
option for compounds with minimal or no UV absorption (such as alcohols, carbohydrates, 
fatty acids and polymers) (Siddiqui et al., 2017).  
1.2.3.2 Sample preparation 
The sample is the biological material that contains the analyte, which is the molecule of interest, 
and the matrix which comprises the remaining sample components (Moldoveanu and David, 
2017d). Therefore, both parts of the sample must be considered to ensure accurate and reliable 
drug concentration quantification. Sample preparation (a.k.a. sample extraction, sample clean-
up or sample treatment) is usually required prior to HPLC analysis to separate the analyte of 
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interest from other interfering substances present in the biological matrix and to minimise or 
possibly eliminate those matrix substances (Kole et al., 2011, Moldoveanu and David, 2017d). 
There are three conventional sample preparation techniques: liquid-liquid extraction (LLE), 
protein precipitating extraction (PPE) and solid phase extraction (SPE) (Kole et al., 2011). 
In LLE, non-polar immiscible organic solvents such as ethyl acetate, chloroform, tert-butyl 
methyl ether (TBME) or hexane are used to partition the analyte of interest into either the 
aqueous or organic layer. Polar compounds are typically concentrated in the aqueous layer 
while non-polar drugs are extracted into the organic layer (Li et al., 2006). 
The PPE method is a fast sample clean-up in which proteins are converted into insoluble 
compounds and precipitated using organic solvents, salts, acids or metal ions. Organic solvents 
such as acetonitrile and methanol reduce the dielectric constant of the plasma protein solution, 
thereby, facilitating electrostatic protein interactions which precipitate proteins (Polson et al., 
2003). However, other endogenous insoluble components in the biological matrix cannot be 
removed by the PPE which can cause more interferences and increase the pressure in the HPLC 
system, thereby, blocking the system or damaging the column (Polson et al., 2003).  
Solid phase extraction resembles the liquid chromatographic process for separating the drug 
from the biological matrix. The SPE apparatus usually consists of a cartridge that contains one 
of many sorbent-packing materials. Intermolecular forces between the sorbent, the sample and 
different solvents lead to the analyte being initially retained within the sorbent but in the final 
step is eluted from the sorbent. Different types of SPE phases include reversed-phase (RP-
SPE), normal-phase and ion exchange (Li et al., 2006). The latter is more selective than RP-
SPE and distinguishes analytes and matrix in terms of their relative hydrophobicity (Majors, 
2013). A typical non-polar SPE has four steps: conditioning the cartridge, loading the samples, 
washing and eluting the analytes, and each of these steps requires optimisation for separating 
the analyte of interest (Majors, 2013).  
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1.2.3.3 Validation of analytical methods 
Analytical method validation is required to demonstrate that the method used to quantitate the 
analyte(s) in a given biological matrix (e.g. plasma, serum, urine, etc.) is suitable for the 
intended use. The fundamental requirements for validation of an analytical method include 
demonstrating selectivity (or specificity), sensitivity, accuracy, precision, linearity of the 
calibration range, recovery and stability of the analyte in pre-spiked samples (i.e. samples 
containing known concentrations of the drug) (Food and Drug Administration, 2001, 
International Conference on Harmonisation, 2005, Tiwari and Tiwari, 2010). When there is a 
requirement to modify the chromatographic conditions or sample preparation techniques, 
revalidation of the modified aspects of the assay should be considered (Dadgar et al., 1995). 
Selectivity (or specificity) describes the ability of an analytical method to distinguish and 
quantitate the analyte of interest from other compounds including endogenous matrix elements, 
metabolite(s), decomposition products, concomitant medication and other exogenous 
xenobiotics in the sample (Food and Drug Administration, 2001). The assay should be selective 
(able to differentiate the target substance) at all concentration ranges of the assay, especially at 
the lower limit of quantification (LLOQ). Blank samples (i.e. matrix sample containing neither 
the drug of interest nor the internal standard) should be analysed for the presence of endogenous 
peaks that may interfere with that of the target substance (Food and Drug Administration, 
2001).  
When small changes in the analyte concentration result in large changes in the analytical 
response function, the method is considered sensitive (Karnes et al., 1991, Causon, 1997). 
Sensitivity is expressed as the LLOQ and the upper limit of quantification (ULOQ) which are 
the limits of calibration or standard curve range. The LLOQ is the lowest concentration of an 
analyte that can be quantified with acceptable precision and accuracy. Any values that fall 
outside the calibration range cannot be quantified reliably (Causon, 1997, Tiwari and Tiwari, 
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2010) and is not acceptable (Peters et al., 2007). Therefore, any values below the LLOQ can 
only be semi-quantitated or presented as qualitative data. The lowest limit of detection (LLOD) 
is the lowest concentration of an analyte in the sample that can be detected or differentiated 
from background noise, but it is not necessarily quantitated as an exact value (International 
Conference on Harmonisation, 2005, Peters et al., 2007). One approach to determine the LLOQ 
and LLOD is based on the standard deviation (SD) of the response and the slope of the standard 
curve (International Conference on Harmonisation, 2005): 
𝐿𝐿𝑂𝐷 =
3.3𝜎
𝑆
 
𝐿𝐿𝑂𝑄 =
10𝜎
𝑆
 
where σ is the SD of the response (e.g. the SD of y-intercepts of the regression lines) and S is 
the slope of the standard curve of the analyte.  
Accuracy (expressed as bias, %) defines the closeness of the mean of the measured values and 
the true values (concentration) whereas the precision (expressed as the coefficient of variation, 
CV, %) refers to the closeness of repeated sample values. The bias and CV should be within 
15 % of the actual values, except for the LLOQ where it should not be more than 20 % 
(International Conference on Harmonisation, 2005). Quality control (QC) samples usually 
comprise of three known concentrations: low, middle and high, each determined with at least 
three replicates that undergo HPLC analysis and are used to confirm both intra- and inter-day 
accuracy and precision in order to satisfy the International Conference of Harmonisation (2005) 
criteria.  
𝐵𝑖𝑎𝑠 (%)  =  
(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 − 𝑡𝑟𝑢𝑒 𝑣𝑎𝑙𝑢𝑒)
𝑡𝑟𝑢𝑒 𝑣𝑎𝑙𝑢𝑒
 × 100 
 𝐶𝑉 (%) =
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝑆𝐷)
𝑚𝑒𝑎𝑛
× 100 
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Recovery (expressed as %) characterises the extraction efficiency of an analytical method. The 
recovery is performed by comparing the analytical results of the extracted spiked samples (at 
three concentrations: low, medium, and high) with unextracted standards at the same initial 
concentration in a simple matrix such as phosphate buffered saline (PBS) or mobile phase that 
represents 100 % recovery. The greater recovery of the analyte from the matrix, the more 
desirable; but in some situations, the recovery might be compromised intentionally for better 
selectivity. Nevertheless, recovery results are acceptable if they are consistent, precise and 
reproducible (Dadgar et al., 1995, Food and Drug Administration, 2001).  
An internal standard (IS) is widely used in LC to increase the accuracy and precision of the 
results by minimising the inherent system errors such as volume errors caused by solvent 
evaporation, sample preparation procedures and injection-to-injection errors. Accordingly, a 
known volume and concentration of the internal standard is added to the standard, QC and 
actual study samples prior to the analysis. Therefore, instead of using the absolute peak height 
or area of the analyte, the ratio of its peak height or area to that of the internal standard is 
applied to plot the standard curve and to determine the concentration of the unknown samples 
(Haefelfinger, 1981, Usher et al., 2015).  
To ensure a reliable assay, the relationship between the analyte concentration in the sample and 
the corresponding detector response should be determined by analysing the pre-spiked matrix-
based standard samples and plotting the corresponding results vs the respective concentrations. 
The standard (calibration) curve is further assessed statistically to check the linearity (Tiwari 
and Tiwari, 2010). The standard curve should consist of a blank sample, a zero sample (i.e. 
matrix sample containing IS), six to eight non-zero (pre-spiked) samples which cover the 
expected range, including the LLOQ. The same biological matrix as the samples in the intended 
study should be used to prepare a standard curve and the QC samples, i.e. spiking the samples 
with known concentrations of the analyte (Food and Drug Administration, 2001). 
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Stability tests should be conducted on the stock solution and QC samples (high and low 
concentrations) to evaluate the drug(s) maintenance during the workup process, laboratory 
conditions, three freeze/thaw cycles (if the real samples are kept frozen) and long-term storage 
(under the same condition as real study samples). The data obtained from the analysis of the 
study samples should be accompanied by information regarding the stability of the drug in a 
given matrix under specific conditions, to ensure that the drug concentration in the samples has 
been maintained during storage, prior to analysis (Dadgar et al., 1995).  
As this research project is interested in the PK profiles of selected antimicrobial drugs in the 
koala, the next section describes some characteristics of the koala to appreciate the relevance 
of the outcomes of the research chapters.  
1.2.4 The koala 
The koala (Phascolarctos cinereus) is an iconic Australian marsupial that epitomises the 
diversity of Australia’s unique fauna. As a significant tourist attraction, the koala’s economic 
contribution to the Australian economy via international and domestic tourism has been 
estimated to be worth between $1.1 to $2.5 billion annually (Hundloe and Hamilton, 1997, 
NSW Government Information, 2017). The koala is a member of the mammalian infraclass 
Marsupialia, and a common characteristic of marsupial species is that they carry and protect 
their young in a pouch (Andrew, 2015). 
Mature koalas weigh 4 to 15 kg, with the average weight between 5 to 8 kg of those that live 
in the more northern and warmer regions of their range. Koalas in QLD are smaller than those 
in southern Australia such as Victoria (Vic.) where mature male koalas average 12 kg 
(Blanshard and Bodley, 2008). Koalas are nocturnal and generally have a sedentary, arboreal 
lifestyle which is facilitated by a low metabolic rate to conserve energy and compensate their 
low energy diet (Dawson and Hulbert, 1970, Blanshard and Bodley, 2008). The body 
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temperature of mature koalas is 35.5 to 36.5 °C (Blanshard and Bodley, 2008). The metabolic 
rate of marsupials is approximately 30 % lower than that of eutherian species (species which 
nourish the foetus via a placenta) (Dawson and Hulbert, 1970).  
The koala diet is almost exclusively Eucalyptus spp. foliage (Hume, 1999). Approximately 90 
% of the koala’s daily energy requirements are met by digestion of the cell content fraction of 
eucalypt leaves. Eucalyptus spp. leaves are highly fibrous, low in protein and contain high 
concentrations of cellulose fibres and a variety of phytochemicals such as phenolics, tannins, 
cyanogenic glycosides and essential oils (EOs). Many of these phytochemicals are described 
as plant secondary metabolites (PSMs) (Freeland and Janzen, 1974, Hume, 1999, Stupans et 
al., 2001, El-Merhibi et al., 2007). Plants use PSMs as a defence to avoid ingestion by 
herbivores or insects, or attack by microbial disease (Freeland and Janzen, 1974). Mature 
koalas are estimated to ingest 62 to 324 g DM day–1 of Eucalyptus foliage (Marsh et al., 2014). 
Consumption of a similar quantity of Eucalyptus oil by most other species would be toxic and 
potentially fatal (Stupans et al., 2001). 
The koala is a monogastric hindgut fermenter. The digested carbohydrates, lipids, and amino 
acids are absorbed in the small intestine (Cork et al., 1983); however, the small intestine is 
relatively short compared to other species, and particulate and soluble materials transit through 
the small intestine rapidly (approximately 6 and 60 minutes, respectively) (Cork and Warner, 
1983). The koala has the largest caecum relative to body size compared to other species 
(Blanshard and Bodley, 2008). Fermentative digestion of their eucalypt foliage diet, some 
protein synthesis and denaturing of secondary compounds occurs slowly in the caecum (Snipes 
et al., 1993, Hume, 1999, Blanshard and Bodley, 2008). Figure 1-4 shows the gastrointestinal 
tract from stomach to rectum of the mature koala.  
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Figure 1-4 Gastrointestinal tract from stomach to rectum of the mature koala, 
drawn by Sally Pope. From ‘Review of some pharmacokinetic and 
pharmacodynamic properties of anti-infective medicines administered to the 
koala (Phascolarctos cinereus)’ by Govendir (2017) in Journal of Veterinary 
Pharmacology and Therapeutics, https://doi.org/10.1111/jvp.12435. 
Plant secondary metabolite absorption in koalas seems to be restricted by some physiological 
defence systems such as the involvement of gut flora to initiate some breakdown of these 
substances (Freeland and Janzen, 1974) and the rapid transit time through the small intestine 
that potentially reduces the degree of absorption (Cork and Warner, 1983). The koala also 
possesses some extremely efficient hepatic metabolic enzymatic pathways such as those 
mediated by cytochrome P450 (CYP) 2C that could accelerate the elimination of some 
absorbed PSMs (McLean and Foley, 1997, Stupans et al., 2001, El-Merhibi et al., 2007, Kimble 
et al., 2014). 
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Wild koalas are found in forests and woodlands of eastern Australia from QLD to Vic. 
Continued clearing of natural koala habitats has fragmented and scattered wild populations in 
some areas of QLD, NSW, Vic. and South Australia (SA) (Blanshard and Bodley, 2008). The 
population of wild koalas has substantially diminished in QLD, NSW and the Australian 
Capital Territory (ACT) due to urban expansion - which necessitated the Australian Federal 
Government officially classifying wild koala populations in these locations as ‘vulnerable to 
extinction’ in April 2012 (Department of Sustainability Environment Water Population and 
Communities, 2012). Wild koala populations are also threatened by bushfires and droughts, 
traumatic injuries from vehicle strikes, predation by feral and domestic species, pollutants and 
disease, particularly the infectious disease chlamydiosis in northern populations (Melzer et al., 
2000, Griffith et al., 2013, Narayan and Williams, 2016). Many rehabilitation centres and non-
governmental organisations are devoted to the care and conservation of koalas (Griffith, 2010). 
Consequently, veterinary therapeutic drugs registered for domestic species are frequently 
administered to treat traumatised and diseased koalas (Blanshard and Bodley, 2008). 
The most significant infectious disease of the koala is chlamydiosis caused by either Chlamydia 
pecorum or Chlamydia pneumoniae (Jackson et al., 1999, Polkinghorne et al., 2013). Clinical 
signs of this disease include ocular and urogenital tract disease which can lead to blindness and 
/ or infertility, respectively (Obendorf and Handasyde, 1990, Polkinghorne et al., 2013). 
Another significant disease in wild and captive koalas is cryptococcosis caused by the fungal 
yeast Cryptococcus gattii that is a part of the Cryptococcus neoformans species complex 
(Krockenberger et al., 2003, Chen et al., 2014). The treatment of both infectious diseases in 
koalas has been challenging (Govendir, 2017). Koala retrovirus (KoRV) is found in the genome 
of many koalas and is considered to increase the risk of other diseases such as chlamydiosis by 
supressing the immune system (Maher and Higgins, 2016).  
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Many studies investigated the anatomical and physiological adaptations of the koala to its diet 
while less attention has been paid to the therapeutic properties of the eucalypt foliage and its 
effect on the koala’s body. Constituents of Eucalyptus plants especially their EOs have shown 
promising applications in medicinal products for human and veterinary use due to their 
reported biological activities including their antimicrobial efficacy (Turek and Stintzing, 
2013). As the last chapter of this thesis is focussed on the antibacterial activity of koala blood 
matrices, the next section provides a summary of reported bioactivities for Eucalyptus spp. 
constituents. 
1.2.5 The constituents and biological activities of Eucalyptus spp.  
The Eucalyptus genus of plants belongs to the Myrtaceae family, native to Australia with 
approximately 900 species and subspecies (Russo et al., 2015). Species grow in a wide range 
of climatic conditions and are widely distributed throughout Australia except in arid central 
Australia and dense rainforests (reviewed Ghisalberti, 1996). Different parts of Eucalyptus 
trees (e.g. roots, leaves and tree gum) have traditionally been used by indigenous Aboriginal 
populations for medicinal purposes such as antiseptics and as a treatment for colds, wounds 
and eye infections (Clarke, 1987, Wigmore et al., 2016). Likewise, in Brazilian folk medicine, 
constituents of Eucalyptus spp. plants are used for a variety of medicinal purposes such as anti-
inflammatory, analgesic and antipyretic remedies and for respiratory infections such as colds, 
flu and sinus congestion (Silva et al., 2003). 
Extracts from Eucalyptus spp. plants reportedly have various biological activities such as 
analgesic, anti-inflammatory (Silva et al., 2003), anti-hyperglycaemic (Gray and Flatt, 1998) 
and antioxidant (Lee and Shibamoto, 2001) properties as well as being used as insect repellents 
(Nerio et al., 2010); eucalypt EOs are responsible for most of these properties. The EOs are 
odorous, volatile, organic compounds produced from the secondary metabolism of aromatic 
plants. They are complex and variable mixtures composed of hydrocarbons (e.g. monoterpenes 
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(C10H16) and sesquiterpenes (C15H24) such as 1,8-cineole and α-pinene) and oxygenated 
compounds (e.g. alcohols, esters, ethers, aldehydes, ketones, lactones, phenols and phenol 
ethers), and are usually concentrated in the leaves, stems, bark or fruit (Conner, 1993, El-
Merhibi et al., 2007, Nerio et al., 2010). Only 10 % of all 3,000 known EOs have commercial 
importance in the cosmetic, food and pharmaceutical industries (Nerio et al., 2010). The 
composition of EOs varies considerably between plant species and varieties as well as within 
the same variety from different geographic areas (Nerio et al., 2010). Plant health, the age of 
the leaves, the season and soil factors as well as habitat and climate can also affect EO 
composition (El-Merhibi et al., 2007, Turek and Stintzing, 2013).  
Additionally, Eucalyptus extracts and EOs have antibacterial and antifungal activities against 
a wide range of microorganisms (Sartorelli et al., 2007, Ghalem and Mohamed, 2008, Gilles et 
al., 2010, Tyagi and Malik, 2011, Elaissi et al., 2011, Wigmore et al., 2016). In-vitro studies 
show that EOs of E. globulus exhibit antibacterial activity against ATCC strains of some 
pathogens including Escherichia coli (E. coli), Bacillus cereus, Klebsiella pneumonia and 
Staphylococcus aureus (S. aureus) (Tohidpour et al., 2010). The S. aureus is the most 
susceptible pathogen to the EOs of E. globulus (MIC to inhibit S. aureus = 51.36 µg/mL). 
Some isolates of methicillin-resistant S. aureus (MRSA) tested in this study also displayed 
susceptibility to the EOs of E. globulus (MIC to inhibit MRSA ≤ 85.6 µg/mL). Similarly, the 
EO of E. globulus MIC was lower to inhibit gram-positive pathogens (B. subtilis and S. aureus) 
(MIC to inhibit both pathogens = 2.25 mg/mL) than gram-negative pathogens (the MIC to 
inhibit E. coli = 4.5 mg/mL; MIC to inhibit Pseudomonas aeruginosa and P. fluorescens = 9 
mg/mL) (Tyagi and Malik, 2011). An alcoholic extract (70 % ethanol) of E. globulus leaves 
was prepared and tested for antibacterial activity against a range of gram-positive and gram-
negative pathogens (Dezsi et al., 2015). Eucalyptus globulus exhibited higher antibacterial 
activity against S. aureus (MIC = 50 µg/mL) and Listeria monocytogenes (MIC = 30 µg/mL) 
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than E. coli, Bacillus subtilis and Salmonella typhimurium (the extract MIC to inhibit all three 
isolates > 100 µg/mL) (Dezsi et al., 2015).  
Essential oils of 20 Eucalyptus species were characterised based on their composition and their 
antibacterial activity inhibiting E. coli, P. aeruginosa, S. aureus and Enterococcus faecalis was 
reported by Elaissi et al. (2011). Antibacterial activity varied considerably with the EOs from 
each plant species and the bacterial strains (Elaissi et al., 2011). Generally, the most susceptible 
and resistant strains were S. aureus and P. aeruginosa, respectively (Elaissi et al., 2011).  
In an in-vivo study, dried leaves of E. globulus were incorporated in the diet (62.5 g/kg) and 
drinking water (2.5 g/L) of male albino rats with or without diabetes. E. globulus inhibited 
candidiasis in both normal and diabetic rats and improved the condition of both groups 
compared to controls (Bokaeian et al., 2010). The EOs extracted from E. globulus also 
stimulated the innate cell-mediated immune response by stimulation of phagocytosis both in 
vivo and in vitro (Serafino et al., 2008). 
Prior to 2010, there were no published studies on PK profiles of any first-line therapeutic drugs 
in koalas. Up till then, the dosage regimens of therapeutic drugs for koalas were similar to that 
administered to dogs and cats (Blanshard and Bodley, 2008).Several studies have been 
published since 2010 on the PK of therapeutic drugs administered to koalas (Griffith et al., 
2010, Govendir et al., 2012, Black et al., 2013a, Black et al., 2013b, Kimble et al., 2013a, 
Black et al., 2014, Govendir et al., 2015, Budd et al., 2017). Most of these demonstrated 
differences in the PK profile such as absorption and metabolism of the investigated drugs in 
koalas compared to other species. Published PK studies in koalas include some antimicrobials 
(fluoroquinolones, fluconazole and phenicols) and the NSAID, meloxicam that are summarised 
below. 
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1.2.6  Pharmacokinetic studies of some therapeutic drugs in the koala 
1.2.6.1 Fluoroquinolones 
The first published study on any therapeutic drug in koalas investigated the absorption of two 
fluoroquinolones, enrofloxacin and marbofloxacin, administered p.o. and s.c. to diseased 
koalas (Griffith et al., 2010). Prior to this study, the suggested dosage of enrofloxacin was 5 
mg/kg p.o. twice daily (Blanshard and Bodley, 2008) for the prophylaxis of some bacterial 
infections and as a potential systemic treatment for chlamydiosis. Both drugs demonstrated 
relative poor oral absorption compared to s.c. administration; however, the extent of s.c. 
absorption was lower than that reported in some other species such as the dog (Griffith et al., 
2010). The suggested dosage of enrofloxacin at 5 mg/kg seemed inefficacious and unlikely to 
fulfil the PK/PD target (Cmax/MIC ratio = 8 – 10) which required the Cmax to be at least 2.5 
µg/mL. Although the clinical signs of chlamydiosis improved with enrofloxacin and the 
bacterial load reduced during the treatment, the bacterial load increased following treatment 
withdrawal (Griffith, 2010). Subsequently, an additional study investigated the disposition of 
enrofloxacin after i.v. injection (10 mg/kg) in clinically normal koalas (Black et al., 2013a). 
The outcome was consistent with the earlier conclusions that enrofloxacin plasma 
concentrations at 10 mg/kg appeared inadequate against chlamydial pathogens but might be 
efficacious to treat pathogenic bacterial infections susceptible to drugs with MICs ≤ 0.03 
µg/mL (Black et al., 2013a). 
1.2.6.2 Phenicols 
As chloramphenicol was the other drug used for the systemic treatment of chlamydiosis in 
koalas in 2012, the PK profile of chloramphenicol base (administered at 60 mg/kg s.c. daily) 
and its effect on chlamydial shedding when administered to koalas infected with chlamydiosis 
was described (Govendir et al., 2012). Despite preventing chlamydial shedding for 2 – 63 days 
after treatment cessation, the dosage failed to control severe urogenital disease (Govendir et 
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al., 2012). A subsequent study reported the PK profile of chloramphenicol sodium succinate 
administered at 25 mg/kg i.v. to clinically normal koalas and compared the PK profile of this 
formulation to the ‘base’ formulation, both administered as single boluses at 60 mg/kg s.c. 
(Black et al., 2013b). The PK profile of the sodium succinate after i.v. injection was similar to 
those reported in other species. However, as expected, there were significant differences 
between the PK of two formulations when administered s.c. The sodium succinate 
demonstrated much higher plasma concentrations and was eliminated much faster than the oily 
base which exhibited an absorption rate limited profile (Black et al., 2013b). When both 
formulations were administered at 60 mg/kg s.c., the median elimination half-life of the sodium 
succinate was 1.45 h and the base was 13.14 h (Black et al., 2013b). 
In 2013, due to the withdrawal of chloramphenicol base formulation from the Australian 
veterinary market, a research project was undertaken to investigate the PK of florfenicol 
following i.v. and s.c. administrations as an alternative to chloramphenicol to treat 
chlamydiosis in koalas (Budd et al., 2017). The results were not promising and florfenicol 
appeared unlikely to be efficacious against chlamydiosis at doses tolerable to koalas. It was 
recommended not to administer florfenicol s.c. as repeated administration increases the risk of 
potentially fatal dysbiosis. 
1.2.6.3 Fluconazole 
The PK profile of the antifungal fluconazole (administered at 10 mg/kg p.o. and i.v.) in 
clinically normal koalas revealed absorption rate limited disposition after oral administration 
(Black et al., 2014). Oral bioavailability was low and variable in contrast with almost complete 
oral bioavailability (1.00) in most other species. The plasma protein binding of fluconazole was 
approximately four times higher than that in other species. Although the Vd exhibited an 
allometric relationship with other species, Cl and t1/2 did not. The Cl of fluconazole was about 
seven times faster in the koala than the value predicted by bodyweight scaling. The suggested 
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dose rate 10 mg/kg every 12 h was predicted to be inadequate in the koala to meet the proposed 
PK/PD target for Cryptococcus gattii (proposed AUC/MIC = 192 vs estimated AUC/MIC = 
median: 6.92, range: 2.57 – 12.66). 
1.2.6.4 Other antimicrobials with severe side effects when administered to koalas  
Although macrolides and tetracyclines are used to treat chlamydiosis in humans (Senn et al., 
2005, Kohlhoff and Hammerschlag, 2015), erythromycin (Brown et al., 1984) and 
oxytetracycline (Osawa and Carrick, 1990) are reported to cause emaciation and death in 
koalas. Some antimicrobials, particularly those active against anaerobic pathogens, can cause 
life-threatening dysbiosis in koalas (Osawa et al., 1993). Doxycycline administration p.o. 
(either 0.25 mg/kg twice daily for 8 days or 2.5-5 mg/kg once daily) and i.m. (2.5 mg/kg once 
weekly for 28 days) caused dysbiosis in koalas (Griffith, 2010).  
1.2.6.5 Non-steroidal anti-inflammatory drugs - meloxicam 
Meloxicam was the most frequently administered NSAID to koalas (de Kauwe et al., 2014). 
The PK profile was investigated following i.v. (0.4 mg/kg), s.c. and p.o. (0.2 mg/kg) 
administration to clinically normal koalas (Kimble et al., 2013a). Meloxicam had extremely 
poor oral bioavailability and rapid Cl in the koala compared to other mammalian species and 
the previously suggested dosage seemed inappropriate in the koala. For example, the half-life 
of meloxicam in koalas is 1.19 h (range: 0.71 – 1.62 h) (Kimble et al., 2013a), 24 h in dogs 
(Busch et al., 1998) and approximately 13 h in humans (Turck et al., 1996). A comparative in-
vitro study using a hepatic microsomal assay revealed that many weakly acidic NSAIDs, 
including flurbiprofen, diclofenac and meloxicam except for indomethacin, are unlikely to have 
PK applicability because of the in-vitro rapid intrinsic hepatic clearance (Clint), indicating a 
faster Cl and shorter t1/2 in the koala (Kimble, 2015).  
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1.2.6.6 What has been learnt from PK studies in koalas? 
The lessons from these aforementioned studies indicate that when drugs are administered orally 
to koalas they are poorly absorbed (such as enrofloxacin, fluconazole and meloxicam); 
however, first pass metabolism could also be a contributing factor; there appears to be some 
differences in drug binding (such as enrofloxacin and fluconazole) to plasma proteins between 
koalas and other species; some drugs such as meloxicam are rapidly metabolised in this species; 
some antimicrobial agents such as erythromycin and oxytetracycline cause emaciation and 
death in koalas so in-vivo antimicrobial studies in the koala must be undertaken carefully.  
This research examined the PK profiles of the antifungal drug posaconazole and the 
antibacterials cefovecin and amoxicillin. The next section summarises the relevant information 
about these three agents in human medicine and veterinary practice.  
1.2.7 Drugs studied in this thesis 
1.2.7.1 Posaconazole 
Posaconazole is a triazole antifungal drug with a chemical formula of C37H42F2N8O4 (illustrated 
in Figure 1-5). It is a third-generation, lipophilic azole with one of the broadest spectrums of 
activity of all azoles (Hof, 2006). Posaconazole is efficacious against dimorphic fungi (such as 
Blastomyces spp., Coccidioides spp., Candida spp. and Histoplasma spp., both in their yeast 
and filamentous forms), Aspergillus spp., dematiaceous fungi (i.e. dark fungi that contain 
melanin in their cell wall) and zygomycetes (i.e. fungi which reproduce sexually by producing 
resistant spores) (Hof, 2006). Posaconazole is also indicated for salvage therapy against other 
drug-resistant, fungal infections (Segal et al., 2005, Ashbee et al., 2013).  
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Figure 1-5 Posaconazole structure; the Figure is modified from the DrugBank database (2017), 
https://www.drugbank.ca/drugs/DB01263 [accessed 29 Aug 2017]. 
1.2.7.1.1 Administration and dosage 
Posaconazole is registered for use in humans and is available as a 40 mg/mL oral suspension, 
delayed release tablets and as an intravenous infusion (Noxafil, MSD, Macquarie Park, NSW) 
and has been used to treat fungal infections in cats (Krockenberger et al., 2010, Evans et al., 
2011), dogs (Kendall and Papich, 2015, Corrigan et al., 2015, Cook et al., 2016), rabbits 
(Perfect et al., 1996) and rats (Ullmann et al., 2007) with minimal adverse effects. 
Oral itraconazole is the current systemic, first-line, broad-spectrum, antifungal drug for most 
subcutaneous and systemic disseminated fungal infections in companion animals. However, 
itraconazole can reduce appetite and cause signs of hepatotoxicity in some cats (Malik et al., 
2005). Fluconazole has been the drug of choice to treat feline cryptococcosis, the most common 
fungal infection in cats in Australia. However, feline cryptococcal meningitis requires more 
aggressive therapy with fluconazole combined with the potentially nephrotoxic drug 
amphotericin B, or amphotericin B with flucytosine (a.k.a. 5-fluorocytosine). Posaconazole is 
used occasionally in Australian veterinary practice to treat fungal infections in cats (McLellan 
et al., 2006, Wray et al., 2008, Krockenberger et al., 2010, Evans et al., 2011) and Aspergillus 
spp. infections in dogs (Corrigan et al., 2015). Posaconazole appears palatable and has a low 
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incidence of adverse effects in humans (Courtney et al., 2003), dogs (Kendall and Papich, 
2015) and cats (Mawby et al., 2016). However, an additional challenge when treating fungal 
infections is the long duration of treatment. Posaconazole’s major disadvantage is cost, which 
can be substantial for months of therapy. One bottle of Noxafil (40 mg/mL; volume of 105 mL) 
costs AU $651.56 (in 2017) which equates approximately to AU $3.25 – 4.00 per day to treat 
a fungal infection in a cat at the current suggested oral dosage (5 – 7.5 mg/kg/day) (Barrs and 
Talbot, 2014). 
1.2.7.1.2 Mechanism of action 
Like other azoles, posaconazole inhibits ergosterol production in the fungal cell membrane by 
binding to and inhibiting CYP (lanosterol-14α-demethylase) which is present in most fungi 
except Pneumocystis and Pythium spp. (Hof, 2006). Posaconazole has a high affinity to bind 
to its target (Hof, 2006). As posaconazole’s chemical structure differs from that of fluconazole 
and voriconazole: it can interact with an additional domain of the target so that it might inhibit 
mutated strains resistant to fluconazole and voriconazole (Hof, 2006). Posaconazole inhibits 
efflux pumps in fungi, so it can remain active when other azoles are already inactive (Hof, 
2006).  
1.2.7.1.3 Pharmacokinetics of posaconazole in some species 
Pharmacokinetic studies have recently been published in the dog (Kendall and Papich, 2015) 
and cat (Mawby et al., 2016).  
Oral absorption is improved by the presence of Fatty food (Krishna et al., 2009a) and when the 
total daily dose is divided into two to four doses (Li et al., 2010). Oral bioavailability was 0.48 
when a 10 mg/kg suspension was administered to recently fed dogs (Nomeir et al., 2000). This 
value was reported as 0.26 (0.08 – 0.79) and 1.59 (0.85 – 5.00) when posaconazole was 
administered to dogs as an oral suspension (6 mg/kg, n = 6) or as delayed-release tablets (mean 
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dose: 6.9 mg/kg, n = 5), respectively (Kendall and Papich, 2015). Depending on the dosage 
and food, oral bioavailability of posaconazole is variable in humans and dogs (Li et al., 2010, 
Kendall and Papich, 2015). Following daily administration of 40 mg/kg for eight consecutive 
days via an oral suspension to fed dogs, serum concentrations were higher than that following 
a single dose, but the AUC0– following a single dose was similar to the AUC0–24 following 
multiple doses indicating no untoward accumulation (Nomeir et al., 2000).  
Posaconazole is highly protein-bound, predominately to albumin, in humans and dogs (> 98 % 
and > 99 %, respectively) (Li et al., 2010, Kendall and Papich, 2015). Posaconazole is widely 
distributed to tissues (Li et al., 2010). The geometric mean of the Vdss in dogs is 3.28 L/kg 
(range: 2.25 – 6.45) (Kendall and Papich, 2015). In humans, it ranges from approximately 5 to 
25 L/kg which may suggest extensive extravascular distribution and penetration into 
intracellular spaces (Li et al., 2010). There is some Phase II metabolism which is responsible 
for biotransformation of posaconazole into the glucuronide conjugate. Cytochrome p450 
(CYP) enzymes do not play a significant role in its metabolism, but posaconazole inhibits 
CYP3A4 and p-glycoprotein and is therefore implicated in some drug interactions (Greer, 
2007, Ashbee et al., 2013). 
Less than 1 % of posaconazole is excreted unchanged in urine and 66 % is excreted unchanged 
in faeces, indicating renal elimination is a minor excretion pathway (Li et al., 2010).  
There is some suggestion that posaconazole should be used cautiously in cats because of their 
inherent decreased rate of glucuronide conjugation. However, case reports of posaconazole 5 
mg/kg p.o. administered once daily for many months to cats demonstrated efficacy with 
minimal adverse effects (McLellan et al., 2006, Wray et al., 2008, Krockenberger et al., 2010, 
Evans et al., 2011). The only adverse effect reported in cats has been erythema and pruritus of 
the pinnae and superficial excoriations of the skin in the affected region from self-trauma 
associated with rubbing (McLellan et al., 2006). 
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Posaconazole is slowly eliminated (Li et al., 2010). The t1/2 of posaconazole in dogs is 
approximately 29, 24 and 42 h when given i.v. (3 mg/kg) and p.o. either by oral suspension or 
delayed-release tablet (6 mg/kg), respectively (Kendall and Papich, 2015). The clearance in 
dogs is 0.08 L/h/kg (Kendall and Papich, 2015). Some PK parameters and indices in dogs after 
i.v. or p.o. administration are summarised in Table 1-1. 
Table 1-1 Pharmacokinetic parameters and indices in dogs after administration of posaconazole p.o. or 
i.v (Kendall and Papich, 2015) 
Parameters/indices  Mean Value (Range) 
i.v. 
3 mg/kg (n = 6)  
oral suspension 
6 mg/kg (n = 6)  
delayed-release tablet 6.9 
mg/kg (n = 5) 
Cmax (µg/mL) 1.29 (0.79 – 2.23) 0.42 (0.19 – 0.81) 1.80 (1.15 – 3.55) 
Tmax (h) - 7.69 (4.18 – 34.28) 9.48 (3.36 – 25.41) 
AUC (0–∞) (μg/mL*h) 38.40 (13.35 – 63.76) 19.73 (6.43 – 75.43) 130.39 (106.81 – 229.70) 
Ka * - 0.35 (0.03 – 0.90) 0.44 (0.07 – 2.36) 
α *(h-1) 1.72 (0.32 – 11.05) - - 
Vdss (L/kg) 3.28 (2.25 – 6.45) - - 
Kel *(h–1) 0.02 (0.02 – 0.03) 0.03 (0.01 – 0.05) 0.02 (0.01 – 0.02) 
Clb (mL/h/kg) 78.13 (47.05 – 224.75) - - 
t1/2 (h) 29.29 (19.93 – 35.71) 23.92 (14.18 – 48.85) 41.71 (31.59 – 60.54) 
MRT (h) 41.95 (28.68 – 51.36) - - 
F (%) - 26 (7.8 – 79.0) 159 (85 – 500) 
*Ka: absorption rate constant, α: distribution rate constant, Kel: elimination rate constant  
1.2.7.1.4 Pharmacodynamic information 
In a model of aspergillosis in neutropaenic rabbits, the minimal highly effective plasma 
concentration was 1 µg/mL (Petraitiene et al., 2001). A trough posaconazole plasma 
concentration of 1 µg/mL increases the probability of treatment efficacy in human patients with 
invasive aspergillosis (Ashbee et al., 2013). Both the posaconazole MIC and the genotype of 
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the invading pathogen are important determinants of exposure-response (PK/PD) relationship 
for efficacious posaconazole therapy (Ashbee et al., 2013). 
The AUC24/MIC is the best predictive PK/PD parameter for triazole efficacy in preclinical 
animal models of disseminated candidiasis (Lewis, 2011, Lepak and Andes, 2014). Preclinical 
PD studies of fluconazole, voriconazole, posaconazole and ravuconazole revealed that their 
antifungal PD target was similar (defined as 50 % of the maximal effect) across the drug class 
as long as the unbound drug concentrations are taken into account (Lewis, 2011, Lepak and 
Andes, 2014). An AUC24/MIC of approximately 25 (range: 12 – 25) is required to achieve 50 
% of the maximal effect of triazole family to treat Candida spp. (Lewis, 2011). Therefore, an 
AUC24/MIC of 25 – 50 would mean that drug concentrations remaining near the MIC over 24 
h period would be expected to achieve this target (1×MIC×24 h) = AUC24 /MIC) (Lewis, 2011, 
Lepak and Andes, 2014). 
Considering the high plasma protein binding of posaconazole (Li et al., 2010, Kendall and 
Papich, 2015), the free concentration of posaconazole (the pharmacologically active part of a 
drug) would be expected to be appreciably less than the MICs for many fungal pathogens and 
therefore, theoretically results in inadequate antifungal efficacy. However, clinical trials in 
humans demonstrate a high degree of clinical efficacy (Lignell et al., 2011, Dolton et al., 2012). 
It was reported that unbound posaconazole concentrations of only 10 % of the known fungal 
MIC in serum have significant antifungal effects against Candida spp. isolates while this effect 
was not seen in protein-free media (Lignell et al., 2011). It was suggested that a flux of protein-
bound posaconazole to its fungal binding target is likely attributable to this observed PD effect 
(Lignell et al., 2011). Furthermore, the high efficacy of posaconazole despite its lower plasma 
/ serum concentration than MIC in clinical trials may also be attributable to its lipophilicity 
which results in high intracellular concentrations. For instance, posaconazole concentrations 
within alveolar cells can be 40 times greater than that in serum. In another study in humans, 
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there were increased intracellular concentrations of posaconazole in peripheral blood 
mononuclear cells (PBMCs) and polymorphonuclear leukocytes (PMNs) compared to the 
plasma concentration after oral posaconazole administration (Conte et al., 2009, Farowski et 
al., 2010).  
1.2.7.2 Cefovecin 
Cefovecin (INN) is a semi-synthetic third-generation cephalosporin of the beta-lactam 
antibacterial group with a chemical formula of C17H18N5NaO6S2 (illustrated in Figure 1-6). It 
was first registered in Australia in 2007 (APVMA, 2007) as an aqueous solution for a bolus 
s.c. administration with a long duration of action to treat specific bacterial infections in dogs 
and cats (Stegemann et al., 2006b, Stegemann et al., 2006c).  
 
Figure 1-6 Cefovecin structure from ‘Pharmacokinetics and pharmacodynamics of cefovecin in dogs’ 
by Stegemann et al. (2006) in Journal of Veterinary Pharmacology and Therapeutics, 29, 6, p: 509. 
 
1.2.7.2.1 Administration and dosage 
Cefovecin has a broad-spectrum of activity against gram-positive and gram-negative pathogens 
(both aerobic and anaerobic) and is approved in many countries to treat bacterial infections 
including those commonly involved in skin infections, infected wounds, abscesses and urinary 
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tract infections in dogs and cats (Stegemann et al., 2007a, Stegemann et al., 2007b, Six et al., 
2009). Cefovecin has a long elimination half-life in dogs and cats (approximately 5 and 7 days, 
respectively) and long antibacterial activity in transudates for at least 14 days (Stegemann et 
al., 2006c, Stegemann et al., 2006b). A single s.c. injection of 8 mg/kg b.w. dosage of cefovecin 
is recommended to be efficacious for at least 10 to 14 days in these species (Stegemann et al., 
2006c, Stegemann et al., 2006b). For infections that require antibacterial action for longer than 
14 days, the injection can be repeated at 14-day intervals on two to four occasions in dogs and 
cats (Prescott, 2013a).  
1.2.7.2.2 Mechanism of action 
Like other beta-lactam antibacterials (such as penicillins, cephalosporins, carbapenems and 
monobactams), cefovecin prevents formation of the bacterial cell wall during cell division by 
interfering with the final stage of peptidoglycan synthesis. Peptidoglycan synthesis in the cell 
wall relies on penicillin binding proteins such as transpeptidase and other peptidoglycan-active 
enzymes. Beta-lactams bind to and inhibit those enzymes that catalyse cross-linkage of 
peptidoglycan polymer units forming the bacterial cell wall (Prescott, 2013a).  
1.2.7.2.3 Pharmacokinetics of cefovecin in some species 
The PK profile of cefovecin has been studied in dogs (Stegemann et al., 2006b), cats 
(Stegemann et al., 2006c), some nonhuman primates (Papp et al., 2010, Raabe et al., 2011, 
Bakker et al., 2011), hens (Thuesen et al., 2009), alpacas (Vicugna pacos) (Cox et al., 2014b) 
as well as some aquatic species (García-Párraga et al., 2010, Steeil et al., 2014, García-Párraga 
et al., 2015, Lee et al., 2016) and non-domesticated animals (Thuesen et al., 2009, Nardini et 
al., 2014, Lee et al., 2016, Sypniewski et al., 2017). Some PK parameters and indices of 
cefovecin in some species have been summarised in Tables 1-2 and 1-3.  
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Cefovecin is primarily eliminated via the kidneys (approximately 70 – 80 %), and liver 
metabolism is minimal (Stegemann et al., 2006b, Papp et al., 2010). 
After s.c. administration of cefovecin, almost the same Cmax was achieved within 6 h in dogs 
and 2 h in cats (121 and 141 µg/mL in dogs and cats, respectively) with almost full 
bioavailability (0.99) for both species (Stegemann et al., 2006b, Stegemann et al., 2006c).  
The PK profile of cefovecin between nonhuman primates and domestic carnivores is not 
consistent (Raabe et al., 2011). The terminal half-lives of cefovecin after s.c. administration 
have been reported in the following species: olive baboons (Papio anubis) [9.17 ± 1.84 h, 
(Raabe et al., 2011)], rhesus macaques (Macaca mulatta) [about 8 h, (Papp et al., 2010, Bakker 
et al., 2011, Raabe et al., 2011)], cynomolgus macaques (Macaca fascicularis) [6.3 ± 1.8 h and 
4.95 ± 1.47 h, (Papp et al., 2010, Raabe et al., 2011)] and squirrel monkeys (Saimiri sciureus) 
[2.6 ± 0.1 h, (Papp et al., 2010)]. These are much shorter than those reported in dogs [133 ± 16 
h, (Stegemann et al., 2006b)] and cats [166 ± 18 h, (Stegemann et al., 2006c)]. The AUC0–96h 
was much lower in nonhuman primates than that in dogs and cats (see Tables 1-2 and 1-3). The 
Cmax of cefovecin in these species is reported as 2 to 3-fold lower than that in dog and cat 
plasma (approximately 40 – 90 µg/mL achieved within ≤ 2 h in nonhuman primates (Papp et 
al., 2010, Bakker et al., 2011, Raabe et al., 2011) compared to 121 µg/mL in dogs (Stegemann 
et al., 2006b) and 141 µg/mL in cats (Stegemann et al., 2006c). However, similarly to dogs and 
cats, a relatively small Vdss was reported in cynomolgus macaques [0.16 ± 0.02 L/kg and 0.105 
± 0.018 L/kg, (Papp et al., 2010, Raabe et al., 2011)] and olive baboons [0.097 ± 0.024 L/kg, 
(Raabe et al., 2011)], likely indicating a high percentage of cefovecin binding to plasma 
proteins in these species (Raabe et al., 2011). High clearance rates of cefovecin were reported 
in olive baboons [9.36 ± 1.38 mL/h/kg, (Raabe et al., 2011)] and cynomolgus macaques [15 ± 
5 and 17.58 ± 2.76 mL/h/kg, (Papp et al., 2010, Raabe et al., 2011)] which were attributed to 
decreased plasma concentrations in these species (Papp et al., 2010).  
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Although in-vitro PPB of cefovecin in nonhuman primates was relatively high at four different 
concentrations ranging from 0.5 to 50 µg/mL [cynomolgus macaques (96.2 to 97.7 %), rhesus 
macaques (93.8 to 97.8 %) and squirrel monkeys (83.6 to 92.1 %) (Papp et al., 2010)], these 
values were less than those reported in dogs [96 to 98.7 %, (Stegemann et al., 2006b)] and cats 
[99.5 to 99.8 %, (Stegemann et al., 2006c)]. The difference in the elimination half-life in 
nonhuman primates, dogs and cats could partly be related to the different percentage of protein 
binding of cefovecin as a greater fraction of free drug is available for kidney filtration in the 
primates (Raabe et al., 2011) and that active renal reabsorption of cefovecin appears to occur 
in dogs and cats but not in nonhuman primates (Raabe et al., 2011).  
The PK profile of cefovecin in hens also differs from that in dogs and cats (Thuesen et al., 
2009). Following s.c. injection in hens, the plasma Cmax (6 ± 2 µg/mL) was attained at 
approximately 17 ± 3 min (Thuesen et al., 2009). The exposure (AUC0–∞) was smaller than that 
in dogs and cats [8 µg.h/mL in hens (Thuesen et al., 2009) vs 10400 µg.h/mL in dogs 
(Stegemann et al., 2006b) and 22700 µg.h/mL in cats (Stegemann et al., 2006c)]. The 
elimination half-life was reported as 0.9 ± 0.3 h (Thuesen et al., 2009) in hens which is much 
shorter than that reported in dogs [133 ± 16 h, (Stegemann et al., 2006b)] and cats [166 ± 18 h, 
(Stegemann et al., 2006c)]. In hens, the mean Cl values were 1252 ± 185 mL.h/kg and the mean 
Vd was 1.6 ± 0.5 L/kg, reflecting lower protein binding of cefovecin as high protein binding 
will result in a longer half-life and a decreased Vd (Thuesen et al., 2009).  
In the alpaca, the Vdss is similar to that of carnivores and nonhuman primates (0.086 ± 0.029 
L/kg in alpacas) (Cox et al., 2014b) (see Table 1-2). However, other PK parameters and indices 
were very different to those described in dogs, cats and nonhuman primates (Cox et al., 2014b). 
The clearance reported as 7.1 ± 1.8 mL/h/kg (Cox et al., 2014b) is much faster than that in dogs 
[0.76 mL/h/kg, (Stegemann et al., 2006b)] and cats [0.35 mL/h/kg,(Stegemann et al., 2006c)] 
but slower than that in nonhuman primates [mean: 14 mL/h/kg, (Papp et al., 2010, Raabe et al., 
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2011)]. The shorter terminal half-life [16.9 h, (Cox et al., 2014b)] compared with cats [166 h, 
(Stegemann et al., 2006c)] and dogs [133 h, (Stegemann et al., 2006b)] could be explained with 
the faster Cl in alpacas (Cox et al., 2014b). The mean PPB of cefovecin in alpacas was 80 % 
(Cox et al., 2014b). 
Table 1-2 Pharmacokinetic parameters and indices in various species following i.v. administration of 
cefovecin (mean ± SD) 
Species  dose 
(mg/kg) 
AUC0–∞  
(µg.h/mL) 
Vdss  
(L/kg) 
Clb  
(mL/h/kg) 
MRT  
(h) 
t1/2  
(h) 
Dogs  
(Stegemann et al., 2006b) 
8 10500 ± 1700 0.12± 0.01 0.76 ± 0.13 165 136 ± 12 
Cats 
(Stegemann et al., 2006c) 
 22900 ± 2970 0.09 ± 0.01 0.35 ± 0.04 256 184 ± 12 
Cynomolgus acaques 
(Papp et al., 2010, Raabe 
et al., 2011) 
2  0.16 ± 0.02 15 ± 5  8.50 ± 1.20 
8  461 ± 75.30 0.11 ± 0.02* 17.58 ± 2.76 6.12 ± 0.89 4.79 ± 0.73 
Olive baboons 
(Raabe et al., 2011) 
8 863 ± 139 0.10 ± 0.02 9.36 ± 1.38 10.50 ± 1.30 8.70 ± 0.78 
Alpacas  
(Cox et al., 2014b) 
8 1187 ± 269 0.09 ± 0.03 7.10 ± 1.80 12 ± 2 10.30 ± 1.60 
*significant difference between males and females 
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Table 1-3 Pharmacokinetic parameters and indices in various species following s.c. administration of 
cefovecin (mean ± SD) 
Species  dose 
(mg/kg) 
Cmax 
(µg/mL) 
Tmax 
(h) 
AUC0–∞  
(µg.h/mL) 
t1/2  
(h) 
Dogs  
(Stegemann et al., 2006b) 
8 121 ± 51 6.20 ± 3 10400 ± 1900 133 ± 16 
Cats  
(Stegemann et al., 2006c) 
8 141 ± 12 2 ± 2 22700 ± 3450 166 ± 18 
Hens 
(Thuesen et al., 2009) 
10 6 ± 2 0.28 ± 0.05 8 ± 1 0.87 ± 0.27 
Squirrel monkeys  
(Papp et al., 2010) 
8 42 ± 9 0.50 (0.50) 128 ± 38* 2.60 ± 0.10 
Rhesus macaques  
(Papp et al., 2010, Bakker et al., 
2011, Raabe et al., 2011) 
8  47 ± 8 2 (0.2 – 4) 520 ± 70* 8 ± 0.60  
8 79 ± 5.70 0.95 ± 0.14 656 ± 79 6.60 ± 1 
8  93.50 ± 6.61 0.87 ± 0.31 965 ± 204 8.40 ± 2.53 
Cynomolgus macaques  
(Papp et al., 2010, Raabe et al., 2011) 
8 46 ± 6  1 (1) 468 ± 97* 6.30 ± 1.80 
8  62.80 ± 13.80 0.75 ± 0.28 546 ± 298 4.95 ± 1.47 
Olive baboons  
(Raabe et al., 2011) 
8 75.90 ± 8.40 2.83 ± 1.83 1130 ± 288 9.17 ± 1.84 
Alpacas 
(Cox et al., 2014b) 
8 108 ± 28 2.80 ± 1.30 1673 ± 579 16.90 ± 8.30 
Bamboo sharks  
(Steeil et al., 2014) 
8 52.08 ± 16.03 0.37 ± 0.14 - 2.02 ± 4.62 
Juvenile green iguanas  
(Thuesen et al., 2009) 
10 35 ± 12 0.33 ± 0 190 ± 0 3.90 ± 0 
Atlantic horseshoe crabs  
(Steeil et al., 2014) 
8 26.01 ± 3.84 0.62 ± 0.31 - 37.70 ± 9.04 
Hermann’s tortoises 
(Nardini et al., 2014) 
8 27.37 ± 4.43 1.22 ± 1.14 220.35 ± 36.18** 20.78 ± 12.62 
Sea otters  
(Lee et al., 2016)  
8 70.60 ± 14.60 2.90 ± 1.50 3447.8 ± 439 41.60 ± 4.70 
Red-eared slider  
(Sypniewski et al., 2017) 
10 32.30 ± 23.80 2.40 ± 1.20 190 ± 54 6.80 ± 1.20 
*AUC0–96h 
**AUC0–last 
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Table 1-4 Percentage of in-vitro PPB of cefovecin in some species 
Species Concentrations 
(µg/mL) 
Plasma protein binding 
(%) 
Dogs (Stegemann et al., 2006b) 10, 25, 50, 100 
200 
300 
96 – 98.7 
72.6 
56.4 
Cats (Stegemann et al., 2006c) 10, 25, 50, 100 
200 
300 
99.5 – 99.8 
82.7 
66.6 
Squirrel monkeys (Papp et al., 2010) 0.05, 0.5, 5 
50 
92.1 – 89.1 
83.6 
Cynomolgus macaques  
(Papp et al., 2010, Raabe et al., 2011) 
0.05, 0.5, 5, 50 97.7 – 96.2 
0.1, 1, 10, 100 82.5 – 88.5 
Rhesus macaques (Papp et al., 2010) 0.05, 0.5, 5 
50 
97.8 – 97.4 
93.8 
Alpacas (Cox et al., 2014b) 1.5, 3.5, 35, 150  69 – 91 (79 ± 10) 
Hermann’s tortoises (Nardini et al., 2014) 1, 5,10  37.9 – 50.2  
Sea otters (Lee et al., 2016) 0.5, 5, 50 78 
1.2.7.2.4 Antibacterial activity of cefovecin 
The antibacterial susceptibilities of a wide range of pathogens (1,660 canine and 981 feline 
isolates) to cefovecin were tested (Stegemann et al., 2006a) (summarised in Table 1-5). The 
MIC90 of cefovecin to inhibit growth of susceptible canine and feline pathogens like 
Staphylococcus pseudintermedius, E. coli and S. aureus were 0.25, 1 and 2 µg/mL, respectively 
(Stegemann et al., 2006a). 
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Table 1-5 Susceptibility of canine and feline pathogens collected in the European Union and the United 
States to cefovecin (Stegemann et al., 2006a) 
Pathogen group (no. of isolates tested; origin)  MIC (μg/ml) 
Mode **  50 % 90 % Range 
S. intermedius (270; European Union) 0.12 0.12 0.25 ≤ 0.06 – 8 
S. intermedius (231; United States) 0.12 0.12 0.25 ≤ 0.06 – > 32 
S. aureus (36; European Union) 1 1 2 0.50 – > 32 
Coagulase-negative Staphylococcus spp. (21; European Union) 0.12 0.25 4 0.12 – 32 
Coagulase-negative Staphylococcus spp. (89; United States) 0.12 0.12 2 ≤ 0.06 – 8 
Coagulase-positive Staphylococcus spp. (24; European Union) 0.25 0.25 0.50 0.12 – > 32 
β-Hemolytic Streptococcus spp. (86; European Union) ≤ 0.06 ≤ 0.06 0.12 ≤ 0.06 – 16 
β-Hemolytic Streptococcus spp. (22; United States) ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 – 8 
S. canis (66; United States) ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 – ≤ 0.06 
Streptococcus spp. (27; United States) ≤ 0.06 ≤ 0.06 0.50 ≤ 0.06 – 0.50 
Enterococcus spp. (31; European Union) > 32 > 32 > 32 ≤ 0.06 – > 32 
Enterococcus spp. (45; United States) > 32 > 32 > 32 ≤ 0.06 – > 32 
P. multocida (193; European Union) ≤ 0.06 ≤ 0.06 0.12 ≤ 0.06 – 2 
P. multocida (188; United States) ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 – 0.12 
E. coli (260; European Union) 0.50 0.50 1 0.12 – > 32 
E. coli (223; United States) 0.50 0.50 1 0.12 – > 32 
Proteus spp. (71; European Union) 0.25 0.25 0.25 0.12 – 8 
P. mirabilis (110; United States) 0.25 0.25 0.50 0.12 – 0.50 
Klebsiella spp. (11; European Union) 0.50 0.50 1 0.25 – 1 
K. pneumoniae (16; United States) 0.50 0.50 1 0.25 – 2 
Enterobacter spp. (39; European Union) 1 1 32 0.12 – > 32 
Enterobacter cloacae (20; United States) 2 1 2 0.50 – 8 
Pantoea agglomerans (23; United States) 0.25 0.25 1 ≤ 0.06 – 2 
Acinetobacter baumannii (16; United States) 16 16 32 8 – 32 
Prevotella spp. (75; European Union) 0.25 0.25 1 ≤ 0.06 – 8 
Prevotella spp. (11; United States) ≤ 0.06 0.25 4 ≤ 0.06 – 8 
Fusobacterium spp. (26; European Union) ≤ 0.06 0.12 1 ≤ 0.06 – 2 
Fusobacterium spp. (66; United States) ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 – 1 
Bacteroides spp. (32; European Union) 0.25 0.25 2 ≤ 0.06 – 8 
Clostridium spp. (15; European Union) 0.25 0.50 16 ≤ 0.06 – > 32 
Peptostreptococcus spp. (21; European Union) 0.50 0.50 1 0.12 – 2 
Porphyromonas spp. (29; United States) ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 
Corynebacterium spp. (11; United States) 1 1 4 0.25 – > 32 
*The information in the Table was extracted from a table in ‘Antimicrobial activity and spectrum of 
cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in 
Europe and North America’ by Stegemann et al. (2006) in Antimicrobial Agents and Chemotherapy, 50, 
7, p: 2288-2290. 
** Mode: most often occurring MIC value 
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1.2.7.3 Amoxicillin 
Amoxicillin (INN) or amoxycillin (ANN) is a broad-spectrum, acid-stable, semi-synthetic 
aminopenicillin antibacterial of the beta-lactam group with a chemical formula of C16H19N3O5S 
(illustrated in Figure 1-7). It is active against gram-positive and some gram-negative pathogens 
(both aerobic and anaerobic) (Papich and Riviere, 2009). Amoxicillin is sensitive to destruction 
by beta-lactamases produced by some bacteria such as Staphylococcus spp. and 
Enterobacteriaceae. These enzymes rupture the beta-lactam ring and could be partly or 
exclusively responsible for the resistance of many bacteria to beta-lactam antibacterials (Papich 
and Riviere, 2009). Therefore, amoxicillin is commonly administered with beta-lactamase 
inhibitors such as clavulanic acid or sulbactam which are potent, irreversible inhibitors of many 
beta-lactamases (Neu and Fu, 1978, Papich and Riviere, 2009, Prescott, 2013a). Clavulanic 
acid, isolated from the culture fluid of gram-positive bacteria Streptomyces clavuligerus, also 
has a beta-lactam structure but weak antibacterial activity (Reading and Cole, 1977, Neu and 
Fu, 1978). Potassium clavulanate is commonly combined with penicillins such as amoxicillin 
(Papich and Riviere, 2009).  
 
Figure 1-7 Amoxicillin structure, the Figure is modified from the DrugBank database (2017), 
https://www.drugbank.ca/drugs/DB01060 [accessed 29 Aug 2017] 
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Amoxicillin/clavulanic acid (INN) or co-amoxiclav (BAN) is registered for use in humans and 
animals. This combination is available in oral and injectable formulations such as palatable 
tablets (50, 250 and 500 mg), palatable drops (amoxicillin trihydrate 50 mg/mL and potassium 
clavulanate 12.5 mg/mL), injectable suspension (amoxicillin trihydrate 140 mg/mL and 
clavulanate potassium 35 mg/mL in a fractionated coconut oil base) and as intra-mammary 
antibacterial for lactating cows in Australia with many generic formulations available. 
Amoxicillin is indicated in humans and in many animal species for treating respiratory, 
gastroenteric, urinary tract, soft tissue and other infections (Palmer et al., 1976, Keefe, 1977, 
Prescott, 2013a). 
1.2.7.3.1 Administration and dosage 
The usual dosage of amoxicillin in animals is 10 to 20 mg/kg p.o. (twice or three times daily) 
or i.m. and s.c. (twice daily) (Prescott, 2013a). Amoxicillin is administered to koalas at a dose-
rate 10 – 12.5 mg/kg (alone, or in combination with clavulanic acid) to treat some bacterial 
infections either p.o., i.m. or s.c., although some clinicians avoid oral administration of this 
drug to koalas p.o. (Blanshard and Bodley, 2008) as it reportedly alters the normal 
gastrointestinal flora resulting in dysbiosis and death (personal communication with Dr Amber 
Gillett Veterinarian, Australia Zoo Wildlife Hospital (AZWH), Beerwah, QLD). 
1.2.7.3.2 Mechanism of action 
Amoxicillin like other beta-lactam antibacterials binds to penicillin-binding proteins (PBPs) 
and interferes with cell wall synthesis, killing susceptible bacteria (Papich and Riviere, 2009).  
With negligible intrinsic antibacterial activity, clavulanic acid irreversibly binds to a wide 
variety of beta-lactamases (Papich and Riviere, 2009), thereby, protecting beta-lactamase 
sensitive penicillins such as amoxicillin and increasing amoxicillin’s efficacy against many 
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species of bacteria. The combination of these two drugs is usually bactericidal at one or two 
dilutions below the MIC compared to when amoxicillin is used alone (Prescott, 2013b). 
1.2.7.3.3 Pharmacokinetics of amoxicillin in some species 
The PK profile of amoxicillin, alone or in combination with clavulanic acid, has been studied 
in humans (Arancibia et al., 1980) and many other species including dogs (Ten Voorde et al., 
1990, Kung and Wanner, 1994), sheep (Craigmill et al., 1992, Carceles et al., 1995a, Elsheikh 
et al., 1999, Fernandez et al., 2007), goats (Carceles et al., 1995a, Carceles et al., 1995b, 
Escudero et al., 1996, Elsheikh et al., 1999), turkeys (Carceles et al., 1995c, Jerzsele et al., 
2011), horses (Wilson et al., 1988, Baggot et al., 1988, Ensink et al., 1992), cows (Rutgers et 
al., 1980, Nouws et al., 1986), chickens (Carceles et al., 1995c, Jerzsele et al., 2009), pigeons 
(Escudero et al., 1998), pigs (AgersØ and Friis, 1998, Anfossi et al., 2002, Reyns et al., 2007), 
the northern elephant seal (Mirounga angustirostris), the Pacific harbor seal (Phoca vituline) 
(Gulland et al., 2000) and tammar wallabies (Macropus eugenii) (McLelland et al., 2009). Co-
administration of amoxicillin with clavulanic acid does not appear to alter the PK profile of 
amoxicillin in any species (Reyns et al., 2007, Baggot and Giguère, 2013). 
Two chemical formulations of amoxicillin are available: sodium and trihydrate. The former is 
rapidly absorbed, reaches a maximum blood concentration within an hour and is suitable for 
i.v., i.m. and s.c. injection while the latter is more stable and has a slower absorption profile to 
prolong the action and may be injected i.m. or s.c. (Papich and Riviere, 2009). After i.v. 
injection of sodium amoxicillin, the plasma concentration falls to its half concentration in less 
than 2 h in all species (see Table 1-6).  
Generally, penicillins distribute within the intravascular spaces and extracellular fluid and, in 
most studies, the Vdss of amoxicillin in horses (Wilson et al., 1988, Ensink et al., 1992), foals 
(Baggot et al., 1988), cows (Rutgers et al., 1980), goats (Craigmill et al., 1992, Carceles et al., 
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1995a, Carceles et al., 1995b, Escudero et al., 1996), sheep (Craigmill et al., 1992, Craig, 1995, 
Fernandez et al., 2007) and dogs (Kung and Wanner, 1994) ranges between 0.1 to 0.3 L/kg 
which is consistent among penicillins. The Vdss appears higher in birds (Carceles et al., 1995c, 
Escudero et al., 1998, Abo El-Sooud et al., 2004, Jerzsele et al., 2011) and pigs (AgersØ and 
Friis, 1998) with the exception of one study that reported lower Vdss of amoxicillin in pigs 
[0.34 L/kg, (Reyns et al., 2007)]. This Vd indicates that amoxicillin could reach intracellular 
concentrations in these species (AgersØ and Friis, 1998, Papich and Riviere, 2009). Plasma 
protein binding of amoxicillin has been studied in chickens [1.63 – 15.5 %, (Abo El-Sooud et 
al., 2004)], dogs [13 %, (Abo El-Sooud et al., 2004)] and humans [17 – 18 %, (Sutherland et 
al., 1972, Abo El-Sooud et al., 2004)].  
Aminopenicillins are metabolised somewhat by hydrolysis of the beta-lactam ring, producing 
microbiologically-inactive metabolites. Facilitated by their relatively low protein binding, 
aminopenicillins and their metabolites are excreted by glomerular filtration and active tubular 
secretion (Papich and Riviere, 2009). A summary of the PK parameters and indices of 
amoxicillin after i.v. administration is provided in Table 1-6.  
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Table 1-6 Pharmacokinetic parameters and indices of amoxicillin sodium after i.v. administration in various 
species (mean ± SD) 
Species dose 
(mg/kg) 
AUC0–∞ 
(mg.h/L) 
Vdss 
(L/kg) 
Clb 
(L/h/kg) 
MRT 
(h) 
t1/2 
(h) 
Horse  
(Wilson et al., 1988, Ensink 
et al., 1992, Errecalde et al., 
2001) 
10 37.0 ± 3.82 0.19 ± 0.01 0.27 ± 0.03 - 1.43 ± 0.28 
10 - 0.32 ± 0.07 0.34 ± 0.05 - 0.66 ± 0.06 
40 42.61 ± 7.43 0.43 ± 0.16 0.44 ± 0.047 - 0.84 ± 0.40 
Foal 
(Baggot et al., 1988) 
20 - 0.26 ± 0.80 0.34 ± 0.46 - 0.74 ± 0.06 
Cow 
(Rutgers et al., 1980) 
4 11.09 ± 0.98 0.27 ± 0.01 0.36±0.01 - 1.34 ± 0.26 
Pig  
(AgersØ and Friis, 1998, 
Reyns et al., 2007) 
9 23.50 ± 3.70 0.55 ± 0.05 0.37 ± 0.06 1.50 ± 0.20 - 
9 17 ± 3.40 0.63 ± 0.17 0.52 ± 0.10 1.20 ± 0.20 - 
20 35.00 ± 5.64 0.34 ± 0.09  0.58 ± 0.09  0.60 ± 0.17  0.37 ± 0.26 
Goat  
(Craigmill et al., 1992, 
Carceles et al., 1995a, 
Carceles et al., 1995b, 
Escudero et al., 1996) 
20 186.17 ± 21.33 0.16 ± 0.02 0.11 ± 0.01 1.52 ± 0.20  
20 185.51 ± 9.81 0.17 ± 0.02 0.11 ± 0.01 1.57 ± 0.09 1.20 ± 0.17 
10 14.91 ± 2.15 0.47 ± 0.259 0.68 ± 0.096 - 1.11 
Sheep  
(Carceles et al., 1995a, 
Fernandez et al., 2007), 11, 
20 231.36 ± 23.15 0.16 ± 0.00 0.09 ± 0.01 1.82 ± 0.19 1.43 ± 0.16 
10 21.83 ± 8.00 - - 0.48 ± 0.15 0.38 ± 0.09 
10 16.73 ± 1.85 0.22 ± 0.02 0.61 ± 0.07 - 0.77 
Chicken  
(Carceles et al., 1995c, Abo 
El-Sooud et al., 2004, 
Jerzsele et al., 2009) 
10 12.81 ± 0.55 0.98 ± 0.07 0.78 ± 0.03 0.88 ± .030 1.28 ± 0.05 
20 16.75 ± 2.31 1.59 ± 0.13 1.19 ± 0.08 1.17 ± 0.14 1.03 ± 0.11 
40 13.85 ± 0.14 1.00 ± 0.02 0.80 ± 0.006 - 1.07 ± 0.02 
Turkey  
(Carceles et al., 1995c, 
Jerzsele et al., 2011),  
10 12.72 ± 0.28 0.70 ± 0.03 0.78 ± 0.02 0.89 ± 0.05 1.28 ± 0.03 
20 19.97 ± 2.00 1.52 ± 0.09 1.00 ± 0.09 1.28 ± 0.16 1.12 ± 0.09 
Dog  
(Kung and Wanner, 1994) 
20 - 0.31 ± 0.102 0.20 ± 0.07 1.60 ± 0.40 - 
Beagle  
(Ten Voorde et al., 1990) 
15 56.45 ± 7.21 - 0.27 ± 0.03 - 1.18 ± 0.13 
Pigeon  
(Escudero et al., 1998) 
20 19.82 ± 1.98 0.99 ± 0.06 - 1.47 ± 0.15 1.22 ± 0.09 
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Amoxicillin trihydrate when injected i.m. to horses and pigs has a half-life of 20.65 h (Wilson 
et al., 1988) and 15.5 h (AgersØ and Friis, 1998), respectively and for dogs and cows, 6.8 and 
8.8 h, respectively (Nouws et al., 1986, Ten Voorde et al., 1990). The shorter terminal half-life 
of amoxicillin trihydrate administered i.m. to chickens, goats, sheep and tammar wallabies (1 
– 2 h) demonstrates rapid elimination in these species (Elsheikh et al., 1999, Abo El-Sooud et 
al., 2004, McLelland et al., 2009). Following i.m. administration of amoxicillin trihydrate, Cmax 
was reached at 15 min in chickens (Abo El-Sooud et al., 2004), 1 h in sheep and goats (Elsheikh 
et al., 1999, Fernandez et al., 2007) and 2 h in tammar wallabies (McLelland et al., 2009). Some 
PK parameters and indices of i.m. amoxicillin administration are provided in Table 1-7. 
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Table 1-7 Pharmacokinetic parameters and indices following i.m. administration of amoxicillin 
sodium and amoxicillin trihydrate in various species (mean ± SD)  
Species  dose 
(mg/kg) 
Cmax 
(µg/mL) 
Tmax  
(h) 
AUC0–∞  
(mg.h/L) 
MRT 
(h) 
t1/2 
(h) 
Amoxicillin sodium 
Sheep 
(Fernandez et al., 2007) 
10 13.42 ± 5.36 0.36 ± 0.21 15.05 ± 1.82 1.07 ± 0.30 0.55 ± 0.15 
Turkeys 
(Carceles et al., 1995c)  
20 8.03 ± 1.23 0.38 ± 0.04 15.27 ± 1.54 1.86 ± 0.17 1.44 ± 0.10 
Chickens 
(Carceles et al., 1995c) 
20 7.99 ± 1.01 0.38 ± 0.05 14.32 ± 1.22 1.51 ± 0.13 1.31 ± 0.09 
Pigeon  
(Escudero et al., 1998)* 
5 5.81 ± 0.85 0.38 ± 0.05 15.06 ± 1.67 1.77 ± 0.19 1.52 ± 0.09 
Amoxicillin trihydrate 
Horse 
(Wilson et al., 1988)  
10 - - 33.43 ± 6.07 - 20.65 ± 9.98 
Pig 
(AgersØ and Friis, 1998) 
14.7 5.10 ± 0.80 2.00 ± 0.70 33.10 ± 3.90 8.80 ± 2.60 15.5 ± 8.30 
Dog  
(Ten Voorde et al., 1990)  
15 7.64 ± 3.91 1.61 ± 0.50 57.40 ± 12.59 - 6.98 ± 3.85 
Cows  
(Nouws et al., 1986) 
10 2.60 ± 1.10 2.60 ± 0.60 28.50 ± 7.20* - 8.80 ± 5.00 
Pre-ruminant calves  
(Nouws et al., 1986)  
10 6.00 ± 2.50 2.40 ± 1.10 53.20 ± 21.50* - 5.80 ± 2.20 
Ruminant calves  
(Nouws et al., 1986) 
10 3.80 ± 0.97 1.90 ± 0.90 24.8 ± 1.46* - 2.90 ± 0.60 
Sheep  
(Fernandez et al., 2007) 
10 2.48 ± 0.54 0.98 ± 0.15 15.40 ± 1.05 8.57 ± 2.78 - 
Tammar wallaby  
(McLelland et al., 2009) 
10 4.51 ± 0.74 2.00 ± 0.00 14.82 ± 4.10 4.03 ± 0.85 1.88 ± 0.60 
Nubian goat  
(Elsheikh et al., 1999) 
10 11.03 ± 0.97 0.85 ± 0.11 28.10 ± 3.03 2.03 ± 0.25 1.05 ± 0.14 
Desert sheep  
(Elsheikh et al., 1999) 
10 9.47 ± 1.33 0.98 ± 0.15 25.21 ± 2.15 2.15 ± 0.16 1.19 ± 0.16 
Chickens 
(Abo El-Sooud et al., 2004) 
10 5.20 ± 0.23 0.26 ± 0.04 10.67 ± 0.43 - 1.09 ± 0.034 
*Data is AUC0–last time 
Bioavailability of amoxicillin varies among species from 0.50 to 0.70 orally and 0.70 to 1.20 
intramuscularly (documented in Table 1-8). This could be explained by interspecies biological 
variation and the use of different sites of injection (Abo El-Sooud et al., 2004). One study 
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demonstrated that the injection site affected amoxicillin absorption in dairy cows which could 
be attributed to the administration to areas with different blood flow (Rutgers et al., 1980). It 
has also been reported that injection into the neck muscle is absorbed more rapidly and 
completely than an injection into the gluteal muscles or rear legs in both cattle and horses 
(Papich and Riviere, 2009). Another study reported that the age of ruminants had an effect on 
the relative systemic availability; there was a higher AUC of the amoxicillin trihydrate in pre-
ruminant calves (3 – 4 weeks) than in 5-month-old ruminant calves and dairy cows (shown in 
Table 1-7). 
Table 1-8 Bioavailability of amoxicillin (p.o. and i.m.) in different species (mean ± SD) 
Species Route 
p.o. i.m. 
Horse  0.10 (Wilson et al., 1988) 
0.50 ± 0.01(Ensink et al., 1992) 
- 
Pig  0.23 ± 0.06 (Reyns et al., 2007) 
0.31 ± 0.15 (AgersØ and Friis, 1998) 
0.38 ± 0.16 (Reyns et al., 2009) 
0.82 ± 0.08 (AgersØ and Friis, 1998) 
Goat  0.27 ± 0.04 (Carceles et al., 1995b) - 
Nubian goat - 0.91 ± 0.09 (Elsheikh et al., 1999) 
Sheep  - 0.73 (Fernandez et al., 2007) 
Desert sheep - 0.95 ± 0.06 (Elsheikh et al., 1999) 
Foal  0.36 ± 0.13 (Baggot et al., 1988) - 
Pre-ruminant calves 0.37 ± 0.07 (Soback et al., 1987) - 
Chicken 0.64 ± 0.03 (Jerzsele et al., 2009) 
0.61 ± 0.03 (Abo El-Sooud et al., 2004) 
0.85 ± 0.05 (Carceles et al., 1995c) 
0.77 ± 0.03 (Abo El-Sooud et al., 2004) 
Turkey 0.60 ± 0.03 (Jerzsele et al., 2011) 0.78 ± 0.05 (Carceles et al., 1995c) 
Dog 0.64 ± 0.18 (Kung and Wanner, 1994) 1.03 ± 0.23 (Ten Voorde et al., 1990) 
Pigeon - 0.76 ± 0.07 (Escudero et al., 1998) 
Cows  - 1.19 ± 0.15 (Rutgers et al., 1980) 
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1.2.7.3.4 Antibacterial activity of amoxicillin  
At AZWH, amoxicillin (with or without clavulanic acid) is used to treat pneumonia in koala 
joeys but is not administered to mature koalas due to a perceived risk of inducing dysbiosis. 
There is a great variation in bacterial species isolated from clinical cases with pneumonia in 
captive or free-ranging koalas. Potential primary or secondary pathogens isolated from koalas 
with pneumonia and / or other respiratory tract pathology include Bordetella bronchiseptica, 
Pseudomonas spp., Streptobacillus moniliformis, Staphylococcus epidermidis, Nocardia 
asteroids, Cryptococcus neoformans complex, Corynebacterium spp., Enterobacter 
agglomerans, Proteus spp., α-haemolytic Streptococcus spp., diphtheroids, Pasteurella spp., 
S. aureus, E. coli and Acinetobacter lwoffii (Blanshard and Bodley, 2008).  
The MIC of ampicillin (used to test the susceptibility of pathogens to amoxicillin) has been 
reported for susceptible strains of E. coli, Staphylococcus spp., Streptococci (β-haemolytic 
group and viridans group) as (≤ 0.25 µg/ml), Listeria spp. (≤ 2 µg/ml), and Enterobacteriaceae 
and Enterococci (≤ 8 µg/ml) (CLSI, 2013b). 
The MIC90 concentrations of amoxicillin/clavulanic acid for many susceptible gram-positive 
and gram-negative pathogens are less than 0.50 µg/mL (Prescott, 2013b) (see Table 1-9). The 
spectrum of activity of amoxicillin/clavulanic acid is similar to that of a first- or second-
generation cephalosporins (Prescott, 2013b). 
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Table 1-9 MIC90 (µg/mL) of amoxicillin/clavulanic acid against selected veterinary pathogens 
(Prescott, 2013b) 
Organism MIC90 Organism MIC90 
Gram-positive cocci 
S. aureus 0.50 S. disgalactiae ≤ 0.13 
S. intermedius* 0.25 S. suis ≤ 0.13 
S. agalactiae ≤ 0.13   
Gram-positive rods 
A. pyrogens 0.25 L. monocytogenes 0.25 
Gram-negative aerobes    
A. pleuropneumoniae 0.50 P. multicida 0.25 
B. bronchiseptica 2 Pseudomonas spp. ≥ 32 
E. coli 8 P. mirabilis 0.50 
H. somni 0.06 Salmonella 2 
M. bovis 0.06   
M. haemolytica 0.13   
Anaerobic bacteria    
B. fragilis 0.50 P. asaccharolytica 1 
C. perfringens 0.50 Fusobacterium spp. ≥ 32 
The Table is from ‘Other Beta-lactam Antibiotics: Beta-lactamase inhibitors, Carbapenems, and 
Monobactams’ in Antimicrobial Therapy in Veterinary Medicine by Giguère, S. et al. (2013), 
5th edition, p: 179. 
* S. intermedius is now named S. pseudintermedius (Devriese et al., 2005) 
1.3 Aims of the thesis 
A significant challenge in veterinary medicine is to avoid blindly extrapolating a drug dosage 
between species which might have significant differences in their anatomy, biochemistry, 
physiology, dietary or behavioural characteristics (Toutain et al., 2010). Biological differences 
can cause numerous interspecies differences in the PK profile of drugs (Toutain et al., 2010). 
The koala is a good example where dosages that were extrapolated from those for dogs and 
cats resulted in surprising and less than ideal PK profiles. Recent published studies confirm 
that extrapolation of dosage regimens from other species to the koala seems inappropriate and 
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currently suggested dose regimens of some drugs such as enroﬂoxacin, marboﬂoxacin, 
fluconazole, florfenicol and meloxicam are insufficient to provide therapeutic plasma 
concentrations in the koala (Griffith et al., 2010, Govendir et al., 2012, Black et al., 2013b, 
Kimble et al., 2013a, Black et al., 2014, Budd et al., 2017). 
Antimicrobials are frequently administered to koalas to treat infectious diseases and the dosage 
regimen used for koalas has traditionally been extrapolated from domesticated animal species 
such as the dog and cat or based on ‘trial and error’ with minimal evaluation of drug efficacy 
(Blanshard and Bodley, 2008, Griffith, 2010). Thus, this research project was undertaken to 
investigate the PK of three antimicrobials in koalas. Two drugs cefovecin and amoxicillin were 
selected due to specific requests by veterinarians – Dr Larry Vogelnest, Senior Veterinarian at 
Taronga Zoo, Mosman, NSW, and Dr Amber Gillette, Senior Veterinarian at AZWH, Beerwah, 
QLD, to better understand these drugs’ specific PK profiles in the koala and to determine the 
applicability of a long-acting cephalosporin cefovecin in selected marsupials by screening the 
in-vitro plasma protein binding. The in-vivo PK of the third drug posaconazole in clinically 
normal koalas was investigated to evaluate it as an alternative for fluconazole to treat 
cryptococcosis. 
As explained in the relevant research chapters, the HPLC with UV detection method was 
problematic for cefovecin and amoxicillin and resulted in low sensitivity of both assays which 
was not ideal for PK studies. Therefore, microbiological methods were also trialled to estimate 
plasma concentrations of these drugs.  
The antibacterial activities of koala plasma and serum were assessed in the last chapter. 
Although the studies in this chapter were not part of the original objectives of this thesis, after 
conducting the microbiological assays in Chapter 6, they were undertaken to assist in 
understanding the variation in the results of broth microdilution inhibition assay over different 
time points of individual koalas and to provide some information of antibacterial activities of 
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koala plasma and serum. This information could be fundamentals for future research to assist 
koalas overcome infectious disease.  
Thus, the specific objectives of this research were: 
1) To develop and validate HPLC-PDA methods to quantify plasma concentrations of the 
antifungal posaconazole and the antibacterials cefovecin and amoxicillin in koala 
plasma 
2) To investigate the PK of posaconazole, cefovecin and amoxicillin in koalas and to use 
the PK profiles of each drug in combination of PD principles to estimate the efficacy 
of current dosage regimens 
3) To determine the in-vitro plasma protein binding of cefovecin in selected Australian 
marsupials in order to evaluate whether cefovecin has therapeutic application in these 
marsupials 
4) To develop microbiological assays to determine cefovecin and amoxicillin 
concentrations in koala plasma in order to confirm the HPLC results of both drugs 
5)  To screen the antibacterial activity of koala plasma and serum against gram-positive 
and gram-negative pathogens and to compare this activity with those from other 
selected species 
Chapter 2 
 
 
 
Pharmacokinetics of posaconazole in koalas 
after intravenous and oral administrations  
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2.1 Abstract 
Posaconazole is a third-generation antifungal drug with a broad-spectrum anti-fungal activity. 
It is registered for use in humans and reportedly has excellent activity to inhibit all 
Cryptococcus spp. serotypes tested in vitro, including isolates with reduced fluconazole 
susceptibility. Posaconazole has been used to treat a variety of fungal infections in dogs and 
cats with minimal adverse effects.  
The PK profile of posaconazole in clinically normal koalas after a single oral dose of 6 mg/kg 
(n = 6) and a single intravenous bolus of 3 mg/kg (n = 2) was investigated. Serial plasma 
samples were collected over 24 h (i.v.) and 36 h (p.o.), and plasma concentrations of 
posaconazole were quantified by validated HPLC assays. A non-compartmental PK analysis 
of the data was performed. Following i.v. administration, estimates of the median (range) of 
plasma Cl and Vdss were 0.15 (0.13 – 0.18) L/h/kg and 1.23 (0.93 – 1.53) L/kg, respectively. 
The median (range) elimination half-life after i.v. and p.o. administration was 7.90 (7.62 – 
8.18) and 12.58 (10.06 – 15.99) h, respectively. Oral bioavailability varied from 0.43 to 1.06 
(median: 0.64). Following oral administration, Cmax (median: 0.73, range: 0.55 – 0.93 µg/mL) 
was achieved in 8 h (range: 6 – 12 h). The in-vitro plasma protein binding of posaconazole was 
99.25 ± 0.29 %. Based on posaconazole PK/PD targets for some yeasts such as disseminated 
candidiasis, posaconazole is predicted to be an efficacious treatment for cryptococcosis in 
koalas. 
2.2 Introduction 
The systemic fungal disease cryptococcosis affects many species including koalas 
(Krockenberger et al., 2002). Cryptococcus gattii is considered the principle pathogen 
responsible for cryptococcosis in koalas and is part of the Cryptococcus neoformans species 
complex comprised of C. gattii and C. neoformans (Krockenberger et al., 2003, Chen et al., 
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2014). The spectrum of presentation of this infection in koalas varies from asymptomatic 
carriage of cryptococcal organisms in the nasal mucosa, subclinical disease, localised disease 
of the nasal cavity to severe systemic disease often with nervous involvement (Krockenberger 
et al., 2002). Colonisation of this fungal yeast among respiratory tract cells with no clinical 
signs is attributed to the close association between koalas and Eucalyptus spp. trees which are 
natural hosts for C. gattii (Ellis and Pfeiffer, 1990, Krockenberger et al., 2002). The interactions 
between host, pathogen and environment is complex and occasionally lead to clinical disease 
affecting approximately 2.5 % of koalas necropsied at The University of Sydney between 1980 
and 2003 (Stalder, 2003).  
Drugs used for the systemic treatment of clinical cryptococcosis in koalas include fluconazole 
(Woods and Blyde, 1997, Wynne et al., 2012, Kido et al., 2012, Govendir et al., 2015), 
itraconazole (Kido et al., 2012, Woods and Blyde, 1997, Wynne et al., 2012) and ketoconazole 
(Woods and Blyde, 1997). A treatment protocol of daily fluconazole administration with 
additional subcutaneous administration of amphotericin is also reported (Woods and Blyde, 
1997, Wynne et al., 2012, Kido et al., 2012, Govendir et al., 2015). Black et al. (2014) 
demonstrated that oral fluconazole administration alone at 10 mg/kg twice daily is unlikely to 
be effective against Cryptococcus gattii. Moreover, therapeutic plasma concentrations (MIC90 
to inhibit C. gattii = 16 µg/ml) were not attained in some infected koalas treated with 
fluconazole orally 10 – 15 mg/kg twice a day with or without amphotericin (Govendir et al., 
2015) and some degree of nephrotoxicity is expected when amphotericin B is administered to 
people and animals (Burgess and Birchall, 1972, Davis et al., 2009). 
Posaconazole has excellent activity to inhibit all Cryptococcus spp. serotypes tested in vitro, 
including isolates with reduced fluconazole susceptibility (Thompson et al., 2009) and has been 
used to treat a variety of fungal infections in dogs and cats with minimal adverse effects 
(McLellan et al., 2006, Wray et al., 2008, Krockenberger et al., 2010, Evans et al., 2011, 
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Corrigan et al., 2015, Cook et al., 2016). Therefore, the aim of this study was to document 
changes in plasma concentrations of clinically normal koalas after a single oral bolus of 6 
mg/kg. Pharmacokinetic data were also obtained from samples collected from two koalas 
administered 3 mg/kg, i.v. On the basis of the PK profiles, it was hypothesised whether the oral 
dosage was likely to be efficacious against C. gattii.  
2.3 Materials and methods 
2.3.1 Intravenous administration of posaconazole  
This part of the experiment was conducted by Associate Professor Merran Govendir in 
association with Drs Cindy Stadler and Julie Barnes at Los Angeles Zoo, California, USA as 
an intravenous posaconazole formulation was only available in the USA at the time of study. 
The PK analysis was undertaken by the author of the thesis. 
The Animal Management Committee at the Los Angeles Zoo approved posaconazole 
administration to two long-term captive female koalas (age: both 13 years; weights: 6.4 kg and 
5.6 kg). These animals were considered clinically normal on the basis of regular physical 
examinations that included blood collection to determine their haematology and biochemical 
analyte values. The koalas were anaesthetised with isoflurane in 100 % oxygen for placement 
of a 20-gauge, 3.75 cm intravenous catheter into the cephalic vein. A cap was attached to the 
catheter and flushed with heparinised saline. The cap and catheter were secured with tape and 
bandage, for drug administration and serial blood collection. Blood (5 mL) was collected into 
lithium heparin tubes to determine baseline haematological and biochemical analyte values (t 
= 0 h). Whilst under general anaesthesia, a single i.v. bolus of Noxafil (Merck, Kenilworth, NJ, 
USA) was administered at 3 mg/kg. After blood samples were collected at 0.25 and 0.5 h, the 
animals were recovered from anaesthesia. Further blood samples were then collected at 0.75, 
1, 2, 4, 8, 12 and 24 h. Samples were centrifuged within 1 h of collection, and plasma 
transferred into plain tubes. Plasma was stored at – 20 °C and protected from light. After 
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recovery, the koalas were housed individually in pens, and supplied with food (various 
Eucalyptus spp.) and water ad-libitum.  
2.3.1.1 Drug analysis 
Samples were couriered on dry ice to the Clinical Pharmacology Laboratory at the College of 
Veterinary Medicine, North Carolina State University, Raleigh, NC, to determine posaconazole 
concentrations as documented elsewhere (Kendall and Papich, 2015) and was performed within 
weeks of sample collection. 
2.3.2 Oral administration of posaconazole 
An oral suspension of posaconazole (Noxafil, MSD, Macquarie Park, NSW) was administered 
to six koalas at Taronga Zoo, Mosman, NSW. This study was approved by Taronga 
Conservation Society Australia; Animal Ethics Committee (AEC) (protocol: 3c/06/15). 
2.3.2.1 Animals 
Six long-term captive koalas, three of each gender, aged 3.3 to 6.9 years (median: 4.3 years) 
and weight 6.7 to 8.1 kg (median: 7.5 kg), were recruited opportunistically from the Taronga 
Zoo, Mosman, NSW, Australia. These animals were considered clinically normal based on 
physical examinations and on the basis of haematological and biochemical analyte values 
within normal reference ranges. During the study, koalas were housed individually in pens and 
supplied with food (various Eucalyptus spp.) and water ad-libitum.  
2.3.2.2 Drug administration and blood collection 
Koalas were anaesthetised with alphaxalone (Alfaxan, Jurox Pty Ltd, Rutherford, NSW) at 3 
mg/kg i.m. and maintained under anaesthesia with isoflurane in 100 % oxygen via a face mask 
for catheter placement as described above. A 20-gauge, 3.75 cm catheter was placed into the 
cephalic vein and bandaged in place for the duration of blood collection. The animals were 
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then recovered from anaesthesia. Blood (5 mL) was collected 2 h after recovery in lithium 
heparin tubes to determine baseline haematology and biochemistry analyte values (t = 0 h). 
The following morning, posaconazole suspension was administered 6 mg/kg p.o. Then, serial 
blood samples (up to 3 mL) were collected into lithium heparin tubes at the following time 
points: 1, 2, 4, 6, 8, 12, 24 and 36 h. The cap and catheter were flushed with heparinised saline 
after each collection. Samples were centrifuged within 1 h of collection, and plasma was 
transferred into plain tubes. Plasma was stored at – 80 °C and protected from light until 
analysis. 
2.3.2.3 Drug Analysis  
Posaconazole concentrations in plasma samples were quantified within weeks of collection at 
the Veterinary Pharmacology Laboratory at The University of Sydney. The HPLC system 
(Shimadzu, Rydalmere, NSW) consisted of a CBM-20A module, a Shimadzu LC-20AT 
delivery unit, DGU-20A degassing solvent delivery unit, SIL-20A auto injector, CTO-20AC 
column oven and SPD-20A diode array detector. A Shimadzu class VP data system (ver. 7.4; 
Shimadzu, Rydalmere, NSW) was used for chromatographic control, data collection, and data 
processing. Chromatographic separation was performed with a Synergy MAX-RP-80 Å [4 µm, 
150 mm × 4.6 mm, (i.e. column packing particle size, column length × internal diameter)] 
(Phenomenex, Lane Cove, NSW) with a 1 mm Opti-guard C-18 pre-column (Choice 
Analytical, Thornleigh, NSW) at ambient temperature. The isocratic mobile phase used was 
the mixture of 50 mM phosphate buffer (pH: 6.2) and acetonitrile (40:60 v/v) at a flow rate of 
1 mL/min and the UV wavelength used for detection was 262 nm. The retention times of 
posaconazole and the IS (itraconazole) were approximately 4.2 and 10.9 min, respectively. 
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2.3.2.4 Sample preparation 
A stock solution of posaconazole (1 mg/mL) and itraconazole as the IS (0.5 mg/mL) were 
prepared in 100 % methanol and acetonitrile, respectively. Posaconazole was further diluted 
with 50 % of methanol to give a series of working solutions of 0.25, 0.5, 1, 2.5, 5, 10, 25, 50 
and 100 µg/mL. Prepared stock solution was stored at – 20 °C and working solutions were 
freshly prepared at each analysis. A working solution of the IS was prepared at the 
concentration of 1 µg/mL in acetonitrile. Blank pooled koala plasma (n = 6) was used for 
validating the chromatographic condition. For the preparation of plasma calibration standards 
(0.0125, 0.025, 0.05, 0.125, 0.25, 0.5, 1.25, 2.5 and 5 µg/mL) and QC samples (0.05, 0.5 and 
5 µg/mL), the appropriate amount of working standard solutions of posaconazole were spiked 
into blank pooled koala plasma and stored at – 20 °C. 
2.3.2.5 Plasma sample extraction  
The proteins within the plasma samples (100 µL) were precipitated by adding 1:1 volume of 
acetonitrile containing 1 μg/mL of the IS and then, sonicated for 5 min and centrifuged twice 
at 14,000 g for 5 min. Following this, 30 µL of the supernatant was directly injected into the 
HPLC system.  
2.3.2.6 HPLC Method validation 
The selectivity was established by analysing blank koala plasma to identify endogenous 
interferences around the retention times of posaconazole and the IS. Posaconazole 
concentrations in plasma samples were quantified via calibration curves (0.0125, 0.025, 0.05, 
0.125, 0.25, 0.5, 1.25, 2.5 and 5 µg/mL); whereby weighted least square regression (1/x) was 
used to normalise the SD of the residuals. The LLOQ was determined based on calibration 
curves using the formula LLOQ = 10 × σ/S in which σ is the SD of the y-intercepts for the 
regression lines and S is the mean slope of the weighted regression lines (n = 3) (International 
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Conference on Harmonisation, 2005). An acceptance criterion for LLOQ was defined as 
precision (CV) and accuracy within ± 20 % of the nominal concentration with repeated analyses 
(International Conference on Harmonisation, 2005). Intra- and inter-day precision, expressed 
as CV (%), were analysed from triplicates of QC samples (0.05, 0.5 and 5 µg/mL), both within 
a day, and on three different days, respectively. Intra- and interday accuracy, expressed as bias 
was determined by a percentage difference between estimated value and the nominal value of 
posaconazole [100 – (estimated value/ nominal value × 100)]. Absolute recovery of 
posaconazole was determined by comparing the peak area of pre-spiked plasma samples at 
concentrations of 0.05, 0.5 and 5 µg/mL (n = 3) and 1 µg/mL of the IS with corresponding 
concentrations of cefovecin and the IS in deionised water. Long-term stability (up to 5 months) 
of posaconazole (0.5 and 5 µg/mL; n = 3) in pre-spiked koala plasma samples at – 20 °C was 
determined. Each assay was conducted in triplicate and statistical data analysis was achieved 
by ANOVA and unpaired student t-tests using GraphPad Prism 7.02 (GraphPad Software, Inc. 
CA, USA), where the minimum significance level for all statistical tests was set at P < 0.05. 
2.3.3 Plasma protein binding assay 
The proportion of posaconazole bound to koala plasma proteins was determined using frozen-
thawed pooled plasma of six clinically normal koalas. In brief, the pH of pooled plasma 
(approximately 8) was adjusted to 7.4 and then analytical grade posaconazole was added to 
plasma aliquots to yield 0.5, 1 and 2.5 µg/mL concentrations. Each concentration (as 5 
replicates) were incubated in a rapid equilibrium chamber (Thermo Fisher Scientific, Scoresby, 
Vic.) at 37 °C for 4 h at 250 rpm during which the unbound drug diffused into a chamber 
containing PBS (according to the manufacturer’s instructions). At the end of incubation, equal 
volumes from each chamber were removed, and after sample preparation, as described above, 
injected to the HPLC system. The percentage of drug bound to the plasma proteins was 
determined using the following equation:  
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PPB (%)  = 100 % − ([
𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑏𝑢𝑓𝑓𝑒𝑟 𝑐ℎ𝑎𝑚𝑏𝑒𝑟
𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑝𝑙𝑎𝑠𝑚𝑎 𝑐ℎ𝑎𝑚𝑏𝑒𝑟
] × 100 %) 
2.3.4 Pharmacokinetic analysis  
Pharmacokinetic parameters and indices for i.v. and p.o. administration were determined as a 
non-compartmental model using PKSolver (Zhang et al., 2010). The Cmax and Tmax were 
determined by visual inspection of the plasma concentration vs. time curve. The elimination 
rate constant (Kel) was estimated by semi-log linear regression of the terminal slope, and 
elimination half-life (t1/2) was estimated by ln 2 / Kel. The AUC and AUMC from 0 to last 
observed concentration (AUC0-t and AUMC0-t, respectively) were determined by the linear 
trapezoidal method. The AUC and AUMC from the last observed concentration to infinity were 
determined by: 
𝐴𝑈𝐶𝑡−∞ =
𝐶𝑙𝑎𝑠𝑡
𝐾𝑒𝑙
 
𝐴𝑈𝑀𝐶𝑡−∞ = (
𝐶𝑙𝑎𝑠𝑡 × 𝑡𝑙𝑎𝑠𝑡
𝐾𝑒𝑙
) + (
𝐶𝑙𝑎𝑠𝑡
𝐾𝑒𝑙
2 ) 
The mean residence time (MRT), clearance (Cl), volume of distribution at steady state (Vdss), 
volume of distribution during pseudoequilibrium (Varea) and oral bioavailability (F) were 
determined by the following equations:  
𝑀𝑅𝑇 =
𝐴𝑈𝐶𝑡−∞ 
𝐴𝑈𝑀𝐶𝑡−∞ 
  
Cl =
𝑑𝑜𝑠𝑒𝑖.𝑣.
𝐴𝑈𝐶 (𝑖.𝑣.) 0–∞
 
𝑉𝑑𝑠𝑠 = 𝐶𝑙 × 𝑀𝑅𝑇 
𝑉𝑎𝑟𝑒𝑎 =
𝐶𝑙
𝐾𝑒𝑙
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𝐹 =
(𝑑𝑜𝑠𝑒𝑖.𝑣. × 𝐴𝑈𝐶𝑝.𝑜.)
(𝑑𝑜𝑠𝑒𝑝.𝑜.  × 𝐴𝑈𝐶𝑖.𝑣.)
 
All PK parameters and indices were expressed as median (range).  
2.4 Results 
2.4.1 Method development and optimisation 
The retention times of posaconazole and the IS were approximately 4.2 and 10.2 min, 
respectively. No endogenous interference was observed at the retention times of both 
posaconazole and the IS. 
The Synergy MAX-RP-80 Å (4 µ, 150 × 4.6 mm) provided the best sensitivity and peak 
resolution of the analytes. A mixture of 60 % acetonitrile and 40 % phosphate buffer (50 mM, 
pH: 6.2) was the best mobile phase to ensure the sharpest (narrow) peaks with minimal 
interference. The chromatograms of QC samples and blank koala plasma are shown in Figure 
2-1. 
 
Figure 2-1 Chromatograms of high QC (5 µg/mL of posaconazole) (A, black trace) and low QC (0.05 
µg/mL) (B, red trace) samples (retention time of 4.2 min); IS (itraconazole) with a retention time of 
10.9 min; and (C, green trace) pooled blank koala plasma at the UV wavelength of 262 nm.  
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2.4.2 HPLC method validation  
2.4.2.1 Selectivity 
Pooled blank koala plasma and extracted koala samples, pre-spiked with posaconazole 
(0.05and 5 µg) and IS (1 µg/mL) were used to check the selectivity of this method. No 
endogenous components from koala plasma interfered with elution of the analytes.  
2.4.2.2 Linearity, LLOQ, accuracy and precision 
The plasma peak ratio (area of posaconazole peak divided by the area of the IS peak) vs the 
concentration was plotted and was linear for the concentration range used (0.0125–5 μg/mL). 
The mean regression calibration curves (n = 3) were expressed as y = 0.866 (± 0.015, SD) x + 
0.01 (± 0.002, SD), with a weighting factor of 1/x and the correlation coefficient value (R2) for 
each curve ≥ 0.9996. Based on the SD of the y-intercepts and the slope of the curves, the LLOQ 
of posaconazole was estimated to be 0.02 µg/mL. Intra- and inter-day precision expressed as 
CVs ranged from 0.83 to 2.35 % and 1.88 to 3.35 %, respectively. Intra- and interday accuracy 
expressed as a percentage of the bias ranged from – 9.54 to 0.84 % and –5.83 to – 0.89 %, 
respectively as illustrated in Table 2-1. These values satisfied the guidelines regarding assay 
reliability (International Conference on Harmonisation, 2005).  
Table 2-1 Precision and accuracy for the QC samples (0.05, 0.5, and 5 µg/mL of posaconazole) 
(triplicates per day for 3 days) 
Nominal concentration 
(µg/mL) 
Measured concentrations 
(µg/mL) 
Precision 
(CV, %) 
Accuracy 
(Bias, %) 
Intraday Interday Intraday Interday Intraday Interday 
0.05 0.05 0.05 4.12 4.52 0.47 – 6.61 
0.5 0.47 0.51 2.92 2.02 5.24 – 1.49 
5 5.20 5.26 2.71 1.88 – 3.92 – 5.22 
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2.4.2.3 Recovery  
The mean absolute recovery rates ± SD of posaconazole from the 0.05, 0.5, and 5 µg/mL QC 
samples (n = 3) were 99.78 ± 3.76 %; 95.62 ± 1.76 %; and 93.98 ± 1.82 %, respectively. The 
mean absolute recovery rate of the IS was 104.95 ± 4.19 % (n = 9).  
2.4.2.4 Stability 
Quality control plasma samples (0.5 and 5 µg/mL posaconazole) were stable at a minimum of 
5 months when stored at – 20 °C. The results are illustrated in Table 2-2. 
Table 2-2 Stability of posaconazole (0.5 and 5 µg/mL) in the QC samples 
during long-term storage at – 20 °C 
Concentration  
(µg/mL) 
Peak area of cefovecin / IS (Mean ± SD) 
First day After 5 months 
0.5 0.06 ± 0.01 0.06 ± 0.00 
5 4.74 ± 0.18 4.71 ± 0.10 
 
2.4.3 Pharmacokinetic results 
The PK parameters and indices estimated for posaconazole are summarised in Table 2-3. The 
plasma concentration vs time curves administered p.o. (n = 6) and i.v. (n = 2) are presented in 
Figure 2-2 A and B, respectively. The AUCextrapolated of the oral curves from three koalas were 
greater than 20 % (range: 20.20 – 27.51 %) of their AUC0–∞ while this value for the other koalas 
were less than 20 % (range: 11.27 – 18.71 %). The in-vitro PPB of posaconazole in pooled 
koala plasma (pooled protein concentration: 64 g/L) was 99.25 ± 0.29 %.   
Chapter 2- Pharmacokinetics of posaconazole in koalas after intravenous and oral administration 
 
72 
 
Table 2-3 Pharmacokinetic parameters and indices (median and range) estimated following 
administration of posaconazole p.o. (6 mg/kg, n = 6) and i.v. (3 mg/kg, n = 2) to normal koalas 
Parameters and indices  Oral administration  
(6 mg/kg) 
Intravenous administration  
(3 mg/kg) 
Cmax (µg/mL) 0.73 (0.55 – 0.93) 6.98 (5.17 – 8.78) 
Tmax (h) 8 (6 – 12) - 
t1/2 (h) 12.58 (10.06 – 15.99) 7.90 (7.62 – 8.18) 
Vdss (L/kg) - 1.23 (0.93 – 1.53) 
Varea (L/kg) - 1.76 (1.40 – 2.14) 
Kel (h–1) 0.06 (0.04 – 0.07) 0.09 (0.08 – 0.09) 
Cl (L/h/kg) - 0.15 (0.13 – 0.18) 
AUC (0–∞) (μg/mL*h) 15.77 (9.47 – 23.32) 20.03 (16.51 – 23.54) 
AUMC (0–∞) (μg/mL*h2) 388.80 (165.08 – 686.02) 155.60 (139.23 – 171.97) 
MRT (h) 23.17 (17.43 – 29.42) 7.87 (7.30 – 8.43) 
Foral 0.64 (0.43 – 1.06) - 
AUC 24/MIC90 * 38.13 (28.51 – 53.16) 72.86  (59.55 – 86.17) 
*Posaconazole MIC90 of Cryptococcus gattii ≤ 0.25 µg/mL (Thompson et al., 2009), AUC/MIC90 
target of 25 has been recommended for disseminated candidiasis (Lewis, 2011). 
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Figure 2-2 Posaconazole plasma concentration vs time curve. A. 6 mg/kg p.o. (median ± IQR) (n = 6), 
LLOQ = 0.02 µg/mL, B. 3 mg/kg i.v. (n = 2), LLOQ = 0.04 µg/mL (Kendall & Papich, 2015). 
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Moreover, in two koalas at the time 0, one extra chromatogram peak was observed around the 
retention time of posaconazole. This peak was identified as alphaxalone by running a working 
solution of alphaxalone through the column and using the diode array detector.  
2.5 Discussion  
This is the first study to report the PK profile of posaconazole in clinically normal koalas and 
indicates that posaconazole could be a useful drug for treating systemic fungal diseases in this 
species. No adverse effects were observed for either the p.o. or i.v. routes in any animal. 
As the intravenous formulation was only available in the US at the time of study, the 
intravenous and oral administration occurred at different zoos, and the plasma drug 
concentrations were quantified by different laboratories, both with a validated posaconazole 
assay. A procedural difference was that the two koalas administered the i.v. formulation 
remained anaesthetised until the 30-minute sample was collected and were then recovered. This 
was a condition stipulated by Los Angeles zoo in order to minimise stress to the animals during 
blood collection at 15 and 30 min after drug administration. As posaconazole is reported to 
undergo some hepatic metabolism and the parent molecule is primarily excreted via the faeces 
in people (Courtney et al., 2003, Krieter et al., 2004), it was not expected that general 
anaesthesia would have significantly delayed drug elimination although the elimination 
pathway/s of these drugs in koalas is/are unknown. The animals that underwent general 
anaesthesia and i.v. administration at Los Angeles Zoo were considerably older (13 years) than 
those that underwent oral administration at Taronga Zoo (median: 4.29 years). However, the 
haematology and biochemical analytes of these animals were within normal ranges.  
The t1/2 of posaconazole in koalas [median (range), i.v.: 7.90 (7.62 – 8.18); p.o.: 12.58 (10.06 
– 15.99) h] was shorter than that reported in dogs [i.v.: 19.93 – 35.71 h; p.o.: 14.18–48.85 h 
(Kendall and Papich, 2015)], cats [i.v.: 57.7 ± 28.4; p.o.: 38.7 ± 15.02 h (Mawby et al., 2016)] 
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and humans [median terminal t1/2: 15 – 35 h; p.o.: 20 – 66 h (Li et al., 2010)]. The shorter t1/2 
in koalas might be explained by higher median Cl (0.15 L/h/kg) and lower Vdss (1.23, range: 
0.93 – 1.53 L/kg) compared to those in dogs [Cl: 0.08 L/h/kg; Vdss: 3.28, range: 2.25 – 6.45 
L/kg, (Kendall and Papich, 2015)] and cats [Cl: 0.028 L/h/kg; Vdss: 1.86 ± 0.299 L/kg, (Mawby 
et al., 2016)]. The t1/2 of the oral posaconazole formulation was longer than that when oral 
fluconazole is administered to koalas [4.69, range: 2.47 – 8.01 h, (Black et al., 2014)] which 
indicates that the oral posaconazole may have a convenient once-daily dosing interval in 
koalas.  
The Tmax (average: 8 h, range: 6 – 12 h) was approximately similar to that recorded in dogs at 
a dosage of 6 mg/kg [average: 7.69 h, range: 4.18 – 34.28 h, (Kendall and Papich, 2015)]. The 
median Cmax of posaconazole (oral suspension 6 mg/kg) in koalas was greater (0.73 µg/mL) 
than that reported for dogs [0.42 µg/mL (Kendall and Papich, 2015)]. 
Posaconazole has a reasonable oral bioavailability range in koalas (median: 0.64, range: 0.43 
– 1.06) which is interesting as bioavailability of oral formulations in koalas is generally lower 
than in other species such as carnivores. For example, the oral bioavailability of meloxicam is 
negligible in koalas (Kimble et al., 2013a) vs 1.00 in dogs (Busch et al., 1998) and that of 
fluconazole in koalas is reported to be variable with a median 0.53 (range: 0.20 – 0.97) (Black 
et al., 2014) while in humans is > 0.90 (Brammer et al., 1990). The oral bioavailability of 
posaconazole was variable across the koalas and such variability has been noted in dogs 
[average: 0.26, range: 0.08–0.79, (Kendall and Papich, 2015)] and humans [variable depending 
on dosage regimen and food, (Li et al., 2010)]. Posaconazole is extremely insoluble which may 
be responsible for such variable oral absorption (Kendall and Papich, 2015). Furthermore, the 
oral absorption of posaconazole can be increased by the presence of food in people (Courtney 
et al., 2004), increased acidity of the gastric and / or small intestinal environment (Krishna et 
al., 2009b) and co-administration with fatty foods or a nutritional supplement (Courtney et al., 
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2004). The pH of the koala forestomach is 2.7 ± 0.1 and hind-stomach is 1.9 ± 0.2 (Cork et al., 
1983) and may have had a role in enhancing posaconazole absorption. 
No metabolites were detected in the plasma of orally administered koalas (via searching for 
any additional chromatogram peaks). This is not surprising as posaconazole is primarily 
excreted in faeces unchanged and to some extent metabolised by glucuronidation with reported 
negligible involvement of oxidative mechanisms (Li et al., 2010, Ashbee et al., 2013). 
Alternatively, the LC conditions for measuring the parent drug may not have been optimal for 
the detection of additional metabolic peaks. 
In this study, p.o. posaconazole was administered with no additional supplement as the 
palatability was acceptable to the koalas. Further investigation of oral absorption when 
administered with a fatty supplement is warranted.  
Posaconazole has been shown to exhibit potent in-vitro activity against many cryptococcal 
species (Sabatelli et al., 2006, Espinel-Ingroff et al., 2012, Pfaller et al., 2013) but posaconazole 
is not considered as primary therapy for cryptococcosis in people owing to the lack of data 
(Perfect et al., 2010). There is also some ambiguity about the required posaconazole plasma 
concentrations that are efficacious for fungal diseases in people (Dolton et al., 2012). It has 
been reported that maintenance of a trough plasma concentration (Cmin) of 1 µg/mL with 
invasive fungal infections increases the probability of therapeutic response (Ashbee et al., 
2013). For example, an average plasma concentration of 1.25 µg/mL is associated with the 
highest clinical response for invasive aspergillosis (Walsh et al., 2007), however, the genotype 
of the pathogen is important when making such recommendations (Ashbee et al., 2013). A 
posaconazole dosage used in this study (6 mg/kg p.o. once daily) failed to maintain plasma 
concentrations above 1 µg/mL over 24 h. However, the AUC24/MIC ratio has also been 
advocated as the most predictive PK/PD index of posaconazole efficacy for yeasts. This target 
is reported to be 25 (range: 12 – 25) for disseminated candidiasis (Lewis, 2011); specifically, 
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17 for disseminated Candida albicans infections (Li et al., 2010). To the best of this author’s 
knowledge, this index has not been established for C. gattii. Given the MIC90 value of 
posaconazole for Cryptococcus gattii (≤ 0.25 µg/mL) (Thompson et al., 2009), the median 
(range) of AUC 0–24/ MIC90 for p.o. suspension at 6 mg/kg and i.v. solution at 3 mg/kg were 
determined as 38.13 (28.51 – 53.16) and 72.86 (59.55 – 86.17), respectively. Thus, the dose of 
6 mg/kg p.o. and 3 mg/kg i.v. exceeded the AUC/MIC target of 25 in all koalas which may 
indicate efficacious antifungal activity of posaconazole. Posaconazole exhibited in-vitro 
plasma protein binding of 99.25 ± 0.29 % in koala plasma which is consistent with that reported 
in dogs (99 %) (Kendall and Papich, 2015) and humans (98 %) (Li et al., 2010). Bound drug 
in the blood serves as reservoir for the physiologically active free drug concentration, and 
therefore, may prolong the drug action (Kratochwil et al., 2002). Taking this into consideration, 
the high degree of binding of plasma proteins to posaconazole might facilitate its efficacy. It is 
generally accepted that only the free fraction of a drug in plasma is pharmacologically active 
(Lignell et al., 2011); given the degree of posaconazole plasma protein binding, the unbound 
posaconazole in the plasma would be far below the MIC for many fungal pathogens but the 
unbound posaconazole concentration of only 10 % of the known fungal MIC in serum have 
demonstrated a significant antifungal effect against Candida spp. while such effect has not 
been observed in protein-free media (Lignell et al., 2011). Therefore, it is suggested that a flux 
of protein-bound posaconazole to its fungal binding target is likely to be responsible for the 
efficacy of posaconazole (Lignell et al., 2011). Other factors that contribute to posaconazole’s 
efficacy may include its lipophilicity, resulting in the intracellular concentration exceeding that 
in serum or plasma (Conte et al., 2009, Farowski et al., 2010, Campoli et al., 2011, Campoli et 
al., 2013).  
A major disadvantage of posaconazole for veterinary medicine is the cost, as a single 105 mL 
bottle of the 40 mg/mL oral formulation (Noxafil, MSD, Macquarie Park, NSW) is 
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approximately AU $651.56 at the time of writing (2017). The present study, however, suggests 
that the oral formulation may well be efficacious for the treatment of systemic fungal diseases 
in koalas. Further studies are required to determine optimal dosage regimens in koalas to 
achieve therapeutic concentrations. Clinical trials are also required to investigate the efficacy 
of posaconazole in infected koalas (either with sub-clinical or clinical infections) as some 
aspects of the fluconazole PK profile varied between clinically normal, sub-clinical (antigen 
positive with no obvious clinical signs of disease) and clinically affected animals (Govendir et 
al., 2015). Further, a repeated dose study is required in koalas with fungal infections. 
Pharmacokinetic study of delayed-release posaconazole tablets may further reduce the 
frequency of drug administration although administration to koalas without crushing the tablet 
is difficult and would likely interfere with the delayed-release properties. Moreover, 
therapeutic drug monitoring of posaconazole during treatment is recommended because of 
interpatient variability in the posaconazole PK profile in humans and dogs (Dolton et al., 2012, 
Kendall and Papich, 2015).
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3.1 Abstract 
Cefovecin is a semi-synthetic, third-generation cephalosporin antibacterial that was first 
registered in Australia in 2007 as an aqueous solution for subcutaneous administration to dogs 
and cats. It is highly bound to plasma proteins (more than 90 %) in dogs, cats and monkeys. 
Binding of drugs to plasma proteins influences drug disposition. Slow release of cefovecin 
from plasma proteins results in a long elimination half-life in dogs and cats. Consequently, 
cefovecin seems to have attracted the interest of veterinarians for the treatment of bacterial 
infections in exotic species. Determination of the degree of cefovecin binding to plasma 
proteins, especially in non-domesticated species, provides valuable information as to whether 
a single bolus of cefovecin may have a prolonged therapeutic action. The aim of this study was 
to determine the in-vitro plasma protein binding of cefovecin in selected Australian marsupials 
and in the horse. An HPLC method to determine cefovecin concentrations in plasma was 
developed and validated. The plasma protein binding of cefovecin was determined by the UF 
method. The percentage of bound cefovecin to plasma protein in the selected marsupial species 
ranged from approximately 13 % (koala) to 36 % (red kangaroo) compared to 93 % in the 
horse. The low proportion of cefovecin binding to marsupial plasma proteins suggests that 
cefovecin will have a shorter duration of action in koalas and other marsupial species than in 
dogs and cats. 
3.2 Introduction 
Stress is a frequent cause of morbidity and mortality in hospitalised, non-domesticated wildlife 
animals (Myers, 2006). Administration of a long-acting antimicrobial is of interest to 
veterinarians, as such a formulation may reduce the amount of handling stress for these animals 
(Papp et al., 2010, Myers, 2006). Binding of drugs to plasma proteins is an important factor 
that influences drug disposition, and particularly for a time-dependent antimicrobial such as 
cefovecin, will also affect efficacy (Olson and Christ, 1996, Kratochwil et al., 2002). Bound 
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drug in the blood stream serves as reservoir for the physiologically active free drug 
concentration, and therefore, prolongs the duration of drug action (Kratochwil et al., 2002). 
However, a high proportion of protein binding may not be the only factor contributing to the 
long half-life of cefovecin in some species. Other factors such as tubular reabsorption in the 
kidneys in dogs and cats may also occur (Stegemann et al., 2006b, Stegemann et al., 2006c). 
Consequently, the study of protein binding across species, especially in wildlife, provides 
valuable information as to whether cefovecin may have applications for the treatment of other 
species. The aim of this study was to determine the in-vitro PPB of cefovecin in some selected 
Australian marsupials including the koala, eastern ring-tailed possum (Pseudocheirus 
peregrinus), common brush-tailed possum (Trichosurus vulpecula), eastern grey kangaroo 
(Macropus giganteus), red kangaroo (Macropus rufus), and Tasmanian devil (Sarcophilus 
harrisii). These species were selected on the request of Dr Larry Vogelnest, senior veterinarian 
at Taronga Zoo (Mosman, NSW). Determination of cefovecin binding to horse plasma proteins 
was also undertaken as a relatively large amount of plasma could be collected with minimal 
adverse effects on the horse (Equus caballus) and cefovecin plasma binding to equine plasma 
proteins has been reported previously as approximately 92 – 93 % (Valitutto et al., 2011). 
Therefore, horse plasma was used for the early development of the cefovecin assay and as a 
positive control.  
3.3 Materials and Methods 
3.3.1 Drug analysis  
Cefovecin concentrations in plasma samples were quantified by HPLC. The HPLC system was 
described previously in Chapter 2. The chromatographic separation was performed with a Luna 
C18 (2) 100 Å New Column, 5 µm, 250 x 4.6 mm (Phenomenex, Lane Cove, NSW) attached 
to a 1-mm Opti-guard C-18 pre-column (Choice Analytical, Thornleigh, NSW). The mobile 
phase was an isocratic mixture of 17 % acetonitrile and 0.1 % formic acid in water (modified 
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from a method provided by Professor Mark Papich [College of Veterinary Medicine, North 
Carolina State University, NC, USA]). The column temperature was maintained at 40 °C. The 
flow rate of mobile phase was set at 1.5 mL/min. The diode array detector was set at the 
wavelength of 261 nm. The total run time for each sample was 17 min. The retention times of 
cefovecin and sulfamethoxazole (IS) were 7.5 and 15.5 min, respectively.  
3.3.2 Sample preparation 
A primary stock standard solution of cefovecin (2 mg/mL) was prepared in water and further 
diluted to obtain a series of working solutions of 20, 40, 100, 200, 500, 5000 and 2000 µg/mL. 
A stock solution of sulfamethoxazole (2 mg/mL) was prepared in acetonitrile. Prepared stock 
solution was stored at – 20 °C and working solutions were freshly prepared at each analysis. 
Blank pooled koala plasma (n = 6) was used for validating the chromatographic condition. For 
the preparation of plasma calibration standards (1, 2, 5, 10, 25, 50 and 100 µg/mL) and QC 
samples (4, 40, and 80 µg/mL), the respective cefovecin working standard solutions were 
spiked into blank pooled koala plasma and stored at – 20 °C. 
3.3.3 Plasma sample extraction  
The proteins within the plasma samples (100 µL) were precipitated by adding a 1:1 volume of 
acetonitrile containing 25 μg/mL of the IS and then centrifuged at 14,000 g for 5 minutes. The 
supernatant was removed and then dried in a Speed Vac concentrator (SPD 121P, Thermo 
Fisher Scientific, Scoresby, Vic.). After reconstituting the samples in 100 μL of mobile phase, 
centrifugation was repeated at the same speed and duration. Following this, 10 μL of 
supernatant was injected into the HPLC system. 
3.3.4 HPLC method validation 
Assay selectivity was established by analysing blank plasma of the selected marsupial species 
(koala, common brush-tailed possum, eastern ring-tailed possum, red kangaroo, eastern grey 
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kangaroo and Tasmanian devil) and the horse to identify endogenous interference around the 
retention times of cefovecin and the IS. Cefovecin concentrations in plasma samples were 
quantified via calibration curves (1, 2, 5, 10, 25, 50 and 100 µg/mL); whereby weighted least 
square regression (1/x) was used. The LLOQ was determined based on calibration curves using 
the formula LLOQ = 10 × σ/S in which σ is the SD of the y-intercepts for the regression lines 
and S is the mean slope of the weighted regression lines (n = 5). An acceptance criterion for 
LLOQ was defined as precision (CV) and accuracy within ± 20 % of the nominal concentration 
with repeated analyses (International Conference on Harmonisation, 2005). Intra- and interday 
precision, expressed as CV (%), were analysed from triplicates of QC samples (4, 40 and 80 
µg/mL), both within a day, and on three different days, respectively. Intra- and interday 
accuracy, expressed as bias was determined by a percentage difference between estimated 
value and the nominal value of cefovecin [100 – (estimated value/ nominal value × 100)]. 
Absolute recovery of cefovecin was determined by comparing the peak area of pre-spiked 
plasma samples at concentrations of 5, 25 and 50 µg/mL (n = 3) and 25 µg/mL of the IS with 
the peak area of corresponding concentrations of cefovecin and the IS in deionised water. The 
stability of pre-spiked plasma (5, 25 and 50 µg/mL) was tested at room temperature for 8 h and 
in 4 °C for 4 days. Three freeze/thaw cycles (over a 5-day period) were assessed with pre-
spiked plasma samples (5, 25 and 50 µg/mL; n = 3). Long-term stability (up to 18 months) of 
pre-spiked plasma samples (5, 25 and 50 µg/mL; n = 3) at – 20 °C was determined. Each assay 
was conducted in triplicate and statistical data analysis was achieved by ANOVA and unpaired 
student t-tests using GraphPad Prism 7.02, where the minimum significance level for all 
statistical tests was set at P < 0.05. 
3.3.5 Blood collection 
Blood collection from koalas was approved by The University of Sydney AEC (protocol: 
2015/877). The animals were considered clinically normal based on regular physical 
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examination and blood collection to check their haematology and biochemical analyte levels. 
Horse blood was obtained from the Horse Unit of SSVS following The University of Sydney 
animal ethics approval (protocol: 2015/736). Blood samples from the other Australian 
marsupials (at least 3 animals per species) were opportunistically collected by the veterinarians 
at Taronga Zoo and after centrifugation, plasma samples were stored at – 20 °C until analysis.  
3.3.6 Plasma protein binding assay  
The in-vitro plasma protein binding of cefovecin was determined by the modified UF assay 
(Dow, 2006). Initially, the non-specific binding of cefovecin to the ultrafiltrate device 
membrane (Centrifree Centrifugal Filters-30K, Merck Millipore, Bayswater, Vic.) was 
determined using phosphate buffer (pH: 7.4) instead of plasma, and was between 4 to 6 %. 
Then, total plasma protein (TPP) concentrations as well as the pH of frozen-thawed, pooled, 
drug-free plasma samples from different species were measured prior to the assay. The pH of 
plasma (approximately 8) was adjusted to 7.4. Fresh horse plasma was also used to compare 
its results with frozen horse plasma. Analytical grade cefovecin was added to 700 µL plasma 
aliquots to yield 10, 50 and 100 µg/mL concentrations. These concentrations were selected as 
it was used previously to determine the in-vitro PPB of cefovecin in dogs and cats (Stegemann 
et al., 2006b, Stegemann et al., 2006c). Samples were incubated for 30 minutes in a water bath 
at 37 °C for horse samples and 36 °C for marsupial samples to mimic their respective body 
temperatures (Dawson and Hulbert, 1970, Degabriele and Dawson, 1979, Tyndale-Biscoe, 
2005). To determine the total drug concentration, 100 µL of plasma from each tube (A) was 
removed, and after sample preparation, injected to the HPLC system. The remaining plasma 
was then transferred to the reservoir of the ultrafiltrate device, which had a membrane of a 
molecular weight cut-off 30 kDa. The ultrafiltrate device was centrifuged with a fixed 45-
degree angle rotor and spun at 5,800 g for 18 minutes at room temperature. After centrifugation, 
the filtrate was used for determining the free drug concentration (C). All samples were prepared 
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and analysed in triplicate and analysed by ANOVA test using GraphPad Prism 7.02 if required. 
The PPB of cefovecin was determined using the following equation:  
PPB (%)  = 100 − ([
𝐶
𝐴
] × 100) 
3.4 Results 
3.4.1 Method development and optimisation 
Based on the UV spectra, the greatest area under the cefovecin peak was at the wavelength of 
261 nm. The retention times of cefovecin and the IS were approximately 7.5 and 15.5 min, 
respectively. No endogenous interference was observed at the retention time of cefovecin nor 
the IS. The chromatograms of pre-spiked (5 and 50 µg/mL of cefovecin) and blank pooled 
koala plasma are shown in Figure 3-1. 
 
Figure 3-1 Chromatograms of extracted pre-spiked koala plasma containing 50 µg/mL (A, black 
trace) and 5 µg/mL (B, red trace) of cefovecin (retention time of 7.5 min) and 25 µg/mL of the IS 
(sulfamethoxazole, retention of 15.5 min); pooled blank koala (C, green trace) plasma at the UV 
wavelength of 261 nm. 
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3.4.2 HPLC method validation 
3.4.2.1 Selectivity 
Pooled blank koala plasma and extracted koala plasma pre-spiked with cefovecin (5 and 50 µg) 
and IS (25 µg/mL) were used to check the selectivity of this method (Figure 3-1). Moreover, 
the selectivity of the method was also checked using the plasma from the other marsupial 
species and the horse. Because of the limited volume of plasma available, only blank plasma 
of these species were used. No endogenous constituents from plasma interfered with the elution 
of the cefovecin nor the IS. 
3.4.2.2 Linearity, LLOQ, accuracy and precision 
The plasma peak ratio (the area of cefovecin peak divided by the area of IS peak) vs the 
concentration was plotted and found to be linear for the concentration range used (1 – 100 
μg/mL). The mean regression calibration curves (n = 5) were expressed as y = 0.027 (± 0.001, 
SD) x – 0.001 (± 0.003, SD), with a weighting factor of 1/x, the correlation coefficient value 
(R2) for each curve ≥ 0.999. Based on the SD of the y-intercepts and the slope of the curves, 
the LLOD and LLOQ of cefovecin were estimated to be 0.34 and 1.02 µg/mL, respectively. 
Intra- and inter-day precision expressed as CVs ranged from 0.97 to 4.29 % and 0.73 to 4.52 
%, respectively. Intra- and interday accuracy expressed as a percentage of the bias ranged from 
–7.31 to 3.31 % and –7.31 to 14.37 %, respectively. These values satisfied the guidelines 
regarding assay reliability (International Conference on Harmonisation, 2005). The average of 
precision and accuracy of QC samples (4, 40, and 80 µg/mL) are summarised in Table 3-1.  
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Table 3-1 Precision and accuracy for the QC samples (4, 40, and 80 µg/mL of cefovecin) (triplicates 
per day for 3 days) 
Nominal 
concentration 
(µg/mL) 
Measured concentrations 
(µg/mL) 
Precision (CV, %) Accuracy (Bias, %) 
Intraday Interday Intraday Interday Intraday Interday 
4 3.98 ± 0.11 3.82 ± 0.11 3.04 2.76 0.42 4.51 
40 40.60 ± 1.74 39.50 ± 1.27 4.29 3.19 – 1.50 1.24 
80 80.70 ± 1.05 77.66 ± 1.49 0.97 1.82 – 0.87 2.93 
 
3.4.2.3 Recovery  
The mean absolute recovery rates ± SD as a percentage of cefovecin from the 5, 25, and 50 
µg/mL QC samples (n = 3) were 82.56 ± 3.88; 92.01 ± 4.09; and 89.01 ± 0.34, respectively. 
The mean absolute recovery rate of the IS was 86.93 ± 2.27 (n = 9).  
3.4.2.4 Stability  
Assessment of the long-term stability of cefovecin in koala plasma demonstrated that QC 
plasma samples (5, 25 and 50 µg/mL cefovecin) were stable when tested after 8 h at room 
temperature, 4 days at 4 °C and 18 months when stored at – 20 °C as demonstrated in Table 3-
2. No significant changes of cefovecin concentration in the QC samples were observed after 
three freeze/thaw cycles over a 5-day period.  
Table 3-2 Stability of cefovecin in koala plasma containing 5, 25, 50 µg/mL of cefovecin during 
freeze/thaw cycles and long-term storage at – 20 °C  
Concentration  
  (µg/mL) 
Peak area of cefovecin / IS (Mean ± SD) 
Freeze/thaw cycles Long-term stability 
First day Last day First day After 18 months 
5 0.12 ± 0.01 0.13 ± 0.01 0.12 ± 0.01 0.12 ± 0.01 
25 0.67 ± 0.03 0.63 ± 0.00 0.68 ± 0.03 0.62 ± 0.02 
50 1.30 ± 0.03 1.26 ± 0.02 1.34 ± 0.02 1.18 ± 0.06 
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3.4.3 In-vitro plasma protein of cefovecin in selected marsupial species 
The reported range of TPP concentrations for the respective species and the measured TPP of 
the pooled samples are provided in Table 3-3. 
Table 3-3 Reference range of TPP and measured TPP of the Australian marsupial species and the horse 
Species Normal range of TPP 
(g/L) 
Measured TPP 
(g/L) 
Koala (Blanshard and Bodley, 2008) 60 – 75 66 
Tasmanian devil (Holz, 2008) 60 ± 6 64 
Eastern grey kangaroo (Vogelnest and Portas, 2008) 60 ± 8 70 
Common brush-tailed possum (Johnson and 
Hemsely, 2008) 
Male: 59 – 79 
Female: 51 – 89 
70 
Eastern ring-tailed possum (Johnson and Hemsely, 
2008) 
43 – 67 56 
Red kangaroo (Vogelnest and Portas, 2008) 64 ± 10 62 
Horse (Riond et al., 2009) 51 – 72 70 
 
The results of in-vitro plasma protein binding of cefovecin in selected Australian marsupial 
species as well as those in the horse are summarised in Table 3-4 and Figure 3-2.  
Table 3-4 In-vitro plasma protein binding (%) of cefovecin (10, 50 and 100 µg/mL) in Australian marsupial 
species and the horse (determined by ultrafiltration) 
Concentration 
  (µg/mL) 
Koala  Tasmanian 
devil 
Eastern  
grey 
kangaroo 
Common   
brush-tailed 
possum 
Eastern  
ring-tailed 
possum 
Red  
kangaroo 
Horse  
10 11.9 11.89 24.05 21.24 35.55 36.46 95.47 
50 11.29 15.99 21.41 27.25 34.17 39.52 92.94 
100 15.46 20.03 19.55 31.03 35.25 32.27 90.18 
Mean ± SD 12.88 ± 2.25 15.97 ± 4.07 21.67 ± 2.26 26.69 ± 4.94 34.99 ± 0.72 36.08 ± 3.64 92.86 ± 2.65 
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Figure 3-2 Mean plasma protein binding values (%) of cefovecin (10, 50 and 100 µg/mL) in selected 
Australian marsupial species and horse (determined by ultrafiltration). The error bars show the SD. 
The mean protein binding values of koala and horse plasma pre-spiked with cefovecin at 
concentration range between 10 to 300 µg/mL were obtained through a different set of 
experiments and are depicted in Figure 3-3. While there were no significant differences 
between bound cefovecin percentages at different concentrations in koala plasma, the PPB 
values of cefovecin at the concentration of 200 and 300 µg/mL decreased considerably in horse 
plasma (P < 0.0001). 
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Figure 3-3 Mean percentage of bound cefovecin (10 to 300 µg/mL) in pooled koala and horse 
plasma determined by ultrafiltration. The table under the graph shows the mean percentage of 
cefovecin bound to plasma proteins of the horse and the koala at different concentrations; the 
mean ± SD of all concentrations for the koala and horse was 12.93 ± 1.13 and 82.58 ± 16.95, 
respectively. The reduction of bound cefovecin at higher concentrations in the horse shows the 
saturation of plasma proteins (P < 0.0001). 
3.5 Discussion 
An HPLC method with a water-based mobile phase and PDA detector was developed and 
validated for the detection of cefovecin in plasma. A simple sample extraction procedure was 
undertaken by protein precipitation with 1:1 volume of acetonitrile. This method, with linearity 
range of 1 – 100 µg/mL and LLOQ of 1.02 µg/mL, was suitable for this in-vitro study. 
Frozen plasma of the Australian marsupial species was used to batch the results. The pH of 
frozen plasma is reported to vary from that of fresh plasma which could affect drug binding to 
plasma proteins (Riviere and Buur, 2011, Riedel, 2013). Therefore, the pH of the samples was 
adjusted to 7.4 prior to the experiments. Moreover, no significant differences were observed in 
the PPB values of cefovecin (10, 50 and 100 µg/mL) when tested with the fresh (mean: 92.66 
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± 1.52 %) vs thawed frozen horse plasma (mean: 92.86 ± 2.65 %). Due to the small amounts 
of plasma obtained from the marsupials, the plasma was frozen prior to assay and it was not 
possible to conclude whether this affected the results. 
The PPB in the selected marsupial species ranged from 12.88 ± 2.25 % (koala) to 36.08 ± 3.64 
% (red kangaroo) which were large differences compared to those in the horse (92.86 ± 2.65 
%) and other studied mammals (Stegemann et al., 2006c, Stegemann et al., 2006b, Bakker et 
al., 2011, Papp et al., 2010, Cox et al., 2014b, Raabe et al., 2011, Valitutto et al., 2011). The 
PPB of cefovecin varies among species (Colclough et al., 2014). It is assumed many drugs bind 
to plasma albumin and interspecies differences in PPB is mostly attributable to differences in 
the amino acid sequences of plasma albumin. Thus, species differences in the conformation of 
plasma albumin could affect its binding capacity (Baggot, 2001, Colclough et al., 2014). Acidic 
drugs such as β-lactam antibiotics largely bind to albumin and basic drugs, e.g. macrolides, 
often bind to other proteins, particularly α1-acid glycoprotein (AAG) (Baggot, 2001, Colclough 
et al., 2014). Cefovecin is a basic drug but there is no published information to which plasma 
protein(s), cefovecin binds, and this was not established in this study.  
Cefovecin shows high protein binding in mammals such as dogs (Stegemann et al., 2006b), 
cats (Stegemann et al., 2006c), lions (Valitutto et al., 2011), squirrel monkeys (Papp et al., 
2010), cynomolgus macaques (Papp et al., 2010, Raabe et al., 2011), rhesus macaques (Papp 
et al., 2010), alpacas (Cox et al., 2014b), tigers, bears and horses (Valitutto et al., 2011) 
(illustrated in Table 1-4). Our results in the horse were consistent with those reported 
previously (92.70 ± 0.26 and 93.99 ± 0.32 for spiked horse plasma containing 1 and 10 µg/mL 
cefovecin, respectively; Valitutto et al. 2011). To this author’s knowledge, the information has 
not been published in a peer-reviewed journal.  
Cefovecin was highly bound to proteins in horse plasma; over a concentration range of 10 –
100 µg/mL, the percentage of protein binding was 94.27 % to 90.69 %. At higher 
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concentrations, 200 and 300 µg/mL, the protein binding reduced to 70.97 % and 53.08 %, 
respectively. This trend is consistent with those reported for dogs (Stegemann et al., 2006b) 
and cats (Stegemann et al., 2006c), indicating saturation of plasma proteins for cefovecin 
binding at the concentration of 200 and 300 µg/mL in these species (Stegemann et al., 2006b). 
This trend was not observed in koala plasma. 
Some birds possess a low PPB capacity for cefovecin (Valitutto et al., 2011). The plasma half-
life in hens is reported to be 0.90 h following s.c. administration. This study demonstrated that 
cefovecin with a 14-day dosing interval is not suitable to treat bacterial infections in hens and 
most likely in several other birds (Thuesen et al., 2009). Similarly, selected Australian 
marsupials showed low PPB of cefovecin. However, the in-vitro PPB could deviate from that 
in the live animal as in-vivo protein binding can be affected by the concentration, structure and 
function of plasma proteins which can vary with age and disease, as well as the presence of 
competing endogenous and exogenous compounds such as dietary constituents or other 
therapeutic drugs (Lindup and Orme, 1981, Sansom and Evans, 1995).  
The dissociation rates of the cefovecin from plasma proteins of these marsupials were not 
determined. Nevertheless, this value can be of great importance when there is a high PPB of a 
drug as high PPB and slow dissociation rate can affect ADME of the drug significantly (see 
section 1.2.2.2 of chapter 1). 
The low proportion of cefovecin binding to plasma proteins in marsupials might indicate that 
cefovecin has a much shorter duration of action in these species and that it might have a 
different duration of efficacy in these species. This should be confirmed by further in-vivo 
studies. An in-vivo study of cefovecin administration to koalas is reported in the next chapter. 
  
Chapter 4 
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4.1 Abstract  
Cefovecin was administered subcutaneously to six koalas at a single dose of 8 mg/kg. Blood 
was collected at 0 h and then serial blood samples were collected 3, 6, 24, 48, 72 and 96 h after 
drug administration. Plasma concentrations of cefovecin were determined using an HPLC 
method. An HPLC method developed to detect cefovecin concentrations < 1 µg/mL did not 
have acceptable accuracy. Therefore, the method validated in Chapter 3 with an LLOQ of 1.02 
µg/mL was used to assay the plasma samples from koalas. Cefovecin plasma concentrations 
were not quantifiable in four koalas and in two other koalas a mean plasma concentration of 
1.04 ± 0.01 µg/mL was quantitated after 3 h. It was concluded that, unlike in dogs and cats, 
cefovecin is likely to have a short duration of action (hours rather than days) in koalas. 
4.2 Introduction 
Cefovecin is administered to koalas prophylactically or to treat bacterial infections by some 
veterinarians, who might assume the same duration of action in koalas as in dogs and cats. The 
result of the in-vitro PPB of cefovecin in the koala (12.88 ± 2.25 %) suggests that a single s.c. 
bolus injection of cefovecin could have a short duration of action in koala plasma. Therefore, 
the aim of this chapter was to investigate cefovecin plasma concentration administered to live 
koalas to confirm whether its duration of therapeutic action in plasma is shorter than that in 
dogs and cats, and to estimate the correct administration frequency in koalas. 
4.3 Materials and Methods 
4.3.1 Animals 
Six captive koalas (3 males and 3 females), aged 3.3 to 6.9 (median: 4.3) years and weight 6.7 
to 8.1 kg (median: 7.5 kg), were recruited opportunistically from Taronga Zoo display 
collection (Mosman, NSW). They were considered clinically normal based on regular physical 
examinations and on the basis of haematological and biochemical analyte values within normal 
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reference ranges. During the study koalas were housed in pens either singly or in groups, and 
supplied with various Eucalyptus spp. and water ad-libitum. This study was approved by 
Taronga Conservation Society Australia with the AEC protocol number of 3c/06/15. 
4.3.2 Drug administration and blood collection 
Koalas were anaesthetised with alphaxalone (Alfaxan, Jurox Pty Ltd, Rutherford, NSW) at 3 
mg/kg i.m. and maintained under anaesthesia with isoflurane in 100 % oxygen via a face mask 
to place a 20-gauge catheter into the cephalic vein. Blood (5 mL) was collected in lithium 
heparin tubes 2 h after recovery to determine baseline haematology and biochemistry analyte 
values, and to confirm the absence of medications (t = 0 h). The next morning cefovecin 
(Convenia, Zoetis Animal Health, West Ryde, NSW) was administered to koalas at 8 mg/kg 
s.c., the same dosage recommended for dogs and cats (Stegemann et al., 2006b, Stegemann et 
al., 2006c). To determine the cefovecin plasma concentration, serial blood samples (up to 3 
mL) were collected into lithium heparin tubes at the following time points: 3, 6, 24, 48, 72 and 
96 h. The cap and catheter were flushed with heparinised saline after each collection. Samples 
were centrifuged within 1 h of collection and plasma was transferred into plain tubes. Plasma 
was stored at – 80 °C, transported promptly on ice to The University of Sydney where the 
samples were stored at – 20 °C and protected from light until analysis. 
4.3.3 New HPLC method optimisation  
The HPLC-PDA method described in the previous chapter had a LLOQ of 1.02 µg/mL suitable 
for an in-vitro assay where concentrations of cefovecin > 1 µg/mL were required to be detected. 
However, to determine cefovecin concentrations in plasma samples collected from koalas after 
s.c. administration of cefovecin, many modifications of the HPLC assay were trialled to 
achieve a lower LLOQ with acceptable accuracy and precision. Such modifications included 
revision of the organic solvent, pH of the mobile phase, sample preparation technique and a 
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change of column. The chromatographic separation with the best results was with a Luna 5u 
C18(2) 100 Å New Column 250 x 4.6 mm (Phenomenex, Lane Cove, NSW) attached to a 1-
mm Opti-guard C-18 pre-column (Choice Analytical, Thornleigh, NSW). The mobile phase 
was an isocratic mixture of 19 % acetonitrile and 81 % potassium phosphate buffer (20 mM) 
adjusted with phosphoric acid to pH 2.15. The column temperature was maintained at 40 °C. 
The flow rate of the mobile phase was set at 1 mL/min and the diode array detector was set at 
the wavelength of 261 nm. Fluconazole was used as the IS. The total run for each sample took 
13 min. The retention times of cefovecin and the IS were 7.7 and 10.5 min, respectively.  
4.3.4 Sample preparation 
To extract cefovecin from plasma samples, LLE and PPE including methods reported in other 
species (Stegemann et al., 2006b, Thuesen et al., 2009, Nardini et al., 2014) were trialled. As 
these techniques resulted in poor recovery and / or selectivity of cefovecin from koala plasma, 
SPE was undertaken to minimise interference by endogenous matrix compounds.  
4.3.4.1 Solid phase extraction using Oasis HLB cartridges 
A SPE method using Oasis HLB cartridges (Hydrophilic-Lipophilic Balance cartridges, 
Waters, Rydalmere, NSW) (Cox et al., 2014a) was used. The cartridges were connected to a 
Vac Elut vacuum manifold (Waters, Rydalmere, NSW) with a maximum vacuum of 5 psi. Each 
plasma sample (100 µL) was mixed with 400 μL of methanol (15 % in water), 25 µL of the IS 
(100 μg/mL) and 25 μL of phosphoric acid (10 % in water). The mixture was vortexed at high 
speed for 5 s, allowed to stand for 5 min, then centrifuged at 10,000 g for 10 min. All SPE 
cartridges were conditioned with 1 mL of methanol then washed with 1 mL water. After loading 
the samples, the cartridges were washed with 1 mL methanol (25 % in water). Cefovecin was 
then eluted with 1 mL methanol and 1 mL methanol with 3 % ammonium hydroxide. The eluate 
was dried in a Speed Vac concentrator (SPD 121P, Thermo Fisher Scientific, Scoresby, Vic.). 
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After reconstituting the samples in 100 μL of mobile phase, the samples were re-centrifuged at 
10,000 g for 5 min and 20 μL of the supernatant was injected into the HPLC system. 
4.3.4.2 Solid phase extraction using Oasis MCX cartridges 
SPE was also performed using a protocol recommended by Waters Corporation (Rydalmere, 
NSW) optimised for cephalexin extraction (a difficult amphoteric analyte with two acid 
dissociation constants (pKa) of 2.6 & 7.3) using Oasis MCX (mixed-mode reversed-
phase/strong cation-exchange) cartridges (Waters Sample Preparation, 2014). Briefly, each 
plasma sample was diluted and acidified with phosphoric acid (4 % in water). After 
conditioning and washing the cartridges (with methanol followed by water), respective aliquots 
were loaded, and the cartridges were washed with formic acid (2 % in water). The cefovecin 
was then eluted with either methanol or 5 % ammonium hydroxide in methanol-acetonitrile 
(60:40 v/v).  
4.3.4.3 Micro-disc solid-phase extraction 
Due to the lack of selectivity of the abovementioned SPE methods and on consultation with 
Agilent Technologies Australia (Mulgrave, Vic.), a more specific cartridge, the ‘SPEC-DAU 
micro-disc’ (Agilent Technologies, Mulgrave, Vic.) was trialled to extract cefovecin. This 
cartridge is a mixed-mode, reversed-phase/strong cation-exchanger (RP/SCX). Cefovecin is a 
polar molecule charged at almost any pH. It has three pKa: the carboxyl has pKa of 2.6, the 
amine has pKa of 3.2 and the amino group on the ring has pKa of 11.1 (information provided 
by Professor Mark Papich, College of Veterinary Medicine, North Carolina State University, 
NC, USA). If the samples containing cefovecin are diluted in an acidic buffer, then conditioned 
with low pH after loading samples into the cartridge; the cefovecin amine moiety will be 
charged (NH4
+) and the acidic group on the cefovecin will be protonated (-COOH) and 
uncharged. If the final elution involves a high pH eluent (such as ammonium hydroxide), the 
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amine moiety becomes neutral and the cefovecin should elute (Majors, 2013). Therefore, the 
method of Li et al. (2004) was modified to extract cefovecin from the plasma samples using 
SPEC-DAU micro-disc SPE cartridges. This method was modified via several preliminary 
experiments to optimise the sample pH, and washing and elution conditions for maximum 
recovery and selectivity. Ultimately, plasma samples (100 µL) were diluted with 800 µL of 0.1 
M potassium phosphate buffer (pH: 6.0) and then spiked with 10 µL of the working IS solution 
(fluconazole 200 µg/mL) to give a final plasma concentration of 20 µg/mL of the IS. The 
SPEC-DAU micro-disc SPE cartridges were connected to a Vac Elut vacuum manifold and 
conditioned with 0.5 mL of methanol followed by washing with 0.5 ml of 0.1 M potassium 
phosphate buffer (pH: 6.0). The samples were then allowed to run through the disc at a flow 
rate of less than 1 mL/min. Subsequently, the cartridges were rinsed with 0.5 mL of 1 M acetic 
acid and dried under vacuum for 2 to 3 min. Then, the tips of the Vac Elut delivery needles 
were wiped. Analytes were eluted twice with 0.5 mL of 5 % ammonium hydroxide in 
acetonitrile-methanol (60:40 v/v). The eluents were dried under vacuum in a Speed Vac 
concentrator and the dried residue was reconstituted in 100 μL of mobile phase. The mixture 
was then vortexed and centrifuged at 14,000 g for 5 min and 20 µL of supernatant was directly 
injected into the HPLC system.  
4.3.5 New HPLC method validation  
The validation was conducted with the HPLC condition and micro-disc SPE as described 
above. The selectivity was established by analysing blank koala plasma to identify endogenous 
interference around the retention time of both cefovecin and the IS. Absolute recovery of 
cefovecin was determined by comparing the peak area of pre-spiked plasma samples at 
concentrations of 0.125, 1 and 4 µg/mL (n = 3) and 20 µg/mL of the IS with corresponding 
concentrations of cefovecin and the IS in the mobile phase. The recovery test was performed 
in duplicate. Cefovecin concentrations in plasma samples were quantified via calibration 
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curves (0.05, 0.125, 0.25, 0.5, 1.25, 2.5 and 5 µg/mL); whereby weighted least square 
regression (1/x) was used. The LLOD and LLOQ were determined based on the SD of the y-
intercepts and the average of the slope of the calibration curves. An acceptance criterion for 
LLOQ was defined as precision (CV) and accuracy within ± 20 % of the nominal concentration 
with repeated analyses (International Conference on Harmonisation, 2005). Nonlinear 
regression by weighting factor 1/x was used to test the linearity of the curve using GraphPad 
Prism 7.02, with a minimum significance level for all statistical tests set at P < 0.05. Intra-day 
precision, expressed as CV (%), was analysed from triplicates of QC samples (0.05, 0.5 and 5 
µg/mL) within a day. Intra-day accuracy, expressed as bias, was determined by a percentage 
difference between estimated value and the nominal value of cefovecin [100 – (estimated value/ 
nominal value × 100)].  
4.3.6 Drug analysis  
As the validation of the HPLC method with the micro-disc SPE sample preparation did not 
satisfy the published guidelines regarding assay reliability (International Conference on 
Harmonisation, 2005) (as explained in Sections 4.4.1 and 4.4.2), although not ideal, the HPLC 
method with LLOD: 0.34 µg/mL and LLOQ: 1.02 µg/mL described in the previous chapter 
was used to analyse cefovecin concentrations in the plasma samples. 
4.4 Results 
4.4.1 New HPLC method optimisation  
The sensitivity (i.e. a reduction in the LLOQ) of the new assay was improved with the following 
chromatographic conditions: a Luna 5µ C18 (2) 100 Å New Column 250 x 4.6 mm and an 
isocratic mixture (pH: 2.15) of 19 % acetonitrile and 81 % potassium phosphate buffer (20 
mM) as the mobile phase. The use of SPEC-DAU micro-disc SPE cartridges enabled high 
selectivity and superior recovery compared to the other sample preparation methods. Therefore, 
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the sample preparation was performed with micro-disc SPE. The chromatograms of QC 
samples and blank koala plasma are shown in Figure 4-1. 
 
Figure 4-1 Chromatograms of high QC (5 µg/mL of cefovecin) (A, black trace) and low QC (0.25 
µg/mL) (B, green trace) samples (retention time of 7.7 min); IS (fluconazole) with a retention time of 
10.5 min; and (C, red trace) pooled blank koala plasma at the UV wavelength of 261 nm.  
4.4.2 New HPLC method validation 
For 0.05, 0.5 and 5 µg/mL of cefovecin, the recovery (%) during the method development was 
69.29 %, 84.63 % and 86.89 %, respectively. However, during validation, the recovery of 
cefovecin across concentrations of interest were inconsistent and varied from 50 to 80 % while 
fluconazole recovery was stable and ≥ 90 % (as documented in Table 4-1).  
Table 4-1 The recovery (%) of cefovecin and the IS (20 µg/mL) from the QC samples (0.125, 1 and 4 
µg/mL, triplicate in each run) using micro-disc SPE 
Repetition Cefovecin concentration (µg/mL) IS concentration 
(fluconazole, 20 µg/mL)  0.125 1 4 
1 53.35 70.91 72.78 92.56 
2 62.01 64.99 80.44 91.19 
Mean ± SD 57.68 ± 6.12 67.95 ± 4.19 76.61 ± 5.42 91.88 ± 0.97 
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Using these conditions, the LLOQ was determined to be 0.23 µg/mL. However, the accuracy 
values of the standard curves exceeded ± 20 % of the nominal concentration (range: – 51.93 to 
55.39). The values of intraday accuracy for the QC samples did not satisfy the published 
guidelines regarding assay reliability (International Conference on Harmonisation, 2005). The 
average precision and accuracy for the QC samples (0.05, 0.5, and 5 µg/mL) are summarised 
in Table 4-2. 
Table 4-2 Precision and accuracy for the QC samples (0.05, 0.5, and 5 µg/mL of cefovecin) (triplicates 
per day for 3 days) 
Nominal concentration 
(µg/mL) 
Intraday measured 
concentrations 
(µg/mL) 
Intraday accuracy  
(Bias, %) 
Intraday precision 
 (CV, %) 
0.05 0.06 ± 0.01 – 20.93 ± 19.13 0.17 
0.5 0.63 ± 0.01 – 25.85 ± 2.30 0.02 
5 5.89 ± 0.83 – 17.75 ± 16.59 0.14 
 
4.4.3 Pharmacokinetic results  
Cefovecin plasma concentrations were determined using the HPLC method described in 
Chapter 3 with the PPE method (LLOD: 0.34 µg/mL and LLOQ: 1.02 µg/mL). Cefovecin 
concentrations were only detectable at time 3 h in two koalas (0.72 ± 0.05 and 0.73 ± 0.07 
µg/mL) and quantifiable at time 3 h in two other koalas (1.03 ± 0.03 and 1.05 ± 0.01 µg/mL). 
No drug was detectable in the plasma of the remaining two koalas nor in the plasma at the other 
time points of the other four koalas (0 h, 6 h, 24 h, 48 h, 72 h and 96 h). Based on these results, 
no further PK analyses were possible. 
4.5 Discussion 
Cefovecin plasma concentrations for the in-vitro study were assayed by HPLC-PDA with 
LLOQ of 1.02 µg/mL (see the previous chapter). Moreover, the HPLC with UV detection has 
been used to detect cefovecin concentration in plasma samples of white bamboo sharks and 
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Atlantic horseshoe with an LLOQ of 0.1 µg/mL (Cox et al., 2014a), and of hen, iguana and 
monkey plasma with an LLOQ of 0.5 µg/mL (Thuesen et al., 2009, Bakker et al., 2011). 
However, several difficulties were encountered to develop a reliable HPLC method with 
greater sensitivity to detect cefovecin concentrations in koala plasma in-vivo.  
First, during method development, endogenous compounds in the koala plasma matrix 
interfered with the cefovecin peak on the chromatogram. Highly heterogeneous biological 
matrices such as plasma can contain many endogenous substances such as proteins and lipids 
which can obscure the drug peaks (including that of the IS) on the chromatogram; this matrix 
can compromise assay selectivity and sensitivity (Hall et al., 2012, Hooshfar and Bartlett, 
2016). The heterogeneity of endogenous substances in koala plasma seems complex, 
presumably due to the koala’s eucalypt foliage diet, causing greater interferences and 
challenges in the HPLC method optimisation for drug analysis (Stupans et al., 2001, Kimble et 
al., 2013b). Moreover, in our laboratory, variable peaks and variations in the endogenous peak 
height and AUC on chromatograms are frequently observed in plasma matrices between koalas 
from different regions of Australia and even within the same region (unpublished 
observations). Therefore, the HPLC method was modified and revalidated with pooled blank 
plasma from the koalas involved in the study. 
Second, as most biological matrices are polar and water soluble, both biological matrices and 
polar compounds such as cefovecin and amoxicillin are eluted early during reversed-phase 
chromatography. Thus, polar components are subject to more interferences by biological 
matrices than non-polar compounds that are eluted later during the separation by reversed-
phase chromatography (Meyer, 2004, Hall et al., 2012).  
Third, the complexity of chemical composition of cefovecin (possessing three pKa) caused 
many obstacles when optimising the new HPLC method. As PPE and LLE did not remove the 
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organic interference in the plasma samples effectively, a more rigorous sample clean-up (SPE) 
was undertaken to eliminate the interferences and increase the method’s sensitivity. Despite 
promising results during the preliminary method development for cefovecin, the accuracy for 
the standard curves and QC samples of cefovecin did not meet the accepted criteria regarding 
assay reliability (International Conference on Harmonisation, 2005). Cefovecin recovery 
varied during validation for as yet unknown reasons. As cefovecin did not exist in either the 
load or wash fractions (fractions collected after loading the samples and washing the cartridges, 
respectively), it might have been retained strongly on the column but was not eluted completely 
even with higher percentages of ammonium hydroxide (up to 8 %). Other possibilities are 
secondary interactions between the sorbent and the analyte, or a highly retentive sorbent that 
could cause irreversible adsorption of some analytes on the cartridges (Majors, 2013, 
CHROMacademy, 2016).  
Initially, two options were considered as the IS: fluconazole and sulfamethoxazole. The latter 
was used in Chapter 3. Both drugs eluted later than cefovecin; however, the fluconazole 
retention time was sooner with the conditions described in Chapter 4, reducing the total run 
time.  
Although bioanalytical methods with better sensitivities as low as 0.05 µg/mL (Stegemann et 
al., 2006c) and 0.005 µg/mL (Papp et al., 2010) are reported using LC-tandem mass 
spectrometry, the equipment was not available to replicate these methods. 
Analysing samples from koalas after cefovecin administration at 8 mg/kg s.c. yielded limited 
pharmacological information but no adverse effects were observed in any koala following 
administration. The paucity of cefovecin concentrations above the LLOQ (1.02 µg/mL) meant 
that the PK indices such as Tmax, Cmax and t1/2 could not to determined and, therefore, one of the 
aims of this chapter, i.e. to estimate the correct administration frequency (see Section 4.2), was 
not met.  
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The low cefovecin concentrations were not thought to be due to poor stability of cefovecin in 
plasma, as cefovecin in koala plasma was stable when tested after 18 months storage at – 20 
°C.  
When planning this study, cefovecin plasma concentrations were expected to be detectable for 
at least four days, therefore, samples were collected up to 96 h. An assay with lower LLOQ 
and collection of blood at more time points prior to 6 h could have facilitated better 
characterisation of some PK indices but, despite many attempts, developing a validated HPLC 
method with greater sensitivity in this species was difficult.  
Administering cefovecin at 8 mg/kg s.c. to dogs gave a mean Cmax of 121 µg/mL (Stegemann 
et al., 2006b). However, the same dose rate administered to koalas achieved a plasma 
concentration of ≤ 1 µg/mL at time 3 h and 6 h. This might be due to the poor bioavailability 
of s.c. cefovecin and / or a fast elimination rate. Similarly, a low Cmax (0.83: 0.66 – 1.52) was 
previously observed following s.c. administration of enrofloxacin (5 mg/kg) which was 
attributed to limited absorption due to poor vascularity around the injection site or fast 
elimination in koalas (Griffith et al., 2010). The previous observations of the low percentage 
of cefovecin PPB (12.88 ± 2.25 %) might suggest a very short half-life of cefovecin in koalas 
as the PPB of cefovecin was reported to be less than 10 % in birds such as brown pelican 
(Pelecanus occidentalis) and American flamingo (Phoenicopterus ruber) (Valitutto et al., 
2011) and negligible in the red-eared slider (a semiaquatic turtle, Trachemys scripta elegans) 
(Sypniewski et al., 2017) and, consequently, the plasma half-life of s.c. cefovecin was 0.87  
0.27 h in Lohmann hens (Gallus gallus domesticus) (Thuesen et al., 2009) and 6.8  1.2 h in 
the red-eared slider (Sypniewski et al., 2017) compared to 5.5 and 6.9 d in the dog and cat, 
respectively (Stegemann et al., 2006b, Stegemann et al., 2006c) (see Table 1-3). The difference 
in half-lives of cefovecin in these species was partly attributed to differences in the binding of 
cefovecin to plasma proteins (Thuesen et al., 2009, Sypniewski et al., 2017).  
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The LC conditions for measuring cefovecin concentrations were not optimal for detecting any 
possible metabolites. Metabolites were not expected as cefovecin hepatic metabolism is 
insignificant in its elimination in dogs and nonhuman primates (Stegemann et al., 2006b, Papp 
et al., 2010). As cefovecin is primarily eliminated via kidneys (Stegemann et al., 2006b, Papp 
et al., 2010), it might be worth investigating its accumulation in urine. This was not attempted 
because low plasma concentrations were not expected, and the additional resources were not 
available to catch urine over four days. Moreover, cystocentesis in conscious koalas is 
challenging due to the koala’s urinary bladder lying within the pelvic cavity, frequently 
surrounded by a large caecocolon (Blanshard and Bodley, 2008).  
Cefovecin, a cephalosporin antibacterial, is described as having time-dependent activity (Craig, 
1995, Jacobs, 2001, Turnidge and Paterson, 2007). Successful therapy is predicted if the 
effective concentration of cefovecin during the dosage interval is maintained above 50 to 70 % 
of the antimicrobial MIC for gram-negative pathogens and less than 40 to 50 % of MIC 
concentration for gram-positive pathogens (Craig, 1995, MacVane et al., 2014, Lee et al., 
2016). To this author’s knowledge, no studies have investigated cefovecin concentrations 
required to inhibit the growth of bacteria isolated from any Australian marsupial species. 
However, the concentration required usually depends on the antimicrobial agent and pathogen 
rather than the host. The MIC90 of cefovecin to inhibit bacterial species like S. intermedius 
(now known as S. pseudintermedius) and E. coli is ≤ 1 µg/mL in dogs and cats (Stegemann et 
al., 2006a) and sea otters (Lee et al., 2016). Thus, the MIC90 of 1 µg/mL was used as the 
therapeutic target of cefovecin to draw some conclusions.  
Therapeutic dosing intervals of cefovecin for dogs and cats were determined using the free 
concentration of cefovecin in plasma and transudate (Food and Drug Administration, 2008). 
Transudate concentrations were not collected for this study. Free plasma concentration of 
cefovecin for two koalas was estimated by multiplying total plasma concentration of cefovecin 
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(mean: 1.04 µg/mL) by 0.87, where 0.87 is free percentage of cefovecin in koala plasma. Thus, 
the mean free cefovecin plasma concentration was considered ≤ 0.9 µg/mL in all koalas at t = 
3 h only.  
A PK/PD integration using the total concentration of cefovecin (T > MIC90) demonstrates that 
a dosing interval of 7.5 h for gram-positive and 4 h for gram-negative pathogens might be 
required for maintaining the target concentration of 1 µg/mL for 40 and 70 % of dosing 
intervals for effective therapy. However, this estimation is only based on the results of two of 
the six koalas and the cefovecin concentration was < 1 µg/mL at t = 3 h in four other koalas. 
Based on the estimated free cefovecin plasma concentration (≤ 0.9 µg/mL), this target 
concentration is unlikely to be maintained after three hours using the current dose of 8 mg/kg 
s.c. for koalas. In contrast to the koala, total cefovecin plasma concentration remained above 
1.0 µg/mL for 21 days when 8 mg/kg was administered s.c. to dogs and cats and the unbound 
cefovecin concentration in transudate was maintained above 1 µg/mL for 8 days in dogs and 3 
days in cats (Stegemann et al., 2006b, Stegemann et al., 2006c). The cefovecin duration in 
plasma above the MIC for pathogens with lower susceptibility to cefovecin (e.g. MIC ≤ 0.25) 
was not established due to the concentrations below the LLOQ. 
On the evidence presented here, albeit the small sample size (the cefovecin plasma 
concentrations of six koalas), this study suggests a single s.c. bolus of cefovecin 8 mg/kg is 
unlikely to be efficacious to treat bacterial diseases for more than 3 h in koalas and does not 
offer the long duration of efficacy that it does in dogs and cats. Cefovecin could be an 
antibacterial option for pathogens with MIC < 1 µg/mL in koalas but to maintain the therapeutic 
concentration of cefovecin above the MIC, a much shorter dosage interval than 14 days such 
as repeating dosage every 6 to 12 h in the koala, might be required. 
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5.1 Abstract  
An HPLC method was developed and validated to detect amoxicillin concentrations in koala 
plasma. Six koalas were injected subcutaneously with 10 mg/kg amoxicillin trihydrate. Serial 
blood samples were collected over 24 h and plasma concentrations of amoxicillin were 
measured using HPLC. Although plasma concentrations were not quantifiable in four koalas, 
the plasma concentrations in one koala at 1, 2 and 4 h were 0.65 ± 0.18, 0.57 ± 0.22 and 0.43 
± 0.21 µg/mL respectively, and in the other koala the concentrations were 0.41 ± 0.0 and 0.41 
± 0.02 µg/mL at 0.5 h and 1 h, respectively. However, the HPLC stability test demonstrated 
that amoxicillin content in plasma reduced by approximately 60 % from the time the samples 
were collected to when the results were finalised (i.e. when stored at – 20 °C for five months). 
Therefore, the results require cautious interpretation.  
5.2 Introduction 
The chapter ‘Koalas’ in ‘Medicine of Australian Mammals’ (Blanshard and Bodley, 2008), 
suggests that amoxicillin at a dose of 10 – 12.5 mg/kg (alone, or in combination with clavulanic 
acid) can be administered p.o., i.m. or s.c. to koalas to treat some bacterial infections; although 
the authors note that some clinicians avoid oral administration to koalas (Blanshard and 
Bodley, 2008). As no information about the PK profile of amoxicillin in koalas exists, upon 
the request of Dr Amber Gillett from the AZWH, this research was conducted to develop an 
HPLC method for quantitating amoxicillin concentrations in koala plasma and to investigate 
plasma concentrations of amoxicillin trihydrate following a single, s.c. injection of 10 mg/kg 
to koalas. 
5.3 Materials and methods 
5.3.1 Animals 
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Six clinically normal, captive koalas (3 males and 3 females), aged 3.64 to 10.44 (median: 
7.17) years and weight 6.8 to 9.2 (median: 8.35) kg, were recruited from the Sydney Taronga 
Zoo display collection. These koalas were considered clinically normal based on regular 
physical examinations and haematological and biochemical analyte values within normal 
reference ranges. The koalas were housed singly or in groups in pens and supplied with various 
Eucalyptus spp. and water ad-libitum. This study was approved by the Taronga Conservation 
Society Australia, AEC protocol number 3d/06/16. 
5.3.2 Drug administration and blood collection 
Koalas were anaesthetised with alphaxalone (Alfaxan, Jurox Pty Ltd, Rutherford, NSW) at 3 
mg/kg i.m. and maintained under anaesthesia with isoflurane in 100 % oxygen via a face mask 
for catheter placement. Blood (5 mL) was collected in lithium heparin tubes to determine 
baseline haematology, biochemistry values and to confirm the absence of medications (t = 0 
h). The animals were then recovered from anaesthesia. The next morning amoxicillin 
trihydrate (Betamox 150 mg/mL, Norbrook Laboratories Australia Pty Ltd, Tullamarine, 
Vic.) was administered at 10 mg/kg s.c., the dose rate currently suggested for koalas 
(Blanshard and Bodley, 2008). To determine amoxicillin plasma concentration, serial blood 
samples (up to 3 mL) were collected into lithium heparin tubes at 0.5, 1, 2, 4, 6, 8, 12 and 24 
h. The cap and catheter were flushed with heparinised saline after each collection. Samples 
were centrifuged within 1 h of collection and plasma was transferred into plain tubes. Plasma 
was stored at – 80 °C and transported on ice within days of collection to The University of 
Sydney, where they were stored at – 20 °C and protected from light until analysis. While the 
amoxicillin assay was undergoing validation for plasma samples of Taronga Zoo koalas, an 
average of 165 days (or 5.5 months) elapsed between the koalas being medicated and the 
confirmation of the amoxicillin concentrations in the koala plasma. 
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5.3.3 Drug Analysis  
Amoxicillin concentrations in plasma samples were quantified by the HPLC system described 
in Chapter 2. Chromatographic separation initially involved comparing the sensitivity of the 
following columns: AtlantisTMdC18, 3 μm, 150 × 2.1 mm (Waters, Rydalmere, NSW), 
Hypersill ODS, 5 μm, 150 × 4.6 mm (Supelco, Bellefonte, Pennsylvania, USA), Nova-Pak 
C18, 4 μm, 300 × 3.9 mm (Waters, Rydalmere, NSW), Synergi MAX-RP 80Å, 4 μm, 150 × 
4.6 mm (Phenomenex, Lane Cove, NSW), Synergi Hydro-RP 80 Å, 4μm, 250 × 4.6 mm 
(Phenomenex, Lane Cove, NSW) and Polaris C18-A, 5 µm, 150 × 4.6 mm (Agilent 
Technologies, Mulgrave, Vic.). Different concentrations of methanol (4 to 20 %) and 20 mM 
sodium phosphate buffer at a range of pH (2 to 7) were trialled to modify the mobile phase and 
to optimise peak resolution and retention times of amoxicillin and the IS. Cefadroxil was 
selected as the IS (Abreu et al., 2003). 
Optimal chromatographic separation was performed with the Polaris C18-A column (5 µm, 
150 × 4.6 mm) attached to a 1 mm Opti-guard C-18 pre-column (Choice Analytical, 
Thornleigh, NSW) at 35 °C. The isocratic mobile phase was 20 mM sodium phosphate buffer 
(pH: 3.15) and methanol (95:5 v/v) at a flow rate of 1 mL/min. The UV wavelength for the 
target analytes was 228 nm. The total run time for each sample was 15 min. The retention times 
of amoxicillin and the IS (cefadroxil) were 7.2 and 9.1 min, respectively. 
5.3.4 Sample preparation 
A stock solution of amoxicillin (0.5 mg/mL) and the IS (125 µg/mL) were prepared in water. 
Amoxicillin was further diluted with water to give a series of working solutions of 5, 10, 20, 
25, 50, 100, 200, 250 and 300 µg/mL. Prepared stock solution was stored at – 20 °C and 
working solutions were freshly prepared for each analysis. Blank pooled koala plasma (n = 6) 
was used for validating the chromatographic condition. For the preparation of plasma 
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calibration standards (0.2, 0.4, 0.8, 1, 2, 4, 8, 10 and 12 µg/mL) and QC samples (0.4, 1 and 8 
µg/mL), the appropriate amount of working standard solutions of amoxicillin were spiked into 
blank pooled koala plasma and stored at – 20 °C. 
5.3.5 Plasma sample extraction  
After trialling numerous procedures (as discussed in Section 5.4), a new LLE method was 
developed to prepare samples for amoxicillin analysis in plasma. Each plasma sample (240 µL) 
was mixed with 10 μL of the IS (125 μg/mL) and 15 μL of phosphoric acid. After mixing for 
15 s, 1700 µL of TBME was added and vortexed for 15 s and then allowed to stand for 5 min. 
After removing the supernatant, to extract the amoxicillin, 700 µL of dichloromethane was 
added to the mixture and vortexed for 15 s. The supernatant was then collected and centrifuged 
for 15 min at 14,000 g. The volume of 40 µL of the supernatant was diluted with 60 µL of the 
mobile phase and after centrifugation at 14,000 g for 15 min, 20 µL was injected into the HPLC 
system. 
5.3.6 HPLC method validation 
Assay selectivity was established by analysing blank koala plasma to identify endogenous 
interference around the retention times of both amoxicillin and the IS. Amoxicillin 
concentrations in plasma samples were quantified via standard curves based on the following 
concentrations: 0.2, 0.4, 0.8, 1, 2, 4, 8, 10 and 12 µg/mL using a weighted least square 
regression (1/x). The LLOQ was determined based on the standard curves using the formula 
LLOQ = 10 × σ/S in which σ is the standard deviation (SD) of the y-intercepts for the regression 
lines and S is the mean slope of the weighted regression lines (n = 7). An acceptance criterion 
for LLOQ was defined as precision (CV) and accuracy within ± 20 % of the nominal 
concentration with repeated analyses (International Conference on Harmonisation, 2005). 
Intra- and inter-day precision, expressed as CV (%), were analysed from triplicates of QC 
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samples (0.4, 1 and 8 µg/mL), within a day and on three days, respectively. Intra- and inter-
day accuracy, expressed as bias, was determined by a percentage difference between estimated 
value and the nominal value of amoxicillin [100 – (estimated value/ nominal value × 100)]. 
Absolute recovery of amoxicillin and the IS was determined by comparing the peak area of 
pre-spiked plasma samples at concentrations of 0.4, 1 and 8 µg/mL (n = 3) and 5 µg/mL of the 
IS with corresponding concentrations of amoxicillin and the IS in the mobile phase. Three 
freeze/thaw cycles (over 6 days) were assessed with pre-spiked plasma samples at three 
concentrations (0.4, 1 and 8 µg/mL; n = 3). Long-term stability of amoxicillin was determined 
with pre-spiked samples at two concentrations (1 and 8 µg/mL; n = 3) when stored for 5 months 
at – 20 °C and protected from light. Each assay was conducted in triplicate and analysed by 
ANOVA and unpaired student t-tests using GraphPad Prism 7.02, with the minimum 
significance level at P < 0.05. 
5.4 Results 
5.4.1 Method development and optimisation 
The Polaris C18-A column provided the best sensitivity and peak resolution of the analytes. A 
mixture of 5 % methanol and 95 % sodium phosphate buffer (20 mM, pH: 3.15) was the best 
mobile phase to ensure the sharpest (narrowest) peaks with minimal interference. Figure 5-1 
illustrates the chromatograms of pre-spiked (0.5 and 2.5 µg/mL of amoxicillin) and blank 
pooled koala plasma. 
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Figure 5-1 Chromatograms of extracted pre-spiked koala plasma containing 2.5 µg/mL (A, black trace) 
and 0.5 µg/mL (B, green trace) of amoxicillin (retention time of 7.2 min) and 5 µg/mL of the IS 
(cefadroxil, retention time of 9.1 min); and pooled blank koala plasma (C, red trace) at a UV 
wavelength of 228. Note the endogenous plasma peaks (in all three traces) prior to 7 min and at 11.5 
min. 
5.4.2 HPLC method validation 
5.4.2.1 Selectivity 
Pooled blank koala plasma and extracted koala plasma pre-spiked with amoxicillin (0.5 and 
2.5 µg) and the IS (5 µg/mL) were used to check the selectivity of this method. No endogenous 
components from koala plasma interfered with elution of the amoxicillin but due to minimal 
interference with the IS peak, the ratio of peak height of the analytes was used instead of the 
ratio of area under the peak.  
5.4.2.2 Linearity, LLOQ, accuracy and precision 
The plasma peak ratio (the height of the amoxicillin peak divided by the height of the IS peak) 
vs the concentration were plotted and found to be linear for the concentration range used (0.2 
– 12 μg/mL). The mean regression calibration curves (n = 7) were expressed as y = 0.1206 (± 
0.0077, SD) x – 0.0214 (± 0.0097, SD), with a weighting factor of 1/x and the correlation 
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coefficient value (R2) for each curve was ≥ 0.99. Based on the SD of the y-intercepts and the 
slope of the curves, the LLOD and LLOQ of amoxicillin were estimated to be 0.13 µg/mL and 
0.39 µg/mL, respectively. Precision (CV) and accuracy of the calibration curves were both ≤ 
20 %. The average of precision and accuracy for the QC samples (0.4, 1, and 8 µg/mL) are 
summarised in Table 5-1. Intra- and inter-day precision, expressed as CVs, ranged from 0.03 
to 1.50 % and 0.031 to 0.20 %, respectively. Intra- and inter-day accuracy expressed as a 
percentage of the bias, ranged from – 6.67 to 10.92 % and – 14.80 to 11.27 %, respectively. 
These values satisfied the ICH guidelines regarding assay reliability (International Conference 
on Harmonisation, 2005). 
Table 5-1 Precision and accuracy for the QC samples (0.4, 1, and 8 µg/mL of amoxicillin) (triplicates 
per day for 3 days) 
Nominal concentration 
(µg/mL) 
Measured concentrations  
(µg/mL) 
Precision 
(CV, %) 
Accuracy 
(Bias, %) 
Intraday Interday Intraday Interday Intraday Interday 
0.4 0.40 ± 0.02 0.41 ± 0.02 0.05 0.07 – 0.72 – 2.00 
1 1.00 ± 0.04 0.97 ± 0.07 0.04 0.08 – 0.18    2.54 
8 7.78 ± 0.24 7.97 ± 0.33 0.03 0.04    2.70    0.35 
5.4.2.3 Recovery  
The mean absolute recovery rates ± SD of amoxicillin from the 0.4, 1, and 8 µg/mL QC samples 
(n = 3) were 72.26 ± 5.23 %; 70.44 ± 2.02 %; and 73.64 ± 3.24 %, respectively. The mean 
absolute recovery rate of the IS was 95.29 ± 7.15 % (n = 9).  
5.4.2.4 Stability 
There was no loss of amoxicillin concentration after three freeze/thaw cycles over 6 days but 
the QC samples (1 and 8 µg/mL amoxicillin in koala plasma) were not stable after 5 months as 
amoxicillin degraded significantly after 5 months at – 20 °C (determined by a reduced AUC of 
the amoxicillin peak compared to time 0). The results are presented in Table 5-2. 
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Table 5-2 Stability of amoxicillin in the QC samples (1 and 8 µg/mL) during long-term storage (5 
months) at – 20 °C 
Concentrations (µg/mL) The AUC reduction after 5 months compared to the time 0 (%) 
1 54.34 
8 63.32 
 
5.4.3 Pharmacokinetic results 
Given the LLOQ (0.39 µg/mL), plasma concentrations of amoxicillin in four koalas were not 
quantifiable at all time points (see Table 5-3).  
  
Chapter 5- Plasma concentrations of amoxicillin administered subcutaneously to koalas 
 
116 
 
Table 5-3 Amoxicillin concentration in koala plasma (n = 6) following s.c. administration at 10 mg/kg, 
LLOQ of the HPLC method: 0.39 µg/mL. The koalas are ordered chronologically by date of amoxicillin 
administration. 
Animals’ information 
Sample collection date 
Sample analyses date 
Amoxicillin concentration (µg/mL) 
Koala number 
Sex 
Weight 
Koala 1 
M  
8.8 kg 
Koala 2 
M 
8.4 kg 
Koala 3 
F 
6.8 kg 
Koala 4 
F 
7.9 kg 
Koala 5 
M 
9.2 kg 
Koala 6 
F 
7.8 kg 
Drug injection date 25 Aug 16 30 Aug 16 13 Sep 16 13 Sep 16 15 Sep 16 21 Sep 16 
Final results date 
(days after drug 
injection) 
17 Feb 17 
(161 d) 
27 Feb 17 
(180 d)  
24 Feb 17 
(164 d) 
23 Feb 17 
(163 d) 
23 Feb 17 
(161 d)  
27 Feb 17 
(159 d) 
Time after drug injection 
      
 0 h - - - 0.18 ± 0.00 0.15 ± 0.00 - 
 0.5 h - - - 0.41 ± 0.00 0.38 ± 0.05 - 
 1 h - - - 0.41 ± 0.02 0.65 ± 0.18 - 
 2 h - - - 0.38 ± 0.01 0.57 ± 0.22 - 
 4 h - - - 0.31 ± 0.04 0.43 ± 0.21 - 
 6 h - - - 0.31 ± 0.02 0.30 ± 0.08 - 
 8 h - - - 0.31 ± 0.02 0.27 ± 0.05 - 
 12 h - - - 0.32 ± 0.01 0.24 ± 0.01 - 
 24 h - - - 0.17 ± 0.01 0.23 ± 0.04 - 
* All values for koalas 1 to 3 and 6 were not detectable 
** The values that are between LLOD (0.13 µg/mL) and LLOQ (0.39 µg/mL) have also been reported 
in this table, however, these values are not necessarily the real values as they are below the LLOQ of the 
HPLC method. 
5.5 Discussion 
An HPLC method with a PDA detector and an isocratic mobile phase was developed to detect 
amoxicillin in koala plasma. As explained in Chapter 4, similar to cefovecin, developing an 
HPLC method to determine amoxicillin concentrations in koala plasma was challenging and 
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required numerous modifications to overcome selectivity issues. Various HPLC methods are 
reported for amoxicillin determination in biological fluids using UV detection (Muth et al., 
1996, Gulland et al., 2000, Hoizey et al., 2002, Abreu et al., 2003, Foroutan et al., 2007, Jerzsele 
et al., 2009) and fluorescence detection (Mascher and Kikuta, 1998, Wibawa et al., 2002). 
Several sample extraction techniques have been reported, such as PPE (Mascher and Kikuta, 
1990, Gulland et al., 2000, Hoizey et al., 2002, Abreu et al., 2003, Jerzsele et al., 2009), LLE 
(Foroutan et al., 2007, Ajitha et al., 2010), SPE (Pingale et al., 2012, Gaikwad et al., 2013) and 
ultrafiltration (Muth et al., 1996, Matar, 2006). Detecting amoxicillin in koala plasma was not 
expected to be so challenging as numerous HPLC methods using UV detection in other species 
are published (summarised in Table 5-4). The intrusion of multiple endogenous peaks within 
the koala plasma matrix eliminated many chromatographic conditions and sample extraction 
techniques that had been used to detect amoxicillin in the biological tissues and fluids of other 
species. The optimal isocratic mobile phase of 5 % methanol and 95 % sodium phosphate buffer 
(20 mM, pH: 3.15) was similar to other published HPLC conditions (Foroutan et al., 2007, 
Ahmed et al., 2011). During method optimisation, as amoxicillin retention time was altered by 
small pH changes, mobile phase solutions with pH values from 2 to 7 were trialled. A pH of 
3.15 produced the best mobile phase condition.  
Based on the UV spectrum consistent with the previous report of Tippa and Singh (2010), the 
maximum response of amoxicillin peak was at the wavelength of 228 nm. However, detection 
wavelengths less than 230 nm reportedly results in greater interference by low-molecular-mass 
endogenous substances, necessitating more rigorous drug extraction (Mascher and Kikuta, 
1998).  
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Table 5-4 A summary of HPLC conditions with UV detection to determine amoxicillin concentrations 
Sample matrix Sample 
preparation * 
Mobile phase Column; 
Thermostat temperature*; 
 UV Wavelength  
Linearity range; 
LLOQ 
(µg/mL) 
Human plasma 
(Muth et al., 
1996) 
Ultrafiltration  
IS: cefadroxil 
Gradient 
Solvent A and B (10 mM 
heptane sulfonate and 30 mM 
sodium dihydrogen phosphate 
in a solution of purified water-
methanol (75:25 and 92:8 v/v, 
respectively) 
(pH: 2.5) 
Spherisorb ODS II (5 
µm, 250 x 4.6 mm); 
40 °C; 
230 nm 
0.05 – 25.4; 
0.05  
Seal plasma 
(Gulland et al., 
2000) 
PPE: perchloric: 
citrate/phosphate 
buffer  
Isocratic 
5 % acetonitrile 
95 % phosphate buffer (pH: 5) 
Zorbax SB-C8 (4.6 mm ×15 cm) 
40 °C; 
229 nm 
0.156 – 10; 
0.656 
Human plasma 
(Hoizey et al., 
2002) 
 
PPE: methanol  
Recovery: 95 – 99 % 
 
Gradient: 
Solvent A (potassium 
dihydrogen phosphate & 
tetramethylammonium chloride 
(pH: 2.5) 
Solvent B (acetonitrile) 
Lichrospher column 100 RP8 
(5-µm, 250×4 mm); 
Ambient temp; 
220 nm 
0.625 – 20; 
0.625 
Human plasma 
(Abreu et al., 
2003) 
PPE: methanol  
IS: cefadroxil 
Recovery: >90 % 
Isocratic 
5 % acetonitrile 
95 % sodium phosphate buffer 
(pH: 4.8) 
Lichrosorb® 10µm RP18; 
Ambient temp; 
229 nm 
1 – 50; 
1 
Human plasma 
(Foroutan et al., 
2007) 
PPE: acetonitrile 
then LLE: 
dichloromethane 
Recovery: 93.8 % 
IS: allopurinol  
Isocratic 
4 % methanol 
96 % sodium phosphate buffer 
(pH: 3) 
Chromolith Performance column 
(RP-18e, 100 mm × 4.6mm); 
- 
228 nm 
0.2 – 12; 
0.015 
 
Broiler chicken 
plasma 
(Jerzsele et al., 
2009) 
PPE: methanol 
Recovery: 95 % 
Isocratic: 
10 % methanol 
90 % potassium phosphate 
buffer  
(pH: 7) 
C18 analytical column (10-µm, 
250 × 4 mm); 
- 
220 nm 
0.2 – 20; 
0.16 
Bulk drug & 
pharmaceutical 
dosage forms 
(Ahmed et al., 
2011) 
Dissolving in mobile 
phase and then 
sonication 
Recovery: 99 % 
Isocratic 
5 % methanol 
95 % potassium phosphate 
buffer  
Hypersil C18 (250 mm × 4.6 
mm);  
Ambient temp; 
254 nm 
20 – 100; 
1.254 
* Some articles do not include the IS used and / or thermostat temperature.  
Numerous sample extraction techniques such as PPE, LLE, SPE and ultrafiltration were trialled 
to clean up the koala plasma samples. Ultimately, sample preparation was undertaken by LLE 
as only this method enabled elimination of interfering substances around the retention time of 
amoxicillin. In LLE, by adding non-polar organic solvent, the sample is partitioned into two 
portions: an aqueous layer which contains the polar compounds and an organic layer which 
concentrates the non-polar compounds (Li et al., 2006).  
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Some publications describe two steps for plasma sample preparation (Foroutan et al., 2007, 
Ajitha et al., 2010). First, plasma proteins are precipitated and then the amoxicillin is extracted 
from the supernatant using dichloromethane. Replicating the published methods did not 
improve assay selectivity. Therefore, LLE was trialled using different organic solvents 
including chloroform, ethyl acetate, heptane, hexane and TBME. A mixture of the different 
volumes of organic solvents (e.g. TBME and ethyl acetate 1:1 volume, etc.) was also tested. 
Then, the aqueous layer of each solution was mixed with dichloromethane to extract 
amoxicillin. Those organic solvents that resulted in cleaner chromatograms underwent the next 
optimisation step to determine whether acidifying the plasma samples improves extraction. 
Ultimately, the procedure with the best selectivity and recovery for amoxicillin involved 
plasma samples initially being acidified with phosphoric acid and then amoxicillin extraction 
with TBME and dichloromethane.  
The assay linearity range selected was 0.2 – 12 µg/mL as the Cmax of amoxicillin trihydrate 
administered via extravascular routes did not exceed 12 µg/mL in most species (see Table 1-
7).  
Initially, the HPLC method was developed to determine the plasma concentration of 
amoxicillin and clavulanic acid (Appendix I); however, clavulanic acid was found to be very 
unstable. There was an approximate 46 % loss of the clavulanic acid in all QC samples (1, 5 
and 10 µg/mL) after one-month storage at – 20 °C (Appendix II). As clavulanic acid acts as a 
potent bacterial beta-lactamase inhibitor, co-administration of amoxicillin with clavulanic acid 
does not appear to alter PK parameters of amoxicillin in any species (Reyns et al., 2007, 
Prescott, 2013a). Therefore, amoxicillin alone was selected for investigation. 
The plasma concentration of amoxicillin was below the LLOQ in most of the koalas and only 
above the LLOQ in two of the six koalas at some time points. However, the stability test 
results do not support these results. Unfortunately, amoxicillin degraded during storage at – 
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20 °C between collection and analysis time, resulting in low amoxicillin concentrations in the 
plasma samples. The amoxicillin HPLC assay was initially developed and validated for koalas 
at AZWH, QLD. This assay had been validated with AZWH koala plasma prior to sample 
collection. However, staffing issues when amoxicillin administration and plasma collection 
were requested prevented AZWH from assisting with the study. Fortunately, Dr Larry 
Vogelnest and the Animal Ethics Committee of the Taronga Zoo approved recruiting 
collection koalas for the study. The Taronga Zoo koala plasma samples showed additional 
interference (different to that of the AZWH koala plasma), which required further assay 
modification and additional validation which delayed quantifying the amoxicillin plasma 
concentrations.  
There are differing reports on amoxicillin stability in human plasma or serum: amoxicillin 
was stable for 50 days in human serum at – 70 °C while amoxicillin concentration degraded 
25 – 35 % when stored at – 20 °C (Mascher and Kikuta, 1998). Amoxicillin was stable for at 
least 1 month in human plasma stored at – 20 °C (Foroutan et al., 2007) and – 70 °C (Matar, 
2006), and for 61 days after storage at – 70 °C (Yaxin et al., 2016). A stock solution of 
amoxicillin was stable at – 70 °C for 4 months (Yaxin et al., 2016). To the best of this author’s 
knowledge, there are no reports of amoxicillin’s stability for more than two months in plasma 
or serum. Our stability test showed about a 60 % reduction in the amoxicillin concentration 
in QC samples stored for 5 months at – 20 °C.  
Amoxicillin (with or without clavulanic acid) is administered to treat bacterial infections, 
especially pneumonia, in koalas. Bacterial species such as B. bronchiseptica and E. coli have 
been isolated from captive and free-ranging koalas with pneumonia (Blanshard and Bodley, 
2008). There is no published information on the plasma breakpoints to inhibit these pathogens 
in koalas. Theoretically such breakpoints are primarily determined by the pathogen and drug 
rather than the host species. The following published information was extrapolated for use in 
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the koala: MIC90 of amoxicillin/clavulanic acid to inhibit the growth of B. bronchiseptica (in 
pigs) = 2 µg/ml (Prescott, 2013b), the MIC90 of amoxicillin to inhibit susceptible strains of E. 
coli (non-urinary) from dogs and cats ≤ 0.25 µg/mL (CLSI, 2013b), and the susceptibility 
breakpoint to inhibit Staphylococci spp. and Streptococci spp.  0.25 µg/mL (CLSI, 2013b). 
As there was approximately 60 % loss of the amoxicillin, the real plasma concentrations of 
the samples above LLOQ can be estimated to be 1.625, 1.425 and 1.05 µg/mL at time 1, 2 
and 4 h, respectively in koala 5, and 1.025 µg/mL at time 0.5 and 1 h in koala 4. These 
estimates suggest that the plasma concentration of amoxicillin at 10 mg/kg s.c. in koalas might 
reach the MIC breakpoints for pathogens inhibited with amoxicillin MIC ≤ 1 µg/ml.  
The PK/PD relationship that determines therapeutic efficacy for time-dependant antibacterials 
such as amoxicillin is the time interval that the drug concentration exceeds the MIC in serum 
or plasma. Although the data are limited, if the amoxicillin concentration exceeded 1 µg/mL 
for at least 4 hours, the frequency of administration would need to be a minimum of every 8 
hours [as the dosage interval should be maintained above 40 to 50 % of the MIC for both 
susceptible gram-positive and gram-negative pathogens (Jacobs, 2001, MacVane et al., 
2014)]. This might be impractical to treat non-domesticated species (injection of a drug every 
8 h) if there are other efficacious antibacterials such as enrofloxacin and chloramphenicol. To 
effectively treat pneumonia, antimicrobials must penetrate the blood-bronchus barrier and 
attain sufficient concentrations at the sites of infection to reach or exceed the antibacterial 
MIC (Valcke et al., 1990, Honeybourne, 1994, Agersø et al., 1998). Lipophilic drugs such as 
enrofloxacin are more likely to reach this site than hydrophilic drugs such as amoxicillin 
(Valcke et al., 1990, Honeybourne, 1994, Papich and Taboada, 2005). As amoxicillin 
concentration in bronchial mucosa is approximately 40 % of its concurrent serum 
concentration (Honeybourne, 1994, Cook et al., 1994), higher dose rates might be required to 
achieve the therapeutic concentration at the site of infection to treat pneumonia in adult koalas. 
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Enrofloxacin could be a better choice to treat pneumonia in koalas, as its PK profile is known 
(Griffith et al., 2010, Black et al., 2013a). Enrofloxacin can be a better choice to treat feral 
animal bites infected by aerobic pathogens, but it has poor efficacy against anaerobic 
pathogens (Giguère and Dowling, 2013). Amoxicillin with or without clavulanic acid is active 
against anaerobic pathogens (Prescott, 2013a) but susceptibility testing against these 
pathogens has not been standardised to predict the amoxicillin concentrations required to 
inhibit anaerobic pathogens injected via bites. Blanshard and Bodley (2008) proposed a dose 
rate of metronidazole, another lipophilic drug, with efficacy against anaerobic pathogens, but 
its PK profile in koalas is not established. 
It might be worth repeating this study to confirm the amoxicillin PK profile in koalas. 
Minimum storage duration and temperatures appear critical to assay amoxicillin. As the 
stability test at – 20 °C was finished in June 2017, repeating the study which required 
reapplication of animal ethics approval and time intensive processes of in-vivo drug 
administration, blood collection and sample analysis were not possible at the late stage of this 
candidature. However, this chapter indicates it is doubtful that repeating this study will do 
anything more than confirm that amoxicillin’s efficacy is too short to provide practical therapy 
in koalas. 
  
 Chapter 6 
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and amoxicillin concentrations in koala 
plasma  
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6.1 Abstract 
Cefovecin and amoxicillin concentrations in koala plasma (using the medicated plasma from 
studies described in Chapters 4 and 5) were determined in agar disc diffusion assays to 
investigate their ability to inhibit the growth of E. coli ATCC 25922 and Bacillus sp. VPB 498. 
The assay sensitivity for both cefovecin and amoxicillin was too low as the lowest detectable 
concentrations were 8 µg/mL for cefovecin and 4 µg/mL for amoxicillin. Consequently, broth 
microdilution inhibition assays were used to test the remaining plasma samples’ abilities to 
inhibit E. coli ATCC 25922. The results indicated the highest cefovecin concentration was at t 
= 3 h, which supports the HPLC results of the cefovecin study. With the amoxicillin samples, 
no significant growth reduction after amoxicillin administration (i.e., samples collected at time 
0.5 h onwards), indicating that amoxicillin concentrations did not exceed 4 µg/mL, the 
amoxicillin MIC to inhibit E. coli ATCC 25922. As reported in Chapter 5, amoxicillin 
instability was likely to have affected this assay.  
6.2 Introduction 
Antimicrobial concentrations in biological fluids have been determined using bioassays and 
chromatographic assays. Bioassays are simpler, faster and cheaper than HPLC methods which 
require costly equipment, and laborious method development and validation. A major 
disadvantage of bioassays is their lower specificity to differentiate the analyte of interest from 
other active metabolites and antimicrobials present in the sample (Perea et al., 2000, Stead, 
2000, Böttcher et al., 2001). Furthermore, microbial inhibition assays tend to be less sensitive, 
accurate and precise than HPLC (Perea et al., 2000, Böttcher et al., 2001). However, the 
bioassay is sufficiently accurate and precise to be used for some drug analyses in biological 
fluids (Foulstone and Reading, 1982, Perea et al., 2000, Driscoll et al., 2012). For instance, an 
agar disc diffusion test to determine plasma concentration of amoxicillin trihydrate in sheep 
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plasma was reported to have a LLOQ of 0.06 µg/mL and accuracy and precision were both 
within  5 % (Fernandez et al., 2007).  
The HPLC methods described in Chapters 3, 4 and 5 did not have ideal sensitivity and could 
not quantitate concentrations lower than 1.02 µg/mL and 0.39 µg/mL for cefovecin and 
amoxicillin in koala plasma, respectively. Therefore, this investigation used additional assays 
to confirm cefovecin and amoxicillin concentrations in the same samples determined by HPLC.  
6.3 Materials and methods 
All microbial procedures used aseptic techniques to avoid extraneous microbial contamination. 
6.3.1 Bacterial strains and culture conditions 
E. coli ATCC 25922 and Bacillus sp. VPB 498 strains were used. The pathogens were sub-
cultured onto tryptose agar plates (Invitrogen, San Diego, CA, USA) and incubated at 35 °C 
for 18 – 24 h. 
6.3.2 Inoculum preparation 
Bacterial colonies selected from the sub-cultured plates were emulsified in Phoenix ID broth 
(Becton, Dickinson & Co., North Ryde, NSW) to produce 0.5 McFarland solution (equivalent 
to 1.5 × 108 CFU/mL, i.e., colony-forming units per mL; a unit to estimate the number of 
viable bacteria in a sample) as determined by a PhoenixSpec TM nephelometer (Becton, 
Dickinson & Co., North Ryde, NSW). 
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6.3.3 Agar disc diffusion assays 
The agar disc diffusion assay was performed according to the Clinical and Laboratory 
Standards Institute (CLSI) standards (CLSI, 2013a) to estimate cefovecin and amoxicillin 
concentrations in samples collected for the in-vivo studies described in Chapters 4 and 5.  
Primary stock solutions of cefovecin (1 mg/mL) and amoxicillin trihydrate (1 mg/mL) were 
freshly prepared in sterile MQ water and phosphate buffer (pH: 6) (CLSI, 2013b), 
respectively, for each assay. Aliquots of the stock solutions were added to pooled koala 
plasma to obtain concentrations of 0.25, 0.5, 1, 2, 4, 8 and 16 µg/mL of cefovecin, and 0.5, 1, 
2, 4, 8, 16 and 32 µg/mL of amoxicillin as a standard curve. The inoculum suspensions of 
both pathogens were spread as a lawn across Mueller-Hinton agar (MHA) plates with a cotton 
swab (Becton, Dickinson & Co., North Ryde, NSW). Then, the standard dilutions and the 
remaining plasma samples of cefovecin and amoxicillin in-vivo studies were applied to 6 mm 
antimicrobial ‘blank’ discs (CT998B; Oxoid Australia Pty Ltd, West Heidelberg, Vic.) in one 
of the following two ways: firstly, discs were placed on the agar plates and 20 µL of each 
sample was pipetted directly onto a disc. Each sample was repeated in triplicate. Secondly, 
for the assay with E. coli only, three discs soaked for 3 h in either each sample or standard 
dilutions were placed at different locations on the agar plates. Blank koala plasma and 
commercial discs containing 30 μg of cefovecin and 2, 10 and 25 μg of amoxicillin (Oxoid 
Australia Pty Ltd, West Heidelberg, Vic.) served as controls. The plates were then incubated 
at 35 °C for 18 – 24 h after which zone diameters of growth inhibition, where possible, were 
measured to the nearest millimetre.  
6.3.4 Broth microdilution inhibition assays 
Due to the apparent low sensitivity of the agar disc diffusion assay to determine cefovecin and 
amoxicillin concentrations in koala plasma, broth microdilution inhibition assays using 
reference strain E. coli ATCC 25922 and sterile 96-well culture plates (Nunclon™ Delta 
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Surface, Thermo Fisher Scientific, Scoresby, Vic.) were performed to determine whether the 
antibacterial agents (apart from endogenous antimicrobial components of plasma) present in 
the koala plasma after drug administration could further reduce the growth of E. coli compared 
to t = 0 h. The inoculum and sample volumes were the same as those prescribed by the CLSI 
for the broth microdilution susceptibility assay (CLSI, 2013a). To prepare the inoculum, a 
solution with 0.5 McFarland turbidity was diluted with Mueller-Hinton broth (MHB) to 
produce a concentration of 1.5 × 106 CFU/mL (CLSI, 2013a). A volume of 100 µL of each 
sample was added to each well of a plate. Into each well, 10 µL of the inoculum was added to 
give a bacterial concentration of 1.5 × 105 CFU/mL and a final volume of 110 µL. Each sample 
was tested at least in duplicate and for each sample a proper blank (as an OD zero) was also 
prepared simultaneously. A well containing MHB only and a positive control (MHB and 
inoculum) were included in each plate to establish that the MHB was uncontaminated and that 
the assay supported bacterial growth, respectively. Wells of six and seven two-fold serial 
standard dilutions of the cefovecin (8 – 0.25 µg/mL) and amoxicillin (32 – 0.5 µg/mL), 
respectively, in MHB were also prepared in triplicate to determine the MIC of cefovecin and 
amoxicillin to inhibit E. coli. Contents of each well were mixed with a pipette, covered and 
incubated for 18 – 24 h at 35 °C. After incubation, the wells were visually examined for ± 
bacterial growth and semi-quantitated by measuring the turbidity at 620 nm (Widdel, 2007) 
relative to the respective blank well as OD zero (an automated microplate reader, Halo LED 96, 
Dynamica Pty Ltd, Clayton, Vic.). The OD zero is the reference optical density (OD) caused by 
the medium which is subtracted from the observed OD to determine the OD caused by the cells 
(Widdel, 2007). The MIC was considered as the lowest concentration of the cefovecin and 
amoxicillin that inhibited visible growth of the bacteria. 
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6.3.5 Statistical analysis 
The mean bacterial growth data between groups were analysed statistically using ANOVA and 
Tukey's multiple comparisons test using GraphPad Prism 7.02, where the minimum 
significance level for all statistical tests was P < 0.05. 
6.4 Results 
6.4.1 Agar disc diffusion assays 
6.4.1.1 Cefovecin 
Neither bacterial strains’ growth was inhibited by any disc impregnated with or soaked in 
cefovecin in-vivo samples (at different time points). A small zone of inhibition of E. coli was 
only observed at the standard dilutions of 8 and 16 µg/mL of cefovecin for soaked discs (see 
Figure 6-1 A). The growth inhibition zones of commercial cefovecin discs 30 µg on E. coli and 
Bacillus sp. lawns were 27 and 15 mm, respectively (see Figure 6-1 A, B and C).  
6.4.1.2 Amoxicillin 
Similar to the cefovecin, there was no growth inhibition of both bacterial strain by any discs 
either impregnated with or soaked in amoxicillin in-vivo samples (at different time points). The 
lowest concentrations of amoxicillin that inhibited E. coli and Bacillus sp. growth were 50 and 
4 µg/mL respectively (Figure 6-1 C and D). For the latter strain, however, the inhibition zone 
margins for all the discs were not distinct. The growth inhibition zones of the commercial 
amoxicillin discs (2, 10 and 25 µg) on the E. coli lawn were 8, 18 and 22 mm, respectively 
(Figure 6-1.C). The corresponding values on the Bacillus sp. lawn were approximately 10, 14 
mm and 16 mm (Figure 6-1 D).  
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Figure 6-1 Agar disc diffusion test of cefovecin and amoxicillin using two isolates (E. coli ATCC 25922 
and Bacillus sp. VPB 498) on MHA. A. Commercial cefovecin discs (CVN: 30 µg) and the discs soaked 
at cefovecin standard dilutions (8 and 16 µg/mL) on the E. coli lawn; B. Commercial cefovecin discs 
(30 µg) on the Bacillus sp. Lawn; C. Commercial amoxicillin discs (AML: 2, 10 and 25 µg) and 
cefovecin (CVN: 30 µg) and the discs impregnated with amoxicillin standard dilutions 32 and 50 µg/mL 
on the E. coli lawn; D. Commercial amoxicillin discs (AML: 2, 10 and 25 µg) and the discs impregnated 
with amoxicillin standard dilutions (4, 8, 16 and 32 µg/mL) on the Bacillus sp. lawn. 
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6.4.2 Broth microdilution inhibition assays 
Unlike the positive controls (MHB and inoculum), there was no bacterial growth in the 
negative controls (MHB only) on each plate. The MIC of cefovecin and amoxicillin to inhibit 
E. coli ATCC 25922 were 0.5 µg/mL [within the range of 0.5 – 2 µg/mL specified by CLSI 
VET01-S2 (CLSI, 2013b)] and 4 µg/mL [within the range of 2 – 8 µg/mL specified by CLSI 
VET01-S2 for ampicillin (CLSI, 2013b)], respectively (Figure 6-2 and 6-3).  
 
Figure 6-2 MIC of cefovecin to inhibit E. coli ATCC 25922 growth, serial dilutions of cefovecin 
were prepared in MHB and incubated with E. coli inoculum at 35 °C for 18 – 24 h. Bacterial growth 
was estimated by measuring the OD620. The lowest concentration of cefovecin that inhibited E. coli 
growth was 0.5 µg/mL.  
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Figure 6-3 MIC of amoxicillin to inhibit E. coli ATCC 25922 growth, serial dilutions of amoxicillin 
were prepared in MHB and incubated with E. coli inoculum at 35 °C for 18 – 24 h. Bacterial growth 
was estimated by measuring the OD620. The lowest concentration of amoxicillin that inhibited E. coli 
growth was 4 µg/mL. 
6.4.2.1 Cefovecin 
The E. coli growth when incubated with koala plasma samples of cefovecin in-vivo study is 
shown in Figures 6-4 and 6-5. Bacterial growth with plasma samples was less than that in the 
positive controls. The E. coli growth was significantly less at time 3 h compared to time 0 h 
(P < 0.0011) and 24 h (P < 0.0156) (see Figure 6-4).  
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Figure 6-4 E. coli growth incubated with plasma samples from six koalas at different time points 
following cefovecin administration at 8 mg/kg s.c. Bacterial growth was estimated by measuring the 
OD620. The symbols represent the mean growth of E. coli at each time point, and the error bars show 
the SE of the means. Different letters indicate a significant difference between means of each group 
(P < 0.05). The P value for the comparison between the mean of time 3 h vs 0 and 24 h was 0.0011 
and 0.0156, respectively. 
Given the individual koala samples (Figure 6-5), lowest E. coli growth was at time 3 h of five 
koalas. Moreover, E. coli had almost no growth with plasma samples at time 6 h of koala 3 and 
time 0 h of koala 5. 
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Figure 6-5 E. coli growth incubated with plasma samples from six koalas at different time points 
following cefovecin administration at 8 mg/kg s.c. Bacterial growth was estimated by measuring the 
OD620. Each column represents the mean growth of E. coli, and the error bars show the SD of the 
means. The cefovecin concentration with the HPLC method (LLOD: 0.34 and LLOQ: 1.02 µg/mL) 
was only detected at time 3 h of koala 1 (1.03 µg/mL), koala 4 (1.05 µg/mL), koala 5 (0.73 µg/mL) 
and koala 6 (0.72 µg/mL). 
6.4.2.2 Amoxicillin 
The E. coli growth incubated with koala plasma samples of amoxicillin in-vivo study is shown 
in Figures 6-6 and 6-7. Similar to the cefovecin, amoxicillin samples inhibited E. coli growth 
compared to the positive controls. Bacterial growth, however, fluctuated between different 
time points and the lowest E. coli growth was at time 0 h and 24 h (see Figure 6-6). E. coli 
growth in individual koala plasma samples collected over 24 h also fluctuated at sequential 
time points. 
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Figure 6-6 E. coli growth when incubated with plasma samples from five koalas at different time points 
following amoxicillin administration at 10 mg/kg s.c. Bacterial growth was estimated by measuring the 
OD620. The symbols represent the mean growth of E. coli at each time point, and the error bars show 
the SE of the means. Different letters indicate a significant difference between means of each group (P 
< 0.05). The P values for the comparison between the mean of time 0 h vs 1 h and 6 h were 0.0068 and 
0.0316, respectively 
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Figure 6-7 E. coli growth incubated with plasma samples from six koalas at different time points 
following amoxicillin administration at 10 mg/kg s.c. The koalas are ordered by date of amoxicillin 
administration as per Table 5.3. Bacterial growth was estimated by measuring the OD620. Each 
column represents the mean growth of E. coli and the error bars the SD of the means. The amoxicillin 
concentration with HPLC method (LLOD: 0.13 and LLOQ: 0.39 µg/mL) was only quantitated in 
koala 4 at time 0.5 h (0.41 µg/mL) and 1 h (0.41 µg/mL), and koala 5 at time 1 h (0.65 µg/mL), 2 h 
(0.57 µg/mL) and 4 h (0.43 µg/mL).  
The assay for koala 6 was conducted separately to other koalas and this koala’s amoxicillin 
concentrations were not incorporated in Figure 6-7. Also, due to the paucity of samples, 75 µL of 
each sample was used instead of 100 µL to run the assay for this koala’s samples.  
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6.5 Discussion 
Although low concentrations of antimicrobials have been detected by some bioassays, the agar 
disc diffusion assay performed here was not sensitive enough to detect concentrations below 8 
µg/mL using E. coli for cefovecin and 4 µg/mL using Bacillus sp. for amoxicillin. The agar 
disc diffusion procedure described by the CLSI was followed (CLSI, 2013a) and commercial 
cefovecin and amoxicillin discs (30, and 2, 10 and 25 µg, respectively) were used as the positive 
controls. The inhibition zones of commercial discs on the E. coli agar plate (cefovecin 30 µg: 
26 – 28 mm and amoxicillin 10 µg: 18 mm) were within the range prescribed by Table 4 of 
CLSI standard VET01-S2 (25 – 30 mm for cefovecin and 16 – 22 mm for ampicillin) (CLSI, 
2013b).  
Initially, the samples were manually applied directly to the top surface of the discs placed on 
the bacterial lawns as this method was successful in previous studies (Wilson et al., 2006, 
Griffith, 2010). However, this method showed low sensitivity. According to the instructions 
for commercial disc preparation (Oxoid Australia, Pty Ltd, West Heidelberg, Vic.), 10 µL of 
an antibacterial stock solution is added to each disc. For example, to have a final concentration 
of 30 µg cefovecin in each disc, 10 µL of cefovecin stock solution 3,000 µg/mL is placed on 
each disc. This commercial disc with 30 µg produced an inhibition zone of 27 mm. In this 
study, 20 µL of the plasma standard solutions containing 0.5, 1, 2, 4, 8 and 16 µg/mL of 
cefovecin were added to each disc, so the concentrations of the respective discs were 0.01, 
0.02, 0.04, 0.08, 0.16 and 0.32 µg, too low to inhibit growth around the discs placed on the E. 
coli lawn. The discs were then soaked in the samples and standard dilutions for 3 h before being 
placed on the bacterial lawns, followed by incubation at 35 °C for 18 – 24 h, but this method 
did not significantly improve sensitivity.  
As a result of low sensitivity with E. coli, the Bacillus sp. was used because it had been 
recommended by Bennett et al. (1966) when testing ampicillin and this in-house strain was 
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used successfully in another study by Wilson et al. (2006). When comparing growth inhibition 
zones of the cefovecin commercial discs on both E. coli and Bacillus sp. lawns, the E. coli 
inhibition zones were larger, indicating E. coli is a more sensitive indicator than Bacillus sp. to 
cefovecin. The presence of colonies within the inhibition zones on the Bacillus sp. lawn (seen 
in Figure 6-1 D) suggests heteroresistance to amoxicillin in this species (El-Halfawy and 
Valvano, 2015). However, due to this assay’s insensitivity, improving the sensitivity and 
investigating the heteroresistance were considered unproductive and abandoned.  
The lack of assay sensitivity of the agar disc diffusion inhibition assay could be attributed to 
interactions between one or more of the following factors: the koala plasma, use of insensitive 
bacterial strains and / or issues with the agar that inhibited drug diffusion (Driscoll et al., 2012). 
Broth microdilution susceptibility assays were more sensitive to inhibit E. coli growth with 
lower concentrations of antibacterial agents. The cefovecin MIC in MHB was determined to 
be 0.5 µg/mL; therefore, cefovecin concentrations greater or equal to 0.5 µg/mL of cefovecin 
present in plasma could inhibit E. coli growth but the actual inhibitory concentration could not 
be quantified. Despite the variation in E. coli growth with plasma samples within the cefovecin 
study, the growth was inhibited more at 3 h than time 0 or 24 h. These findings are consistent 
with the HPLC results, where cefovecin concentrations were 0.7 – 1 µg/mL in four koalas at 
time 3 h. Although broth microdilution assays cannot be relied on alone because of the 
endogenous antimicrobial activity of plasma components (Hirsch, 1960, Taylor, 1983, 
Yeaman, 1997, Tang et al., 2002), they confirmed the cefovecin HPLC results by 
demonstrating maximum E. coli inhibition at 3 h.  
The amoxicillin samples did not reduce E. coli growth significantly in samples collected at 
time 0.5 h onwards, indicating low concentrations of amoxicillin in plasma samples (i.e. lower 
than the amoxicillin MIC to inhibit E. coli). Broth microdilution assays of amoxicillin samples 
were undertaken almost 5 to 6 months after sample collection (shortly after HPLC analysis). 
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At this time, the long-term stability of amoxicillin in koala plasma at – 20 °C had not been 
established. However, stability test results indicate that amoxicillin present in koala plasma 
samples had been largely degraded. Degradation of amoxicillin is mainly due to the hydrolysis 
of the beta-lactam ring (Hou and Poole, 1971) which produces microbiologically-inactive 
metabolites (Papich and Riviere, 2009) unlikely to inhibit E. coli growth.  
The bioassays were only employed as an adjunctive assay to confirm the HPLC results. The 
cefovecin broth microdilution assays further support the idea that a single bolus injection does 
not confer sustained antibacterial activity in koalas. The amoxicillin broth microdilution assays 
demonstrated no significant changes in E. coli growth after drug administration, which also 
implies amoxicillin concentrations lower than the MIC to inhibit E. coli (4 µg/mL). These 
results are consistent with the HPLC results, indicating low concentrations of amoxicillin. 
The intriguing, unique finding from the cefovecin broth microdilution assay was the variability 
of antibacterial activity between clinically normal koalas even before they were medicated, and 
between sequential time points of an individual koala. The reason for this variation in E. coli 
growth is explored further in the next chapter. 
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7.1 Abstract 
The comparative antibacterial activities of plasma, serum, delayed-coagulation serum and 
heated serum of koalas and selected species were investigated by broth microdilution inhibition 
assay using two reference strain pathogens (E. coli ATCC 25922 and S. aureus ATCC 29213). 
Compared to the positive controls, both pathogens grew less when incubated with the blood 
matrices of all species studied. Koala samples varied significantly in inhibiting growth of both 
pathogens compared to those of the other species. 
7.2 Introduction 
Whole blood and its components such as serum and plasma, with or without platelets, are 
recognised to possess antimicrobial activity (Hirsch, 1960, Taylor, 1983, Yeaman, 1997, Tang 
et al., 2002, López-Medrano et al., 2016). Plasma is the supernatant produced after centrifuging 
blood mixed with an anticoagulant such as sodium or lithium heparin, citrate or oxalate (Uges, 
1988). Serum, in contrast to plasma, excludes fibrinogens (clotting proteins), and is the 
resulting supernatant when whole blood is allowed to clot and then centrifuged (Uges, 1988). 
Constituents of serum and plasma that exhibit antimicrobial activity include complement, 
lysozyme enzymes, antibodies and small antimicrobial peptides (AMPs) (Taylor, 1983). 
Additionally, an activated coagulation system contributes to innate immunity by entrapping 
bacteria inside the clot and producing AMPs (Taylor, 1983, Berends et al., 2014).  
The in-vitro antimicrobial activity of eucalypt extracts and EOs (Sartorelli et al., 2007, Ghalem 
and Mohamed, 2008, Gilles et al., 2010, Tyagi and Malik, 2011, Elaissi et al., 2011) suggests 
a hypothesis that the almost exclusive eucalypt diet of koalas could have a synergistic effect 
on the antimicrobial activity of koala plasma and / or serum. Although their diet is based on 
the ingestion of one specific plant genus, wild and captive koalas prefer a variety of eucalypt 
species foliage in their diet (Blanshard and Bodley, 2008). The diet of wild koalas can include 
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a diverse range of Eucalyptus leaves based on tree abundance and species variety within their 
habitat (Callaghan et al., 2011, Marsh et al., 2014). For example, eight wild koalas monitored 
for two weeks at Philip Island, Vic., mainly preferred Eucalyptus viminalis, Eucalyptus 
globulus and Eucalyptus ovata foliage from 139 trees they visited (Marsh et al., 2014). At 
Taronga Zoo, koalas are fed a variety of Eucalyptus species simultaneously, including 
Eucalyptus amplifolia, Eucalyptus microcorys, Eucalyptus molucanna, Eucalyptus punctate, 
Eucalyptus robusta, Eucalyptus scoparia and Eucalyptus tereticornis (personal 
communication with Taronga Zoo staff).  
The chemical composition and biological activities of many Eucalyptus species have been 
studied (discussed in Chapter 1, Section 1.2.5). Eucalypt EOs are estimated to account for 16 
% of the total digestible energy intake by koalas (El-Merhibi et al., 2007). The susceptibility 
of pathogens to a range of Eucalyptus species EOs varies significantly (Elaissi et al., 2011). 
For example, EOs extracted from E. viminalis (Elaissi et al., 2011) and E. globulus (Tyagi and 
Malik, 2011) inhibited S. aureus more than E. coli while E. ovata (Elaissi et al., 2011) and E. 
robusta (Sartorelli et al., 2007) inhibited E. coli more than S. aureus.  
Whilst research has focused on the koala’s physiological and anatomical adaptations to deal 
with its almost exclusive eucalypt foliage diet, little has focussed on the therapeutic properties 
and effects of a eucalypt diet on the koalas’ susceptibility or resistance to infectious diseases. 
To the best of this author’s knowledge, there is no published information about the baseline 
antibacterial activity of koala blood matrices. Thus, this study aimed to evaluate the 
antibacterial activity of koala plasma and to compare it with that of other species. Additionally, 
the antibacterial activities of serum, delayed-coagulation serum (DCS) and heated serum (HS) 
of koalas and sheep (Ovis aries) to inhibit E. coli and S. aureus were also compared. Delayed-
coagulation serum collected after slow coagulation of the blood for experiment 2 is platelet-
free and is the blood matrix with the lowest antibacterial activity in humans and rabbits (Hirsch 
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1960). Hirsch (1960) used the term plasma serum to differentiate the serum collected after 
delayed coagulation of the blood from normal serum (Hirsch, 1960). A third experiment 
undertaken compared the antibacterial activities of plasma and serum in inhibiting E. coli and 
S. aureus.  
7.3 Materials and methods 
All the following microbial procedures were undertaken using aseptic technique to avoid 
extraneous microbial contamination of the assays. 
7.3.1 Bacterial strains, culture conditions and inoculum preparation 
Reference strains E. coli ATCC 25922 and S. aureus ATCC 29213 were used and sub-
cultured onto tryptose agar plates (Invitrogen, San Diego, CA, USA) and incubated at 35 °C 
for 18 – 24 h. Individual bacterial colonies were selected and emulsified in Phoenix ID broth 
(Becton, Dickinson & Co., North Ryde, NSW). A PhoenixSpec TM nephelometer (Becton, 
Dickinson & Co., North Ryde, NSW) was used to produce a solution of 0.5 McFarland 
turbidity (1.5 × 108 CFU/mL). Solutions were further diluted with MHB to produce an 
inoculum of 1.5 × 106 CFU/mL. 
7.3.2 Broth microdilution inhibition assays 
Plasma, serum, HS and DCS samples were tested for antibacterial activity by broth 
microdilution assay to inhibit both reference strains using 96-well culture plates (Nunclon™ 
Delta Surface, Thermo Fisher Scientific, Scoresby, Vic.). The inoculum and sample volumes 
were the same as prescribed for the broth microdilution susceptibility assay (CLSI, 2013a): a 
volume of 100 µL of each sample was added to each well. To each well, 10 µL of inoculum 
was added to give a bacterial concentration of 1.5 × 105 CFU/mL and a final volume of 110 
µL. Samples were tested in triplicate and for each sample, proper blanks were prepared 
concurrently. For every assay run, a well containing only MHB and a positive control (MHB 
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and inoculum only) were included in each plate to establish that the MHB was 
uncontaminated and that the assay supported bacterial growth, respectively. Contents of each 
well were mixed with a pipette and the plates were covered and incubated for 18 – 24 h at 35 
°C. After incubation, the wells were visually examined for ± bacterial growth and semi-
quantitated by measuring the turbidity at 620 nm (Widdel, 2007) relative to the respective 
blank well as OD zero (an automated microplate reader, Halo LED 96, Dynamica Pty Ltd, 
Clayton, Vic.).  
7.3.3 Experimental design 
7.3.3.1 Experiment 1: Antibacterial activities of koala, cow (Bos taurus) and horse plasma 
to inhibit E. coli and S. aureus 
Plasma samples underwent broth microdilution inhibition assay against each reference strain. 
Blood samples were obtained opportunistically from clinically normal, unmedicated koalas 
at Taronga Zoo (n = 5), Sydney, Wildlife World, Darling Harbour (n = 4) (both located in 
central Sydney, NSW), Port Macquarie Koala Hospital in regional/semiurban NSW (n = 4), 
and Currumbin Wildlife Hospital in semi-urban QLD (n = 2). Blood samples collected 
opportunistically from clinically normal horses (n = 2) and cows (n = 2) at the SSVS farms 
were used for comparison. Sodium heparin was used as the anticoagulant for all samples. 
Blood samples were centrifuged for 15 min at 4,000 g and the plasma supernatant was 
collected promptly and stored at – 20 °C away from light until analysis.  
To assess the antibacterial activity of sodium heparin, 1 mL MHB was added to nine 
commercial blood collection (green-top) tubes containing 102 IU sodium heparin (BD 
Vacutainer Plastic Blood Collection Tubes with sodium Heparin 367874, North Ryde, 
NSW) and vortexed thoroughly. Then, 200 µL from each tube was added to the first well of 
three rows to perform eight two-fold dilutions (from 102 to 0.8 IU/mL). Each row of the serial 
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dilutions was inoculated either with 10 µL of E. coli or S. aureus at a density of 105 CFU/mL. 
One row of the serial dilutions without any bacteria served as negative controls.  
7.3.3.2 Experiment 2: Comparative activities of serum, DCS and HS of the koala vs 
sheep to inhibit E. coli and S. aureus 
The abilities of serum, DCS and HS to inhibit E. coli and S. aureus were also determined by 
broth microdilution inhibition assay.  
Blood samples were obtained opportunistically from five clinically normal, unmedicated 
koalas at Taronga Zoo, Mosman, NSW and five sheep from the SSVS farm. The blood was 
divided for serum and DCS preparation. To prepare the serum, the blood was drawn into plain 
clotting tubes (without anticoagulant) and allowed to clot at room temperature. The samples 
were then centrifuged for 15 min at 4,000 g and the serum supernatant was collected. The 
samples were stored at – 20 °C away from light until analysis. Before the assay, some sera 
were also incubated at 56 °C for 15 – 30 min to inactivate complement (Hein-Kristensen et 
al., 2013) and were then rapidly cooled on ice. 
Platelet-free delayed-coagulation serum (DCS) samples were prepared according to Hirsch 
(1960). The 15 mL centrifuge tubes (Labtek Pty Ltd, Brendale, QLD) were placed into 50 mL 
centrifuge tubes (Labtek Pty Ltd, Brendale, QLD) filled with water and then frozen. Blood 
was collected directly into the cold 15 mL tubes followed by centrifugation for 20 min at 
4,000 g at 0 °C. Subsequently, the supernatant was collected and incubated at 37 °C for 1.5 
h. After centrifugation, the clear serum was removed and stored at – 20 °C and kept away 
from light until analysis.  
7.3.3.3 Experiment 3: Comparative antibacterial activities of koala plasma and serum to 
inhibit E. coli and S. aureus 
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Due to the limited blood volume that can be collected from koalas, there was no possibility to 
compare the ability of koala plasma vs serum to inhibit bacterial growth in experiment 2. 
Therefore, this experiment tested for differences between the antibacterial activities of plasma 
vs serum against both pathogens. 
Blood samples were obtained opportunistically from three clinically normal, unmedicated 
koalas from Taronga Zoo and one koala from the Port Macquarie Koala Hospital. 
Approximately 7 – 8 mL of blood from each animal provided plasma and serum as described 
in experiments 1 and 2. The samples were stored at – 20 °C and kept away from light until 
analysis. 
7.3.4 Statistical analysis 
The mean bacterial growth data between groups were analysed by ANOVA and Tukey's 
multiple comparisons test using GraphPad Prism 7.02, with a minimum significance level of P 
< 0.05. 
7.4 Results 
7.4.1 Experiment 1: Antibacterial activities of koala, cow and horse plasma to inhibit 
E. coli and S. aureus 
Koala plasma exhibited a wider range of relative growth inhibition of both E. coli and S. aureus 
compared to that of cow and horse plasmas (see Figure 7-1 A and B). The growth of E. coli 
and S. aureus incubated with plasma from all species were less than the positive controls (P < 
0.0001) and cow and horse plasma inhibited the growth of S. aureus significantly more than 
koala plasma (P < 0.0001).  
None of the sodium heparin concentrations (0.80 – 102 IU/mL) inhibited the growth of either 
E. coli or S. aureus. 
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Figure 7-2 A and B demonstrates the antibacterial activity of koala plasma based on animal 
geographic location. All plasma samples inhibited E. coli and S. aureus growth to various 
degrees, and the bacterial growth was significantly less than the respective positive controls (P 
< 0.0001). The only significant difference between locations was between the samples from 
Darling Harbour, NSW and from Currumbin, QLD (P < 0.0001). This observation should be 
interpreted with caution as the Currumbin data only incorporate two koalas, of which the 
plasma of one was very inhibitory and the plasma from the other was far less inhibitory. 
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Figure 7-1 E. coli ATCC 25922 (A) and S. aureus ATCC 29213 (B) growth 
incubated with different plasma samples at 35 °C for 18 – 24 h. Koala plasma 
samples were from 15 adult koalas. Cow and horse plasma samples were from 
two animals each. All animals were clinically normal and un-medicated. The 
growth of the pathogens was estimated by measuring the OD620. Each datum is 
a replicate. The middle line is the mean and whiskers are the minimum and 
maximum values (range). Different letters indicate a statistical difference 
between means of each group in each graph (P < 0.0001). 
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Figure 7-2 E. coli ATCC 25922 (A) and S. aureus ATCC 29213 (B) growth 
incubated with koala plasma samples from four different locations at 35 °C for 
18 – 24 h. The growth of the pathogens was estimated by measuring the OD620. 
Each datum is a replicate. The middle line is the mean and whiskers are the 
minimum and maximum values (range). Different letters indicate a significant 
difference between means of each group in each graph (P < 0.0001). 
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7.4.2 Experiment 2: Comparative activities of serum, DCS and HS of koala vs sheep 
to inhibit E. coli and S. aureus 
Inhibition of E. coli and S. aureus by koala and sheep DCS, serum and HS are illustrated in 
Figure 7-3 A and B, respectively. Bacterial growth in all groups was less than the respective 
positive controls (P < 0.0001). Inhibition of E. coli and S. aureus by sheep DCS, serum and HS 
had similar means and ranges. Likewise, koala DCS and serum exhibited similar means of 
activity against both pathogens. Koala DCS and serum resulted in lower mean of E. coli growth 
(i.e. greater inhibition) than HS (P < 0.0001). There was a significant difference between mean 
growth inhibition of S. aureus by koala serum and HS (p = 0.0227). Sheep samples inhibited 
E. coli more than the koala samples (P < 0.0001).  
Koala samples for both experiments exhibited more variability (as represented by the OD620 
range) to inhibit pathogens’ growth compared to cow, horse and sheep samples.  
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Figure 7-3 E. coli ATCC 25922 (A) and S. aureus ATCC 29213 (B) growth 
incubated with different matrices of koalas (n = 5) and sheep (n = 5) blood at 
35 °C for 18 – 24 h. DCS = delayed-coagulation serum; HS = heated serum. 
The matrices were prepared from the same blood collection from each animal. 
The growth of the pathogens was estimated by measuring the OD620. Each 
datum is a replicate. The middle line is the mean and whiskers are the minimum 
and maximum values (range). Different letters indicate a significant difference 
between means of each group in each graph (P < 0.05).  
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7.4.3 Experiment 3: Comparative antibacterial activities of koala plasma and serum 
to inhibit E. coli and S. aureus 
The last experiment demonstrated the same mean antibacterial activity of koala plasma and 
serum against E. coli; however, koala serum inhibited S. aureus more than plasma (P < 
0.0001). Koala plasma inhibited E. coli more than S. aureus. Koala serum had similar 
antibacterial activities against both pathogens. Similar to the other experiments, koala samples 
had variable antibacterial activity against both pathogens. 
 
 
Figure 7-4 E. coli ATCC 25922 (A) and S. aureus ATCC 29213 (B) growth 
incubated with koala plasma (n = 4) or serum (n = 4) at 35 °C for 18 – 24 h. The 
plasma and serum were prepared from the same blood collection from the same 
animal. The growth of the pathogens was estimated by measuring the OD620. 
Each datum is a replicate. The middle line is the mean and the whiskers the 
minimum and maximum values (range). Different letters indicate a significant 
difference between means of each group (P < 0.05). 
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7.5 Discussion 
Comparative, objective, bacterial growth inhibition assays with plasma, DCS, serum and HS 
established baseline antibacterial activities of koala plasma and serum. Blood-derived fluids of 
all species studied significantly inhibited bacterial growth compared to positive controls, 
attributed to innate antimicrobial constituents of serum and plasma.  
In this study, E. coli ATCC 25922 and S. aureus ATCC 29213 represented gram-negative and 
gram-positive pathogens respectively. These bacterial species have been isolated from koalas 
with infectious diseases such as pneumonia and other respiratory tract infections and erosive 
dermatitis due to bite wounds (Blanshard and Bodley, 2008).  
The antibacterial activity of sodium heparin (≤ 102 IU/mL) in the 5 mL plasma collection tubes 
was evaluated to confirm that it did not contribute to the antibacterial activity of the plasma 
samples. Heparin concentrations ≥ 125 IU/mL and ≥ 250 IU/mL inhibited the growth of S. 
aureus and E. coli respectively (Rosett and Hodges, 1980); however, 102 IU did not inhibit 
growth of E. coli or S. aureus in this study. 
In experiment 1, whilst both pathogens appeared completely inhibited by cow and horse plasma 
(two animals of each species) in-vitro, they displayed much variation in susceptibility to koala 
plasma. This experiment could be improved by including samples from more cows and horses. 
The cow and horse (and sheep in experiment 2) were chosen as are large animals and blood 
was collected from these species opportunistically during veterinary students’ practical 
sessions.  
The possible effects of age, sex, degree of relatedness of koalas from different locations and 
environmental factors such as diet require further investigation with more individuals. These 
factors were not investigated as koala familial relationships were not available from three 
locations other than Taronga Zoo. Although two Taronga Zoo koalas in experiment 1 and three 
Chapter 7- Investigation into the antibacterial activities of plasma, serum, delayed-coagulation serum and 
heated serum of koalas and other selected species 
 
153 
 
koalas in experiment 3 were related, their samples did not display similar antibacterial 
activities.  
The DCS was described by Hirsch (1960) to investigate the antibacterial activity of rabbit and 
human blood matrices. This study reported antibacterial activity as a reciprocal of the 
bactericidal titre, and the lowest antibacterial activity (< 10) was observed with rabbit DCS 
against S. aureus, Bacillus megaterium and B. subtilis compared to serum (320 – 3200) and HS 
(160 – 3200). Rabbit serum and DCS both had the same, low antibacterial activity (32) against 
E. coli. In contrast, human serum and DCS displayed the same higher antibacterial activity 
(256) against E. coli. Heating rabbit and human serum (< 2) largely inactivated the antibacterial 
activity against E. coli. In experiment 2, there were no significant differences in the 
antibacterial activities between DCS and serum samples of koalas and sheep against both 
pathogens; however, heating reduced the ability of koala serum to inhibit bacterial growth. The 
increased bacterial growth associated with koala HS could be due to inactivation of labile 
antimicrobial properties (such as complement) (Taylor, 1983) but this could also be attributed 
to the inactivation of volatile and thermolabile eucalypt components such as terpenoids derived 
from the diet in koala blood matrices (Turek and Stintzing, 2013). Further evaluations of EOs 
in serum and HS might be required to confirm the factors involved in this reduction. The 
negligible effect of heating on sheep serum antibacterial activity indicates that some heat-stable 
properties other than complement could be responsible for the antibacterial activity (Taylor, 
1983).  
In experiment 2, unfortunately no koala plasma was processed from the animals’ whole blood 
to be compared with the serum. Koalas are not large animals (on average 6 to 10 kg) and it was 
challenging to obtain sufficient blood to obtain DCS, unheated and heated serum samples 
assayed in triplicate. Therefore, experiment 3 was undertaken to compare koala plasma and 
serum antibacterial activity processed from the same whole blood collection from each animal. 
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The results revealed that koala plasma and serum are likely to result in the same relative 
inhibition of E. coli. Nevertheless, the antibacterial activity of koala serum against S. aureus 
was superior to that of plasma, possibly due to different protein concentrations between plasma 
and serum. Human plasma has greater concentrations of fibrinogen and osteopontin (OPN) 
than human serum (Ayache et al., 2006) but human serum has higher concentrations of 11 
chemokine factors and some platelet-related factors (Ayache et al., 2006) that contribute to the 
antimicrobial activity of blood matrices (Tang et al., 2002, Yang et al., 2003). Differences 
between the antibacterial activity of plasma and serum is reported (López-Medrano et al., 
2016). Human serum has better antibacterial action than plasma against E. coli while human 
plasma exhibited greater antibacterial activity against Legionella pneumophila (López-
Medrano et al., 2016).  
Experiments 1 and 3 showed that koala plasma inhibited E. coli more than S. aureus. Gram-
negative pathogens such as E. coli are more susceptible to serum antibacterial activity such as 
complement cascade than gram-positive pathogens such as S. aureus (Rowley and Wardlaw, 
1958, Taylor, 1983). Nevertheless, in experiment 3 koala serum exhibited almost the same 
antibacterial activity against E. coli and S. aureus. The same antibacterial activity of plasma 
and serum against E. coli but superior activity of serum against S. aureus, could indicate that 
antimicrobial properties of plasma and serum that inhibit E. coli are the same but serum 
possesses extra components with superior activity against S. aureus than the plasma. These 
components could be related to antimicrobial peptides released during coagulation process 
which only happens as a precursor to serum removal. For example, when fibrinogen is 
converted to fibrin via thrombin activation, an antimicrobial peptide (GHR28) is released from 
the fibrinogen β-chain (Påhlman et al., 2013) which has significant antibacterial activity against 
S. aureus but not E. coli (Påhlman et al., 2013). However, the activity of koala serum to inhibit 
S. aureus has been equivocal with broad variation.  
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The variability in the inhibition of bacterial growth by koala plasma and / or serum was the 
most significant observation from all three experiments as individual variability in the 
antimicrobial activity of serum within a species is supposed to be low (Taylor, 1983). It was 
hypothesised (although it cannot be concluded) that the variable antibacterial inhibition of 
koala plasma and serum could be due to genetic factors that affect immune system efficacy in 
inhibiting microbial growth. Additionally, undulations in dietary constituents’ concentrations 
in plasma/serum due to intermittent feeding and nutrient absorption could also have a role in 
this variation. Moreover, volatile plant compounds are prone to fluctuate naturally in 
composition due to plant health, leaf age, season, soil factors and the microenvironment and 
climate (El-Merhibi et al., 2007, Turek and Stintzing, 2013). Consequently, the different 
bioactivities of Eucalyptus spp. might vary the content of nutrients and compounds present in 
plasma or serum.  
Establishing the factor(s) responsible for variation in plasma/serum antimicrobial activities 
may not be easy; however, investigating changes in serum or plasma antimicrobial activity 
using serial blood collection with respect to ingestion of a specific eucalypt species and 
monitoring the feeding time of koalas might be the next step. As the variation in antibacterial 
activity is a significant finding, these experiments could be expanded to include comparing the 
plasma or serum activities of other eucalypt folivores such as the common brush-tailed possum 
and eastern ring-tailed possum. Similar antimicrobial variations in the serum or plasma of these 
marsupials would provide stronger evidence that ingestion of eucalypt constituents is a 
significant factor.  
Further investigations into the effects of a eucalypt diet on the koala’s immune system might 
help establish new treatments, especially for chlamydiosis, exploiting therapeutic aspects of 
different Eucalyptus species to control koalas’ infectious diseases. The findings of this chapter 
open a further line of inquiry into the role of Eucalyptus extracts and EOs in inhibiting 
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Chlamydia spp. classified as obligate intracellular gram-negative bacteria. Investigations into 
whether blood matrices’ transport antibacterial activity to the cells and contribute to controlling 
this pathogen, which causes significant morbidity in koalas, are warranted. Furthermore, this 
research suggests studies to evaluate possible synergistic effects of a eucalypt foliage diet with 
immune system components including WBC, platelets, RBC and blood matrices (serum and 
plasma) in controlling cryptococcal infections or even viraemias such as active koala retrovirus 
(KoRV) infections. 
  
 Chapter 8 
 
 
 
Final discussion   
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8.1  General discussion and limitations of this research project 
Many observations from this research contribute significantly to expanding knowledge 
concerning antimicrobials for koalas and other Australian wildlife species. The previously 
undocumented findings include: 
 Generating the first report of the PK profile of posaconazole in koalas and a 
consequent prediction that it is likely to be an efficacious antifungal drug in this 
species. Posaconazole was also the first drug documented to have reasonable oral 
absorption in koalas (bioavailability (F) = median: 0.64, range: 0.43 – 1.06).  
 Demonstrating that cefovecin has a short duration of action in koalas with a single s.c. 
administration. Hypothetically, there might be some accumulation with multiple 
administrations, but this was not investigated in this research. The outcomes 
documented in Chapter 4 will stop wildlife veterinarians from administering a single 
bolus of cefovecin to koalas, assuming that a single bolus provides koalas with 
adequate antibacterial protection for days. Cefovecin was also found to have a low 
percentage of binding to plasma proteins in other selected Australian marsupials and 
in these species is likely to have a similar short duration of action in vivo. 
 Very surprisingly, in attempting to confirm the plasma concentrations of cefovecin 
and amoxicillin in koala plasma using bioassays, variable antibacterial activity of 
koala blood matrices was observed. This requires investigation to explain such 
variation and whether it is due to fluctuations of eucalypt constituents’ concentrations 
in the circulation and / or other factors. 
An additional strength of this research was that for all three antimicrobial drugs an HPLC 
method was developed and rigorously validated to ensure endogenous plasma interferences 
were eliminated and to increase the accuracy and precision of each assay. Difficulties in 
optimising the methods to detect drugs in koala plasma prompted extensive literature reviews 
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to appraise the most applicable LC procedures and to help find solutions to assay these drugs 
in koala plasma. However, many endogenous peaks in koala plasma required customisation 
of HPLC conditions for this species to maximise sensitivity and selectivity with the available 
equipment.  
The HPLC-PDA method developed and validated to determine posaconazole concentration 
was highly sensitive and could detect posaconazole concentrations as low as 0.02 µg/mL using 
100 µL koala plasma. This sensitivity exceeded the methods validated for dog plasma [LLOQ: 
0.04 µg/mL using 500 µL plasma (Kendall and Papich, 2015)], cat plasma [LLOQ: 0.05 µg/mL 
using 500 µL plasma (Mawby et al., 2016)] and rat plasma [LLOQ: 0.05 µg/mL using 200 µL 
plasma (Khalil et al., 2015)]. The advantage of this method was the use of small volumes of 
koala plasma (100 µL) with a convenient protein precipitation extraction that is beneficial with 
limited sample volumes. The method could also detect itraconazole (the internal standard for 
the posaconazole assay) without endogenous interference.  
This research project provided valuable information about the stability of posaconazole and 
cefovecin in both stock solutions and koala plasma stored at – 20 °C for 5 and 18 months, 
respectively, indicating both drugs are stable at – 20 °C for these durations. Although cefovecin 
samples were analysed by HPLC within two months after collection, there were stability QC 
samples stored at – 20 °C available after 18 months and those samples could be assayed 
accurately for up to 18 months, which is advantageous when batching samples. 
This research also found amoxicillin is unstable in plasma samples stored at – 20 °C. 
Amoxicillin is a first-line antibacterial frequently administered to animals (often combined 
with a beta-lactamase inhibitor) and it is very useful to know it loses 4 % of its detectable mass 
after 1 month and up to 50 to 60 % after 5 months stored at – 20 °C (documented in Chapter 
5). 
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A major unexpected finding was the difficulty extracting cefovecin and amoxicillin from the 
plasma samples and then assaying them by HPLC. However, another strength of this research 
was to utilise an alternative method (bioassays) to confirm the HPLC results. Broth 
microdilution inhibition in this project was assayed according to the CLSI standard (CLSI, 
2013a) which specifies that visual inspection is sufficient to detect bacterial growth inhibition. 
However, Bacterial growth was also estimated by measuring the turbidity at 620 nm (OD620).  
The plates were carefully vortexed to remove any cell clots that may influence OD620 values 
prior to measuring the turbidity using an automated microplate reader. Although the wells 
were also examined visually, the OD620 approach provided an objective and quantitative 
method to compare bacterial growth inhibition between time points (Chapter 6) and treatment 
groups (Chapter 7) rather than just relying on a visual, binary appraisal of  bacterial growth. 
The proportions of posaconazole and cefovecin bound to plasma proteins were determined 
using two methods, ultrafiltration and equilibrium dialysis, which were introduced in Chapter 
1, Section 1.2.2.2, the equilibrium dialysis method was described in Chapter 2, Section 2.3.3 
and the ultrafiltration method was described in Chapter 3, Section 3.3.6. Initially, the 
percentage of cefovecin bound to plasma proteins of selected species was determined by UF. 
Although this assay was relatively simple and practical, each replicate required at least 700 µL. 
The percentage of bound posaconazole to koala plasma proteins was determined by equilibrium 
dialysis assay using the commercial ‘Rapid ED’ (Thermo Fisher Scientific, Scoresby, NSW). 
The RED device enabled running the assay with smaller volumes of plasma samples, as each 
replicate only required a plasma volume of 100 to 500 µL. Therefore, this method was 
advantageous when only small sample volumes are available. In this research, pooled plasma 
samples from the same sources underwent both methods to compare the PPB results obtained 
for cefovecin and posaconazole (illustrated in Appendix III, Table A-2 and A-3). The PPB 
results in koala and horse plasma obtained by the ED were slightly greater than those obtained 
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by the UF method. However, both methods produced accurate results consistent with published 
reports. The difference between the ED and UF PPB are minimal and not expected to have any 
clinical implications. The PPB of posaconazole in horse, dog and cat plasmas determined by 
the ED are presented in Appendix III, Table A-3. The value in the dog (99 ± 0.18 %) is 
consistent with literature reports > 99 % using UF assay (Kendall and Papich, 2015).  
One of the limitations encountered was the small numbers of animals in each study. Koalas are 
very valuable animals. All these studies relied on Taronga Zoo providing some of their display 
animals, and six mature animals were recruited for each in-vivo study (oral posaconazole, 
cefovecin and amoxicillin). The pool of available mature koalas was further restricted by 
excluding mature females with pouch young and koalas involved in other studies. Although 
not statistically ideal, pharmacological studies with treatment groups based on six clinically 
normal mature individuals are considered publishable for non-domesticated animals (e.g., 
Gharibi et al. (2017).  
Another limitation was the volume of blood available from each animal during each 
pharmacological study and comparative antibacterial study as described in Chapter 7. Koalas 
are not large, so collecting adequate volumes of plasma was challenging. Sample preparation 
methods were undertaken to extract maximal drug from low plasma volumes. For example, it 
wasn’t possible to use 500 µL plasma that had been used in some assays to perform PPE 
(Kendall and Papich, 2015) or LLE (Foroutan et al., 2007). Thus, sample extraction was 
optimised to use 100 µL and 240 µL of plasma for PPE and LLE, respectively.  
There were Two significant challenges in the HPLC method optimisation for both cefovecin 
and amoxicillin: i) there was significant interferences by endogenous compounds in the koala 
plasma around the peaks of interest on the chromatograms and ii) the drugs themselves were 
problematic for extraction and assay by HPLC. Koala plasma seems to have a complicated 
heterogeneous matrix probably due to the animals’ eucalypt diet (Kimble et al., 2013b) which 
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can interfere with the analyte of interest, particularly those with polar chemical properties 
(such as cefovecin and amoxicillin) because biological matrices are mainly polar and are 
eluted simultaneously with polar drugs early in reversed phase chromatography (Meyer, 2004, 
Hall et al., 2012). Blank koala plasma from the same (see Figure 8-1) or different regions of 
Australia (see Figure 8-2) using the same HPLC conditions and sample preparation techniques 
resulted in variable endogenous peak heights, variable AUC and variable peaks in the 
chromatograms. 
 
Figure 8-1 Chromatograms of blank plasma from five koalas at Taronga Zoo. Each coloured trace is a 
chromatogram of an individual koala. Arrows show significant differences between the chromatograms; 
two koalas have extra peaks at 2.4 and 4.8 min. Also, the AUC and height of the peaks at 1.7 and 2.2 
min vary between individuals. Chromatographic separation was performed with a Synergy MAX-RP 
80Å at ambient temperature. An isocratic mobile phase consisted of 50 mM phosphate buffer (pH: 6.2) 
and acetonitrile (40:60 v/v) at a flow rate of 1 mL/min and a UV wavelength of 262 nm. Samples were 
prepared with protein precipitating extraction using 1 to 1 volume of acetonitrile.  
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Figure 8-2 Chromatograms of pooled blank koala plasma from Taronga Zoo (blue) and Port Macquarie 
Koala Hospital (red). Arrows show significant differences between the chromatograms; an extra peak 
appears at 5.8 min of the Taronga Zoo sample. Also, the AUC and height of the peaks at 2.8 and 4.2 
min vary between the two samples. Chromatographic separation was performed with a Synergi Hydro-
RP 80Å at 35 °C. An isocratic mobile phase consisted of sodium phosphate buffer (50 mM, pH: 3.15) 
and methanol (95:5 v/v) at a flow rate of 1.2 mL/min and a UV wavelength of 228 nm. Samples were 
prepared with protein precipitating extraction using 1 to 1 volume of methanol.  
Higher assay sensitivity for cefovecin might have permitted the detection of lower drug 
concentrations in the plasma and facilitated generation of a more comprehensive PK profile 
such as a more accurate half-life and the possibility of PK/PD integration to predict likely 
efficacy against specific pathogens. Although multiple methods were trialled to increase 
sensitivity, most of these methods (applicable to extracting the drug from other species) were 
not successful. The method developed and validated for the cefovecin in-vivo assay (described 
in Chapter 4) did not satisfy the guidelines regarding assay reliability due to variations in 
cefovecin recovery as the lower concentrations of the calibrators in the standard curve and the 
QC samples containing 0.05 and 0.5 µg/mL of cefovecin had poor accuracy. The reason for 
such variation was not understood. It could be strong retention of cefovecin on the SPE 
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cartridges and / or irreversible adsorption of cefovecin on these cartridges due to secondary 
interactions between the sorbent and cefovecin (Majors, 2013, CHROMacademy, 2016).  
When planning the in-vivo cefovecin study, the cefovecin was not expected to be detected so 
rapidly in the in-vivo samples and cefovecin plasma concentration fell to < 1 µg/mL by 6 h. 
In hind-sight if such a study was to be repeated in koalas, it is recommended that blood 
collection time points to be concentrated in first 6 h after drug administration as cefovecin 
plasma concentration fell to < 1 µg/mL by 6 h. 
Detection of amoxicillin in koala plasma posed similar problems to those encountered detecting 
cefovecin in koala plasma. However, an additional problem was amoxicillin instability over 
time. The amoxicillin assay was initially validated based on the plasma of koalas from AZWH 
(QLD). When the time came to medicate the koalas, personnel issues prevented the study at 
Australia Zoo. Dr Larry Vogelnest and Taronga Zoo (NSW) agreed to conduct the study. 
Endogenous compounds in the samples from these koalas interfered with the amoxicillin peak 
and the assay required further modification and revalidation; HPLC assay of these samples 
occurred 5.5 months after arrival. Although the candidate worked consistently between 
September 2016 and February 2017 to measure amoxicillin concentrations in the plasma 
samples, the stability test showed that amoxicillin QC samples were unstable after 5 months 
stored at – 20 °C. Therefore, the results of amoxicillin chapter indicating low plasma 
concentrations of amoxicillin was likely, in part, to be attributable to amoxicillin instability. 
The in-vivo PK study of amoxicillin in koalas is required to be repeated to confirm the PK 
profile of amoxicillin in koalas. This component could not be repeated at the late stage of this 
candidature as repeating the study required reapplication of animal ethics approval and time-
intensive processes of in-vivo drug administration, blood collection and sample analyses.  
More thorough PK profiles were not determined due to the low cefovecin (because of low 
HPLC method sensitivity) and amoxicillin (because of poor stability) concentrations detected 
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in most plasma samples at many time points. Although studies of intravenously administered 
cefovecin and amoxicillin might have provided greater drug plasma concentrations and 
facilitated calculations of drug Vd and Cl, unlike posaconazole, formulations that can be 
administered i.v. are not available for these drugs. When planning these studies, it was thought 
that evaluating these drugs using the route by which they are administered to koalas would 
provide the most relevant information.  
Only clinically normal koalas were recruited for this project and PK studies of these three drugs 
were not investigated in diseased koalas. Drug PK profiles between sick and clinically healthy 
animals can differ (Lees et al., 2009). Illness conditions can affect drug absorption, distribution, 
metabolism and elimination, thereby, influencing the PK profile in diseased individuals (Smith 
et al., 2012). For example, severe infections such as bacteraemia or pneumonia that stimulate 
the systemic inflammatory response syndrome (i.e. the presence of at least two of the following 
conditions: fever, leucocytosis or leukopenia, tachycardia, tachypnoea and hypotension) can 
increase the Vd, particularly that of hydrophilic antibacterials such as beta-lactams that 
generally have a low Vd (Blot et al., 2014).  
8.2 Recommendations and directions for future research  
8.2.1 Use of alternative drug determination methods 
Based on the results of HPLC method developments for two polar drugs, other methods could 
be superior to HPLC-UV for quantitating polar drugs in koala plasma or serum due to the 
compromised sensitivity and selectivity of this HPLC method. Alternatively, based on the 
availability of other analytical instruments and time to develop a new method, or to implement 
methods reported in the literature, other bioanalytical methods with higher sensitivity and 
selectivity such as HPLC with florescence detection, LC/MS or electrochemical detection 
could be superior for analysing polar drugs in complex biological fluids. 
  
A pilot study prior to the experimental PK studies is suggested to improve the study design, 
select the appropriate time points for sample collection, select standard curve ranges for HPLC 
methods and check if endogenous interference will be a problem. 
8.2.2 Investigation of itraconazole PK profile and its evaluation as a treatment for 
fungal disease in koalas 
Although posaconazole showed promising efficacy for treating fungal disease in koalas, its cost 
is a major disadvantage for veterinary practice (a single 105 mL bottle of the 40 mg/mL oral 
formulation, Noxafil costs approximately AU $650 in 2017). Itraconazole is a cheaper broad-
spectrum antifungal used in koalas, and its PK profile in the koala needs to be described. There 
are no published studies of itraconazole’s PK profile in koalas and as a result of this research a 
method to detect itraconazole in koala plasma is now available for a future in-vitro [hepatic 
metabolism studies (Kimble et al., 2014)] and / or in-vivo studies. 
8.2.3 Investigating factors responsible for the variability of antibacterial activity of 
koala blood matrices 
Microbiological assays were initially undertaken to confirm the HPLC findings. However, an 
intriguing finding from the broth microdilution assay was the variability of antibacterial 
activity between clinically normal koalas even before they were medicated, and between 
sequential time points for an individual koala from both the cefovecin and amoxicillin in-vivo 
samples. This variation led to studying the antibacterial activity of koala plasma and serum in 
Chapter 7. Similar to the observed variability in the chromatograms of koala plasma, 
antibacterial activities of both koala plasma and serum varied considerably. Several factors can 
contribute to such variations and the reasons are not clear. As the koalas tested in Chapter 7 
were clinically normal and unmedicated, genetic factors could cause this variation. In addition, 
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as specialist eucalypt folivores, the koala diet could contribute to this variability as digestion 
of Eucalyptus spp. (with variable bioactivities) can vary the content of nutrients and 
compounds present in plasma or serum. Further investigations are required to discover the 
reason for such variability in the antibacterial activity of koala blood matrices.  
8.2.4 Effects of different Eucalyptus spp. leaf extracts and EOs on pathogenic 
microorganisms such as Chlamydia and Cryptococcus spp.; diet therapy in koalas and 
other Eucalyptus spp. folivores 
Given the biological activities of Eucalyptus spp. foliage, some in-vitro assays can be 
conducted to test the antimicrobial activities of different Eucalyptus spp. against Chlamydia 
and Cryptococcus spp. Effective eucalypt species can be explored for further in-vivo studies to 
control and treat infectious disease in koalas. As immuno-stimulatory (Serafino et al., 2008) 
and anti-inflammatory (Silva et al., 2003) activities of some Eucalyptus EOs are reported, 
exploring interactions between the diet and the koala immune system is warranted. These 
experiments can be expanded to other Eucalyptus herbivores such as the common brush-tailed 
possum and eastern ring-tailed possum. 
8.3 Conclusions 
Results in this thesis indicate promising efficacy of posaconazole to treat systemic fungal 
diseases in koalas. A single s.c. bolus of cefovecin 8 mg/kg is unlikely to be efficacious to 
treat bacterial diseases for more than 3 h and does not offer the long duration of efficacy seen 
in dogs and cats. The in-vivo PK study of amoxicillin should be repeated due to the instability 
of amoxicillin stored at – 20 °C. Variable antibacterial activities of koala plasma and serum 
could imply synergistic antimicrobial effects of Eucalyptus spp. with innate antimicrobial 
components of koala blood matrices. The reasons for this variability require further 
investigation.
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Appendix I- HPLC method to determine amoxicillin and clavulanic acid concentrations 
in koala and horse plasma 
Amoxicillin/clavulanic acid concentrations in plasma samples were quantified with HPLC. 
Chromatographic separation was performed with a Synergi Hydro-RP 80Å, (4μm, 250×4.6 
mm) (Phenomenex, Lane Cove, NSW) with a 1 mm Opti-guard C-18 pre-column (Choice 
Analytical, Thornleigh, NSW) at 35 °C. The isocratic mobile phase consisted of sodium 
phosphate buffer (50 mM, pH: 3) and methanol (96 : 4 v/v) (Foroutan et al., 2007) at a flow 
rate of 1.4 mL/min and the UV wavelength used for detection was 228 nm. The retention time 
of clavulanic acid, the IS (allopurinol) and amoxicillin were approximately 5.5, 6.4 and 11.2 
min, respectively. The total run time for each sample was 19 min. 
For drug extraction from plasma samples, protein precipitation was performed by adding a 1:1 
volume of methanol followed by centrifugation at 14,000 g for 10 min. The supernatant was 
removed and after further centrifugation at the same speed and duration, 10 μL of supernatant 
was injected into the HPLC system. 
A chromaotgram of amoxicillin, clavulanic acid and the IS is provided in Figure A-1 
 
 
 
FOROUTAN, S., ZARGHI, A., SHAFAATI, A., KHODDAM, A. & MOVAHED, H. 2007. 
Simultaneous determination of amoxicillin and clavulanic acid in human plasma by isocratic 
reversed-phase HPLC using UV detection. Journal of Pharmaceutical and Biomedical 
Analysis, 45, 531-534. 
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Figure A-1 Chromatograms of extracted pre-spiked koala plasma (black trace) containing 10 µg/mL 
of clavulanic acid (A, retention time of 5.5), 5 µg/mL of IS (allopurinol, retention time of 6.4 min) and 
5 µg/mL of amoxicillin (B, retention time of 11.2 min); and blank koala plasma (green trace) at a UV 
wavelength of 228. 
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Appendix II- Summary of stability test results of amoxicillin and clavulanic acid 
conducted in October 2014  
Table A-1 Stability of amoxicillin and clavulanic acid in koala plasma pre-spiked with 1, 5 and 10 
µg/mL of both drugs when stored at different temperatures  
Concentrations 
(µg/mL) 
Storage 
temperature  
(°C) 
Storage period 
(d) 
The AUC reduction compared to 
the time 0 (%) 
Amoxicillin Clavulanic 
acid 
1 + 4 4 17.91 47.55 
10  19.69 71.13 
1 – 20 28 3.66 47.28 
5  0.97 45.14 
10  0 46.15 
1 – 80 34 0 17.61 
10  7.25 23.84 
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Appendix III- Comparison of equilibrium dialysis and ultrafiltration for the 
determination of PPB values of cefovecin and posaconazole  
Table A-2 In-vitro plasma protein binding (%) of cefovecin (10, 50 and 100 µg/mL) in the koala 
and horse determined by equilibrium dialysis and ultrafiltration.  
Cefovecin  
concentration 
  (µg/mL) 
Koala Horse 
Equilibrium 
dialysis 
Ultrafiltration  Equilibrium 
dialysis 
Ultrafiltration 
10 19.37 11.9 95.60 95.47 
50 16.85 11.29 94.79 92.94 
100 16.21 15.46 92.56 90.18 
Mean ± SD 17.48 ± 1.67 12.88 ± 2.25 94.32 ± 1.58 92.86 ± 2.65 
The PPB of cefovecin was determined using frozen-thawed pooled plasma of five and three 
clinically normal koalas and horses. For equilibrium dialysis, the incubation temperature was 37 
°C for both animals. Incubation for ultrafiltration was at 36 °C for koalas and 37 °C for horses. 
 
Table A-3 In-vitro plasma protein binding (%) of posaconazole (0.5, 1, 2.5 and 5 µg/mL) in the 
koala, horse, dog and cat determined by equilibrium dialysis and ultrafiltration.  
Posaconazole 
concentration 
  (µg/mL) 
Koala Horse Dog* Cat* 
Equilibrium 
dialysis 
Ultrafiltration  Equilibrium 
dialysis 
Equilibrium 
dialysis 
Equilibrium 
dialysis 
0.5 98.92 97.81 97.35 98.87 99.70 
1 99.44 - - - - 
2.5 99.41 96.85 98.58 99.14 95.19 
5 - 95.66 - - - 
Mean ± SD 99.25 ± 0.43 96.77 ± 1.08 97.96 ± 0.87 99.00 ± 0.18 97.45 ± 3.18 
The frozen-thawed pooled plasma of six koalas, three horses, six dogs and six cats was used to 
determine the PPB of posaconazole using equilibrium dialysis; the incubation temperature was 37 
°C for all species. The same koala samples also underwent ultrafiltration assay at 36 °C. Cat and dog 
plasma were residual plasma from hospital patients submitted to Veterinary Pathology Diagnostic 
Services (VPDS), SSVS. 
